<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00468845</url>
  </required_header>
  <id_info>
    <org_study_id>A0081153</org_study_id>
    <nct_id>NCT00468845</nct_id>
  </id_info>
  <brief_title>Study Of The Efficacy And Safety Of Pregabalin Compared To Placebo For Treatment Of Post-Surgical Pain From Hysterectomy</brief_title>
  <official_title>A Multiple Dose, Randomized, Double-Blind Multicenter Study Of The Efficacy And Safety Of Pregabalin Compared To Placebo In The Treatment Of Patients With Post-Surgical Pain From Hysterectomy</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Pfizer</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Pfizer</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      To assess the efficacy of pregabalin compared to placebo on pain following hysterectomy ,
      measured using subject reported assessments of pain.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>June 2007</start_date>
  <completion_date type="Actual">October 2010</completion_date>
  <primary_completion_date type="Actual">May 2010</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Double (Participant, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Worst Pain Using the Modified Brief Pain Inventory - Short Form (m-BPI-sf)</measure>
    <time_frame>Day 2 (24 hours post surgery [PS])</time_frame>
    <description>Modified Brief Pain Inventory - Short Form (m-BPI-sf): participant rated 11-point Likert rating scale ranged from 0 (no pain) to 10 (worst pain imaginable).
Least Square (LS) Means adjusted for treatment, pooled center and salpingo-oophorectomy strata.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Current Pain - Pain With Movement Caused by Sitting</measure>
    <time_frame>Day 1 (day of surgery), up to 7 days PS, Discharge, 2 and 4 weeks PS</time_frame>
    <description>Participant sat upright from supine position, followed by 120 second (sec) rest period, during which participant asked to rate pain with movement. Assessment performed 3 times each day of hospital stay, with 1 daily assessment at 24 (+/- 2) hour interval from end of surgery. Current pain reported on 11 point Likert scale 0 (no pain) to 10 (worst pain imaginable). LS Means adjusted for treatment, pooled center and salpingo-oophorectomy strata.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Current Pain - Pain With Movement Caused by Peak Expiratory (PEF) Test</measure>
    <time_frame>Day 1, up to 7 days PS, 2 and 4 weeks PS</time_frame>
    <description>Current pain with movement caused by peak expiratory flow (PEF) test as reported by participant on 11 point Likert scale 0 (no pain) to 10 (worst pain). Assessment performed 3 times each day of hospital stay, with 1 daily assessment at 24 (+/- 2) hour interval from end of surgery. PEF test performed 3 times, with 120sec rest periods in between. At beginning of each rest period, participant asked to rate pain caused by forced expiration. LS Means adjusted for treatment, pooled center and salpingo-oophorectomy strata.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Area Under the Curve (AUC) Pain - Pain With Movement Caused by Sitting</measure>
    <time_frame>48 +/- 4 hours PS</time_frame>
    <description>Time-normalized AUC of pain with movement caused by sitting reported by participants. Participant sat upright from supine position, followed by a 120sec rest period, during which the participant asked to rate pain with movement. Assessment performed 3 times each day of hospital stay, with 1 daily assessment at 24 (+/- 2) hour interval from end of surgery. Current pain reported on 11 point Likert scale 0 (no pain) to 10 (worst pain imaginable). LS Means adjusted for treatment, pooled center and salpingo-oophorectomy strata.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Area Under the Curve (AUC) Pain - Pain With Movement Caused by Peak Expiratory Flow (PEF) Test</measure>
    <time_frame>48 +/- 4 hours PS</time_frame>
    <description>Time-normalized AUC of pain reported by participants with movement caused by PEF test. Pain reported by participant on 11 point Likert scale 0 (no pain) to 10 (worst pain). PEF test performed 3 times, with 120sec rest periods in between. At beginning of each rest period, participant asked to rate pain caused by forced expiration. LS Means adjusted for treatment, pooled center and salpingo-oophorectomy strata.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Current Pain at Rest</measure>
    <time_frame>8, 16, 24, 32, 40, 48 hours PS</time_frame>
    <description>Pain reported by participants at rest (numeric rating scale (NRS) - Current Pain) on an 11 point Likert scale 0 (no pain) - 10 (worst pain). Pain at rest during the hospital stay was assessed just before each Pain with Movement assessment. Assessment performed 3 times each day of hospital stay, with 1 of daily assessments at 24 (+/- 2 ) hour intervals from end of surgery. LS Means adjusted for treatment, pooled center and salpingo-oophorectomy strata.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Area Under the Curve (AUC) of Pain at Rest During the First Two Days of Hospital Stay</measure>
    <time_frame>48 +/- 4 hours PS</time_frame>
    <description>Time-normalized AUC of pain reported by participants on 11 point Likert scale 0 (no pain) to 10 (worst pain). LS Means adjusted for treatment, pooled center and salpingo-oophorectomy strata.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Total Cumulative Dose of Opioids Following Surgery</measure>
    <time_frame>24, 48 Hours PS, Discharge (day 3 up to day 7 PS)</time_frame>
    <description>Total cumulative dose was calculated as milligram (mg) of morphine equivalent and included opioids administered by any route. LS Means adjusted for treatment, pooled center and salpingo-oophorectomy strata.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Integrated Analgesic Score</measure>
    <time_frame>0-24, 24-48, 48-72 hours PS</time_frame>
    <description>The integrated analgesic score (a combination of opioid use and either worst pain, or pain at rest, or pain caused by sitting, or pain caused by forced expiration as defined by Silverman et al 1993) was the sum of percent differences from mean rank for pain and opioids and ranged from -200 to 200 where lower values represent improvement. LS Means adjusted for treatment, pooled center and salpingo-oophorectomy strata.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Non-opioid Rescue Medication - Paracetamol</measure>
    <time_frame>24, 48, 72 hours PS, Discharge (day 3 up to day 7 PS), Week 1, 2, 3, 4 PS,</time_frame>
    <description>The amounts of non-opioid rescue medications, paracetamol, used by the participants during the study, including anti-emetic medications.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Anxiety Before and After Surgery</measure>
    <time_frame>Surgery day before first dose and 1 hour after first dose, Day 1, 2, 3, 4, 5 PS and Discharge (day 3 up to day 7 PS)</time_frame>
    <description>Participant anxiety reported on Visual Anxiety Scale (VAS), 0 (not at all anxious) to 100 (extremely anxious). LS Means adjusted for treatment, pooled center and salpingo-oophorectomy strata</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Non-opioid Rescue Medication - Ibuprofen</measure>
    <time_frame>24, 48, 72 hours PS, Discharge (day 3 up to day 7 PS), Week 1, 2, 3, 4 PS</time_frame>
    <description>The amounts of non-opioid rescue medications, ibuprofen, used by the participants during the study, including anti-emetic medications.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percent Change From Baseline in Peak Expiratory Flow</measure>
    <time_frame>Baseline, every 8 hours (up to 232 hours) PS, and Discharge (Day 3-7 PS flexible)</time_frame>
    <description>Change from baseline= PEF at x hours minus PEF at baseline; possible values ranged from 0-900 liters/minute (higher values indicated better lung function). LS Means adjusted for treatment, pooled center and salpingo-oophorectomy strata.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Timed Up-and-Go (TUG)</measure>
    <time_frame>Day 1, 2, 3, 4, 5 PS and Discharge (day 3 up to day 7 PS)</time_frame>
    <description>Functional mobility test performed once a day at 24 hour intervals from surgery after the pain with movement assessment. LS Means adjusted for treatment, pooled center and salpingo-oophorectomy strata.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Average Daily Pain</measure>
    <time_frame>Day 2, 3, 4, 5, 6, 7, PS; week 2, 3, 4 PS</time_frame>
    <description>Post-discharge average pain as measured in daily participant diaries NRS an 11 point Likert scale ranged from 0 (no pain) to 10 (worst pain). LS Means adjusted for treatment, pooled center and salpingo-oophorectomy strata.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Worst Daily Pain</measure>
    <time_frame>Discharge (day 3 up to day 7 PS), Day 7, 14, 28 PS</time_frame>
    <description>Post-discharge worst pain as measured in daily participant diaries NRS an 11 point Likert scale that ranged from 0 (no pain) to 10 (pain as bad as you can imagine). LS Means from ANOVA model with terms of treatment, pooled center, salpingo-oophorectomy strata and baseline worst pain score.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Sleep Interference</measure>
    <time_frame>Daily post hospital discharge ( Day 2-7 PS), Week 2, 3, 4 PS</time_frame>
    <description>Sleep interference post surgery measured daily in participant diaries; NRS of how pain interfered with sleep during the last 24 hours, ranged from 0 (does not interfere) to 10 (completely interferes). LS Means adjusted for treatment, pooled center and salpingo-oophorectomy strata.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Brief Pain Inventory-Short Form (m-BPI-sf): Pain Interference Index Scores</measure>
    <time_frame>Baseline, Discharge (day 3 up to day 7 PS), Day 7, 14, 28 PS</time_frame>
    <description>m-BPI-sf: participant-rated 11 point Likert rating scale ranging from 0 (does not interfere) to 10 (completely interferes) with functional activities (general activity, mood, walking ability, relations with other people, sleep, normal work, and enjoyment of life) in past 24 hours. LS Means adjusted for treatment, pooled center and salpingo-oophorectomy strata.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Brief Pain Inventory-Short Form (m-BPI-sf): Pain Severity Index Scores</measure>
    <time_frame>Baseline, Discharge (day 3 up to day 7 PS), Day 7, 14, 28 PS</time_frame>
    <description>m-BPI-sf: participant rated 11-point Likert rating scale ranging from 0 (no pain) to 10 (worst pain possible). Pain severity index is the mean of item scores 2, 3, and 4 (pain right now, worst pain, and average pain level).
LS Means adjusted for treatment, pooled center and salpingo-oophorectomy strata.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Participant Satisfaction With Study Medication - Surgery Day</measure>
    <time_frame>Day 1</time_frame>
    <description>Participant satisfaction with study medication using the Global Evaluation of Study Medication questionaire. Participants overall impression (global evaluation) of the study medication was recorded by the participant by answering the following question: How would you rate the study medication you received for pain? Excellent 4; Good 3; Fair 2; Poor 1.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Participant Satisfaction With Study Medication - Day 1 PS</measure>
    <time_frame>Day 1 PS</time_frame>
    <description>Participant satisfaction with study medication using the Global Evaluation of Study Medication questionaire. Participants overall impression (global evaluation) of the study medication was recorded by the participant by answering the following question: How would you rate the study medication you received for pain? Excellent 4; Good 3; Fair 2; Poor 1.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Participant Satisfaction With Study Medication - Day 2 PS</measure>
    <time_frame>Day 2 PS</time_frame>
    <description>Participant satisfaction with study medication using the Global Evaluation of Study Medication questionaire. Participants overall impression (global evaluation) of the study medication was recorded by the participant by answering the following question: How would you rate the study medication you received for pain? Excellent 4; Good 3; Fair 2; Poor 1.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Participant Satisfaction With Study Medication - Day 3 PS</measure>
    <time_frame>Day 3 PS</time_frame>
    <description>Participant satisfaction with study medication using the Global Evaluation of Study Medication questionaire. Participants overall impression (global evaluation) of the study medication was recorded by the participant by answering the following question: How would you rate the study medication you received for pain? Excellent 4; Good 3; Fair 2; Poor 1.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Participant Satisfaction With Study Medication - Day 4 PS</measure>
    <time_frame>Day 4 PS</time_frame>
    <description>Participant satisfaction with study medication using the Global Evaluation of Study Medication questionaire. Participants overall impression (global evaluation) of the study medication was recorded by the participant by answering the following question: How would you rate the study medication you received for pain? Excellent 4; Good 3; Fair 2; Poor 1.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Participant Satisfaction With Study Medication - Day 5 PS</measure>
    <time_frame>Day 5 PS</time_frame>
    <description>Participant satisfaction with study medication using the Global Evaluation of Study Medication questionaire. Participants overall impression (global evaluation) of the study medication was recorded by the participant by answering the following question: How would you rate the study medication you received for pain? Excellent 4; Good 3; Fair 2; Poor 1.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Participant Satisfaction With Study Medication - Discharge</measure>
    <time_frame>Discharge (day 3 up to day 7 PS)</time_frame>
    <description>Participant satisfaction with study medication using the Global Evaluation of Study Medication questionaire. Participants overall impression (global evaluation) of the study medication was recorded by the participant by answering the following question: How would you rate the study medication you received for pain? Excellent 4; Good 3; Fair 2; Poor 1.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Participant Satisfaction With Study Medication - Day 7 PS</measure>
    <time_frame>Day 7 PS</time_frame>
    <description>Participant satisfaction with study medication using the Global Evaluation of Study Medication questionaire. Participants overall impression (global evaluation) of the study medication was recorded by the participant by answering the following question: How would you rate the study medication you received for pain? Excellent 4; Good 3; Fair 2; Poor 1.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Participant Satisfaction With Study Medication - Day 14 PS</measure>
    <time_frame>Day 14 PS</time_frame>
    <description>Participant satisfaction with study medication using the Global Evaluation of Study Medication questionaire. Participants overall impression (global evaluation) of the study medication was recorded by the participant by answering the following question: How would you rate the study medication you received for pain? Excellent 4; Good 3; Fair 2; Poor 1.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Participant Satisfaction With Study Medication - Day 28 PS</measure>
    <time_frame>Day 28 PS</time_frame>
    <description>Participant satisfaction with study medication using the Global Evaluation of Study Medication questionaire. Participants overall impression (global evaluation) of the study medication was recorded by the participant by answering the following question: How would you rate the study medication you received for pain? Excellent 4; Good 3; Fair 2; Poor 1.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Pain Treatment Satisfaction Scale (PTSS): Satisfaction With Current Pain Medication</measure>
    <time_frame>Discharge (day 3 up to day 7 PS), Day 28 PS</time_frame>
    <description>Satisfaction with current pain medication ranged from 0 (worst possible response) to100 (best possible response). LS Means adjusted for treatment, pooled center and salpingo-oophorectomy strata.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Pain Treatment Satisfaction Scale (PTSS): Impact of Current Pain Medication</measure>
    <time_frame>Discharge (day 3 up to day 7 PS), Day 28 PS</time_frame>
    <description>Impact of current pain medication response scale: 0 (worst possible response) to 100 (best possible response). LS Means adjusted for treatment, pooled center and salpingo-oophorectomy strata.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Quality of Life Using EuroQol (EQ-5D) Health State Profile</measure>
    <time_frame>Discharge (day 3 up to day 7 PS) and day 28 PS</time_frame>
    <description>Participant rated questionnaire assessed current health for 6 domains: mobility/self-care/ usual activities/pain/discomfort/anxiety and depression. Scoring developed by EuroQol Group assigned a utility value for each domain in the profile. Scores ranged from 1 better health (no problems) to 3 worst health (eg, &quot;confined to bed&quot;). Score transformed and resulted in a total score range -0.594 to 1.000; higher score=better health state. Health profile scores estimated using Dolan computational algorithms 1997 and 2001. LS Means adjusted for treatment/pooled center/salpingo-oophorectomy strata.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Time to Meet Hospital Discharge Criteria</measure>
    <time_frame>Day 1 up to Day 7 PS</time_frame>
    <description>Mean time from end of surgery to meet protocol defined hospital discharge criteria: participant no longer received parental opioids, was able to dress and mobilize without assistance, and had normal intake of food and fluids.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Time to Actual Discharge</measure>
    <time_frame>Day 1 up to Day 7 PS</time_frame>
    <description>Mean time from end of surgery to actual hospital discharge. Participant was expected to remain at the hospital for a minimum of 2 days following surgery.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Incidence of Chronic Post-operative Pain</measure>
    <time_frame>3 and 6 Months PS</time_frame>
    <description>Chronic post-operative pain as a result of abdominal hysterectomy as reported by participants on PS questionaire of pain within last 24 hours in area affected by surgery.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Total Clinically Meaningful Event (CME) Score</measure>
    <time_frame>Surgery Day, Day 1, 2, 3, 4, 5 PS, Discharge (day 3 up to day 7 PS), Day 7, 14, 28 PS</time_frame>
    <description>Total CME score calculated by summing the number of Clinically Meaningful Events (CMEs) across symptoms. CME for each symptom will be defined using the Opioid-Related Symptom Distress Scale (OR-SDS) a participant rated scale of symptoms within the last 24 hours. Total CME score could range from 0 to 9. LS Means adjusted for treatment, pooled center and salpingo-oophorectomy strata.</description>
  </secondary_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Actual">501</enrollment>
  <condition>Pain, Postoperative</condition>
  <arm_group>
    <arm_group_label>1</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>2</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>3</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>pregabalin (Lyrica)</intervention_name>
    <description>150 mg/day double blind (divided doses)</description>
    <arm_group_label>1</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>pregabalin (Lyrica)</intervention_name>
    <description>300 mg/day double blind (divided doses)</description>
    <arm_group_label>2</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>matched placebo</intervention_name>
    <description>matched placebo</description>
    <arm_group_label>3</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  The subject will have elective total abdominal hysterectomy using a transverse
             incision with or without bilateral salpingo-oophorectomy. The total hysterectomy may,
             however, be cervix-sparing.

          -  The subject is expected to remain at the hospital (or intermediate care facility) for
             a minimum of 2 days following surgery.

          -  The subject's preoperative health is graded as the American Society of
             Anesthesiologist P1 to P2.

        Exclusion Criteria:

          -  Subjects having vaginal hysterectomy (whether laparoscopically assisted or not)

          -  Subjects having additional procedures (such as those involving the bladder) at the
             same time as the total abdominal hysterectomy

          -  The use of nerve block, spinal anesthesia or epidural anesthesia for post-surgical
             pain control

          -  Subjects who have been using any opioid medications 2 weeks or more continuously
             within 3 months prior to the screening visit.

          -  The subject has taken any NSAID or any analgesic other than acetaminophen within 3
             days prior to surgery or is unwilling to abstain from NSAIDs or other analgesics,
             except as specified in the protocol, during the study. (Subjects taking &lt;325 mg per
             day of aspirin at a stable dose for at least 30 days before the first dose of study
             medication will be allowed to continue their aspirin regimen for the duration of the
             study).
      </textblock>
    </criteria>
    <gender>Female</gender>
    <minimum_age>25 Years</minimum_age>
    <maximum_age>70 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Pfizer CT.gov Call Center</last_name>
    <role>Study Director</role>
    <affiliation>Pfizer</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Pfizer Investigational Site</name>
      <address>
        <city>Mobile</city>
        <state>Alabama</state>
        <zip>36608</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Pfizer Investigational Site</name>
      <address>
        <city>Glendale</city>
        <state>Arizona</state>
        <zip>85308</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Pfizer Investigational Site</name>
      <address>
        <city>Phoenix</city>
        <state>Arizona</state>
        <zip>85020</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Pfizer Investigational Site</name>
      <address>
        <city>Phoenix</city>
        <state>Arizona</state>
        <zip>85023</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Pfizer Investigational Site</name>
      <address>
        <city>Phoenix</city>
        <state>Arizona</state>
        <zip>85027</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Pfizer Investigational Site</name>
      <address>
        <city>Glendale</city>
        <state>California</state>
        <zip>91206</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Pfizer Investigational Site</name>
      <address>
        <city>Pasadena</city>
        <state>California</state>
        <zip>91105</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Pfizer Investigational Site</name>
      <address>
        <city>Miami</city>
        <state>Florida</state>
        <zip>33136-1096</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Pfizer Investigational Site</name>
      <address>
        <city>Miami</city>
        <state>Florida</state>
        <zip>33136</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Pfizer Investigational Site</name>
      <address>
        <city>Philadelphia</city>
        <state>Pennsylvania</state>
        <zip>19104</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Pfizer Investigational Site</name>
      <address>
        <city>Pittsburgh</city>
        <state>Pennsylvania</state>
        <zip>15213</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Pfizer Investigational Site</name>
      <address>
        <city>Pittsburgh</city>
        <state>Pennsylvania</state>
        <zip>15232</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Pfizer Investigational Site</name>
      <address>
        <city>Houston</city>
        <state>Texas</state>
        <zip>77024</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Pfizer Investigational Site</name>
      <address>
        <city>Houston</city>
        <state>Texas</state>
        <zip>77054</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Pfizer Investigational Site</name>
      <address>
        <city>Calgary</city>
        <state>Alberta</state>
        <zip>T2N 2T9</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Pfizer Investigational Site</name>
      <address>
        <city>Montreal</city>
        <state>Quebec</state>
        <zip>H2X 3J4</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Pfizer Investigational Site</name>
      <address>
        <city>Sherbrooke</city>
        <state>Quebec</state>
        <zip>J1H 5N4</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Pfizer Investigational Site</name>
      <address>
        <city>Praha 5</city>
        <zip>150 06</zip>
        <country>Czech Republic</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Pfizer Investigational Site</name>
      <address>
        <city>Kowloon</city>
        <zip>0</zip>
        <country>Hong Kong</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Pfizer Investigational Site</name>
      <address>
        <city>Shatin</city>
        <country>Hong Kong</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Pfizer Investigational Site</name>
      <address>
        <city>Johannesburg</city>
        <state>Gauteng</state>
        <zip>1829</zip>
        <country>South Africa</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Pfizer Investigational Site</name>
      <address>
        <city>Krugersdorp</city>
        <state>Gauteng</state>
        <zip>1752</zip>
        <country>South Africa</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Pfizer Investigational Site</name>
      <address>
        <city>Pretoria</city>
        <state>Gauteng</state>
        <zip>0157</zip>
        <country>South Africa</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Pfizer Investigational Site</name>
      <address>
        <city>Newcastle</city>
        <state>KwaZulu Natal</state>
        <zip>2940</zip>
        <country>South Africa</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Pfizer Investigational Site</name>
      <address>
        <city>Ladysmith</city>
        <state>KZN</state>
        <zip>3370</zip>
        <country>South Africa</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Pfizer Investigational Site</name>
      <address>
        <city>Cape Town</city>
        <state>Western Cape</state>
        <zip>7500</zip>
        <country>South Africa</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Pfizer Investigational Site</name>
      <address>
        <city>Parktown</city>
        <zip>2193</zip>
        <country>South Africa</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Pfizer Investigational Site</name>
      <address>
        <city>Cadiz</city>
        <zip>11009</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Pfizer Investigational Site</name>
      <address>
        <city>Madrid</city>
        <zip>28031</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Pfizer Investigational Site</name>
      <address>
        <city>Madrid</city>
        <zip>28046</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Pfizer Investigational Site</name>
      <address>
        <city>Valencia</city>
        <zip>46010</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Pfizer Investigational Site</name>
      <address>
        <city>Lund</city>
        <zip>221 85</zip>
        <country>Sweden</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Pfizer Investigational Site</name>
      <address>
        <city>Orebro</city>
        <zip>701 85</zip>
        <country>Sweden</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Pfizer Investigational Site</name>
      <address>
        <city>Stockholm</city>
        <zip>182 88</zip>
        <country>Sweden</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Pfizer Investigational Site</name>
      <address>
        <city>Bangkoknoi</city>
        <state>Bangkok</state>
        <zip>10700</zip>
        <country>Thailand</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Pfizer Investigational Site</name>
      <address>
        <city>Muang</city>
        <state>Chiang Mai</state>
        <zip>50200</zip>
        <country>Thailand</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Pfizer Investigational Site</name>
      <address>
        <city>Muang</city>
        <state>Khon Kaen</state>
        <zip>40002</zip>
        <country>Thailand</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Pfizer Investigational Site</name>
      <address>
        <city>Leicester</city>
        <state>Leicestershire</state>
        <zip>LE1 5WW</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Pfizer Investigational Site</name>
      <address>
        <city>Edinburgh</city>
        <state>Scotland</state>
        <zip>EH16 4SA</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Pfizer Investigational Site</name>
      <address>
        <city>Birmingham</city>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Pfizer Investigational Site</name>
      <address>
        <city>Liverpool</city>
        <zip>L8 7SS</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Pfizer Investigational Site</name>
      <address>
        <city>Livingstone</city>
        <zip>EH54 6PP</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Canada</country>
    <country>Czech Republic</country>
    <country>Hong Kong</country>
    <country>South Africa</country>
    <country>Spain</country>
    <country>Sweden</country>
    <country>Thailand</country>
    <country>United Kingdom</country>
    <country>United States</country>
  </location_countries>
  <link>
    <url>https://trialinfoemail.pfizer.com/pages/landing.aspx?StudyID=A0081153&amp;StudyName=Study%20Of%20The%20Efficacy%20And%20Safety%20Of%20Pregabalin%20Compared%20To%20Placebo%20For%20Treatment%20Of%20Post-Surgical%20Pain%20From%20Hysterectomy</url>
    <description>To obtain contact information for a study center near you, click here.</description>
  </link>
  <verification_date>June 2011</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>May 1, 2007</study_first_submitted>
  <study_first_submitted_qc>May 1, 2007</study_first_submitted_qc>
  <study_first_posted type="Estimate">May 3, 2007</study_first_posted>
  <results_first_submitted>April 29, 2011</results_first_submitted>
  <results_first_submitted_qc>April 29, 2011</results_first_submitted_qc>
  <results_first_posted type="Estimate">May 26, 2011</results_first_posted>
  <last_update_submitted>June 7, 2011</last_update_submitted>
  <last_update_submitted_qc>June 7, 2011</last_update_submitted_qc>
  <last_update_posted type="Estimate">June 9, 2011</last_update_posted>
  <responsible_party>
    <name_title>Director, Clinical Trials Disclosure Group</name_title>
    <organization>Pfizer, Inc</organization>
  </responsible_party>
  <keyword>pain after hysterectomy</keyword>
  <keyword>amount of opioids used</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Pain, Postoperative</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Pregabalin</mesh_term>
  </intervention_browse>

  <clinical_results>

    <participant_flow>
      <group_list>
        <group group_id="P1">
          <title>Pregabalin 150mg</title>
          <description>Pregabalin 75 mg twice a day (150 mg/day total)</description>
        </group>
        <group group_id="P2">
          <title>Pregabalin 300 mg</title>
          <description>Pregabalin 150 mg twice a day (300 mg/day total)</description>
        </group>
        <group group_id="P3">
          <title>Placebo</title>
          <description>Matching placebo capsule</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="162"/>
                <participants group_id="P2" count="170"/>
                <participants group_id="P3" count="169"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>Received Treatment</title>
              <participants_list>
                <participants group_id="P1" count="161"/>
                <participants group_id="P2" count="166"/>
                <participants group_id="P3" count="167"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="141"/>
                <participants group_id="P2" count="136"/>
                <participants group_id="P3" count="139"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="21"/>
                <participants group_id="P2" count="34"/>
                <participants group_id="P3" count="30"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Adverse Event</title>
              <participants_list>
                <participants group_id="P1" count="9"/>
                <participants group_id="P2" count="14"/>
                <participants group_id="P3" count="11"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Lost to Follow-up</title>
              <participants_list>
                <participants group_id="P1" count="2"/>
                <participants group_id="P2" count="1"/>
                <participants group_id="P3" count="2"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Other</title>
              <participants_list>
                <participants group_id="P1" count="4"/>
                <participants group_id="P2" count="9"/>
                <participants group_id="P3" count="5"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>No longer willing to participate</title>
              <participants_list>
                <participants group_id="P1" count="5"/>
                <participants group_id="P2" count="6"/>
                <participants group_id="P3" count="10"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Randomized, not treated</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
                <participants group_id="P2" count="4"/>
                <participants group_id="P3" count="2"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>Pregabalin 150mg</title>
          <description>Pregabalin 75 mg twice a day (150 mg/day total)</description>
        </group>
        <group group_id="B2">
          <title>Pregabalin 300 mg</title>
          <description>Pregabalin 150 mg twice a day (300 mg/day total)</description>
        </group>
        <group group_id="B3">
          <title>Placebo</title>
          <description>Matching placebo capsule</description>
        </group>
        <group group_id="B4">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="162"/>
            <count group_id="B2" value="170"/>
            <count group_id="B3" value="169"/>
            <count group_id="B4" value="501"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age, Customized</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>25-44 years</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="77"/>
                    <measurement group_id="B2" value="76"/>
                    <measurement group_id="B3" value="88"/>
                    <measurement group_id="B4" value="241"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>45-70 years</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="84"/>
                    <measurement group_id="B2" value="90"/>
                    <measurement group_id="B3" value="79"/>
                    <measurement group_id="B4" value="253"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Unspecified</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="1"/>
                    <measurement group_id="B2" value="4"/>
                    <measurement group_id="B3" value="2"/>
                    <measurement group_id="B4" value="7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Gender</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>Female</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="162"/>
                    <measurement group_id="B2" value="170"/>
                    <measurement group_id="B3" value="169"/>
                    <measurement group_id="B4" value="501"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Male</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Worst Pain Using the Modified Brief Pain Inventory - Short Form (m-BPI-sf)</title>
        <description>Modified Brief Pain Inventory - Short Form (m-BPI-sf): participant rated 11-point Likert rating scale ranged from 0 (no pain) to 10 (worst pain imaginable).
Least Square (LS) Means adjusted for treatment, pooled center and salpingo-oophorectomy strata.</description>
        <time_frame>Day 2 (24 hours post surgery [PS])</time_frame>
        <population>Modified intent-to-treat (mITT) population: participants who received at least 1 dose study drug, had at least 1 post baseline safety and efficacy evaluation, took all pre-surgery medication, had no complications during surgery with discontinuation, no PS infection with additional hospitalization/readmission, had primary efficacy measurement PS</population>
        <group_list>
          <group group_id="O1">
            <title>Pregabalin 150mg</title>
            <description>Pregabalin 75 mg twice a day (150 mg/day total)</description>
          </group>
          <group group_id="O2">
            <title>Pregabalin 300 mg</title>
            <description>Pregabalin 150 mg twice a day (300 mg/day total)</description>
          </group>
          <group group_id="O3">
            <title>Placebo</title>
            <description>Matching placebo capsule</description>
          </group>
        </group_list>
        <measure>
          <title>Worst Pain Using the Modified Brief Pain Inventory - Short Form (m-BPI-sf)</title>
          <description>Modified Brief Pain Inventory - Short Form (m-BPI-sf): participant rated 11-point Likert rating scale ranged from 0 (no pain) to 10 (worst pain imaginable).
Least Square (LS) Means adjusted for treatment, pooled center and salpingo-oophorectomy strata.</description>
          <population>Modified intent-to-treat (mITT) population: participants who received at least 1 dose study drug, had at least 1 post baseline safety and efficacy evaluation, took all pre-surgery medication, had no complications during surgery with discontinuation, no PS infection with additional hospitalization/readmission, had primary efficacy measurement PS</population>
          <units>Units on a scale</units>
          <param>Least Squares Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="151"/>
                <count group_id="O2" value="149"/>
                <count group_id="O3" value="156"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="7.1" spread="0.18"/>
                    <measurement group_id="O2" value="7.2" spread="0.18"/>
                    <measurement group_id="O3" value="7.4" spread="0.18"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.1378</p_value>
            <p_value_desc>Weighted Z-score test method of Fisher (1998) and Cui et al (1999)applied to maintain alpha level. A step down procedure for multiple comparisons to control the maximum experiment wise type I error rate at 0.05 level. 300mg tested prior to 150mg.</p_value_desc>
            <method>ANOVA</method>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O2</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.4710</p_value>
            <p_value_desc>Weighted Z-score test method of Fisher (1998) and Cui et al (1999)applied to maintain alpha level. A step down procedure for multiple comparisons to control the maximum experiment wise type I error rate at 0.05 level. 300mg tested prior to 150mg.</p_value_desc>
            <method>ANOVA</method>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Current Pain - Pain With Movement Caused by Sitting</title>
        <description>Participant sat upright from supine position, followed by 120 second (sec) rest period, during which participant asked to rate pain with movement. Assessment performed 3 times each day of hospital stay, with 1 daily assessment at 24 (+/- 2) hour interval from end of surgery. Current pain reported on 11 point Likert scale 0 (no pain) to 10 (worst pain imaginable). LS Means adjusted for treatment, pooled center and salpingo-oophorectomy strata.</description>
        <time_frame>Day 1 (day of surgery), up to 7 days PS, Discharge, 2 and 4 weeks PS</time_frame>
        <population>mITT; n = number of evaluable participants analyzed for the given time point; N=number of evaluable participants analyzed; Results presented for only those timepoints PS where at least 4 participants in each treatment arm completed the questionnaire at baseline and respective time point.</population>
        <group_list>
          <group group_id="O1">
            <title>Pregabalin 150mg</title>
            <description>Pregabalin 75 mg twice a day (150 mg/day total)</description>
          </group>
          <group group_id="O2">
            <title>Pregabalin 300 mg</title>
            <description>Pregabalin 150 mg twice a day (300 mg/day total)</description>
          </group>
          <group group_id="O3">
            <title>Placebo</title>
            <description>Matching placebo capsule</description>
          </group>
        </group_list>
        <measure>
          <title>Current Pain - Pain With Movement Caused by Sitting</title>
          <description>Participant sat upright from supine position, followed by 120 second (sec) rest period, during which participant asked to rate pain with movement. Assessment performed 3 times each day of hospital stay, with 1 daily assessment at 24 (+/- 2) hour interval from end of surgery. Current pain reported on 11 point Likert scale 0 (no pain) to 10 (worst pain imaginable). LS Means adjusted for treatment, pooled center and salpingo-oophorectomy strata.</description>
          <population>mITT; n = number of evaluable participants analyzed for the given time point; N=number of evaluable participants analyzed; Results presented for only those timepoints PS where at least 4 participants in each treatment arm completed the questionnaire at baseline and respective time point.</population>
          <units>Units on a scale</units>
          <param>Least Squares Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="147"/>
                <count group_id="O2" value="141"/>
                <count group_id="O3" value="149"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>24 Hours PS (n=147, 141, 149)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="5.21" spread="0.188"/>
                    <measurement group_id="O2" value="5.53" spread="0.194"/>
                    <measurement group_id="O3" value="5.28" spread="0.189"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>48 Hours PS (n=142, 141, 142)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3.57" spread="0.185"/>
                    <measurement group_id="O2" value="3.71" spread="0.189"/>
                    <measurement group_id="O3" value="3.67" spread="0.189"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>72 Hours PS (n=83, 90, 75)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2.80" spread="0.239"/>
                    <measurement group_id="O2" value="3.04" spread="0.225"/>
                    <measurement group_id="O3" value="3.20" spread="0.257"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>96 Hours PS (n=29, 31, 26)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2.31" spread="0.425"/>
                    <measurement group_id="O2" value="3.20" spread="0.383"/>
                    <measurement group_id="O3" value="3.20" spread="0.444"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>120 Hours PS (n=14, 15, 12)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2.89" spread="0.584"/>
                    <measurement group_id="O2" value="2.84" spread="0.527"/>
                    <measurement group_id="O3" value="2.36" spread="0.633"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>144 Hours PS (n=2, 5, 5)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.86" spread="1.496"/>
                    <measurement group_id="O2" value="1.26" spread="1.177"/>
                    <measurement group_id="O3" value="2.00" spread="1.010"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Discharge (n=141, 135, 144)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2.67" spread="0.175"/>
                    <measurement group_id="O2" value="2.99" spread="0.181"/>
                    <measurement group_id="O3" value="2.42" spread="0.176"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 14 (n=126, 120, 128)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.08" spread="0.140"/>
                    <measurement group_id="O2" value="1.37" spread="0.145"/>
                    <measurement group_id="O3" value="1.30" spread="0.143"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 28 (n=138, 138, 142)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.70" spread="0.126"/>
                    <measurement group_id="O2" value="0.91" spread="0.129"/>
                    <measurement group_id="O3" value="0.76" spread="0.127"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <groups_desc>24 hours PS</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.7752</p_value>
            <method>ANOVA</method>
            <method_desc>LS Means from ANOVA model with terms of treatment, pooled center and salpingo-oophorectomy strata.</method_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O2</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <groups_desc>24 hours PS</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.3375</p_value>
            <method>ANOVA</method>
            <method_desc>LS Means from ANOVA model with terms of treatment, pooled center and salpingo-oophorectomy strata.</method_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <groups_desc>48 hours PS</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.7029</p_value>
            <method>ANOVA</method>
            <method_desc>LS Means from ANOVA model with terms of treatment, pooled center and salpingo-oophorectomy strata.</method_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O2</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <groups_desc>48 hours PS</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.8618</p_value>
            <method>ANOVA</method>
            <method_desc>LS Means from ANOVA model with terms of treatment, pooled center and salpingo-oophorectomy strata.</method_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <groups_desc>72 hours PS</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.2117</p_value>
            <method>ANOVA</method>
            <method_desc>LS Means from ANOVA model with terms of treatment, pooled center and salpingo-oophorectomy strata.</method_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O2</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <groups_desc>72 hours PS</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.6255</p_value>
            <method>ANOVA</method>
            <method_desc>LS Means from ANOVA model with terms of treatment, pooled center and salpingo-oophorectomy strata.</method_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <groups_desc>96 hours PS</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.0942</p_value>
            <method>ANOVA</method>
            <method_desc>LS Means from ANOVA model with terms of treatment, pooled center and salpingo-oophorectomy strata.</method_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O2</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <groups_desc>96 hours PS</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.9907</p_value>
            <method>ANOVA</method>
            <method_desc>LS Means from ANOVA model with terms of treatment, pooled center and salpingo-oophorectomy strata.</method_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <groups_desc>120 hours PS</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.4678</p_value>
            <method>ANOVA</method>
            <method_desc>LS Means from ANOVA model with terms of treatment, pooled center and salpingo-oophorectomy strata.</method_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O2</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <groups_desc>120 hours PS</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.5500</p_value>
            <method>ANOVA</method>
            <method_desc>LS Means from ANOVA model with terms of treatment, pooled center and salpingo-oophorectomy strata.</method_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <groups_desc>144 hours PS</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.9333</p_value>
            <method>ANOVA</method>
            <method_desc>LS Means from ANOVA model with terms of treatment, pooled center and salpingo-oophorectomy strata.</method_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O2</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <groups_desc>144 hours PS</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.7396</p_value>
            <method>ANOVA</method>
            <method_desc>LS Means from ANOVA model with terms of treatment, pooled center and salpingo-oophorectomy strata.</method_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <groups_desc>Discharge</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.2932</p_value>
            <method>ANOVA</method>
            <method_desc>LS Means from ANOVA model with terms of treatment, pooled center and salpingo-oophorectomy strata.</method_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O2</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <groups_desc>Discharge</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.0164</p_value>
            <method>ANOVA</method>
            <method_desc>LS Means from ANOVA model with terms of treatment, pooled center and salpingo-oophorectomy strata.</method_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <groups_desc>Day 14</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.2468</p_value>
            <method>ANOVA</method>
            <method_desc>LS Means from ANOVA model with terms of treatment, pooled center and salpingo-oophorectomy strata.</method_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O2</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <groups_desc>Day 14</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.7022</p_value>
            <method>ANOVA</method>
            <method_desc>LS Means from ANOVA model with terms of treatment, pooled center and salpingo-oophorectomy strata.</method_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <groups_desc>Day 28</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.7257</p_value>
            <method>ANOVA</method>
            <method_desc>LS Means from ANOVA model with terms of treatment, pooled center and salpingo-oophorectomy strata.</method_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O2</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <groups_desc>Day 28</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.3854</p_value>
            <method>ANOVA</method>
            <method_desc>LS Means from ANOVA model with terms of treatment, pooled center and salpingo-oophorectomy strata.</method_desc>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Current Pain - Pain With Movement Caused by Peak Expiratory (PEF) Test</title>
        <description>Current pain with movement caused by peak expiratory flow (PEF) test as reported by participant on 11 point Likert scale 0 (no pain) to 10 (worst pain). Assessment performed 3 times each day of hospital stay, with 1 daily assessment at 24 (+/- 2) hour interval from end of surgery. PEF test performed 3 times, with 120sec rest periods in between. At beginning of each rest period, participant asked to rate pain caused by forced expiration. LS Means adjusted for treatment, pooled center and salpingo-oophorectomy strata.</description>
        <time_frame>Day 1, up to 7 days PS, 2 and 4 weeks PS</time_frame>
        <population>mITT; n = number of evaluable participants analyzed for the given time point; N=number of evaluable participants analyzed; Results presented for only those timepoints PS where at least 4 participants in each treatment arm completed the questionnaire at baseline and respective time point.</population>
        <group_list>
          <group group_id="O1">
            <title>Pregabalin 150mg</title>
            <description>Pregabalin 75 mg twice a day (150 mg/day total)</description>
          </group>
          <group group_id="O2">
            <title>Pregabalin 300 mg</title>
            <description>Pregabalin 150 mg twice a day (300 mg/day total)</description>
          </group>
          <group group_id="O3">
            <title>Placebo</title>
            <description>Matching placebo capsule</description>
          </group>
        </group_list>
        <measure>
          <title>Current Pain - Pain With Movement Caused by Peak Expiratory (PEF) Test</title>
          <description>Current pain with movement caused by peak expiratory flow (PEF) test as reported by participant on 11 point Likert scale 0 (no pain) to 10 (worst pain). Assessment performed 3 times each day of hospital stay, with 1 daily assessment at 24 (+/- 2) hour interval from end of surgery. PEF test performed 3 times, with 120sec rest periods in between. At beginning of each rest period, participant asked to rate pain caused by forced expiration. LS Means adjusted for treatment, pooled center and salpingo-oophorectomy strata.</description>
          <population>mITT; n = number of evaluable participants analyzed for the given time point; N=number of evaluable participants analyzed; Results presented for only those timepoints PS where at least 4 participants in each treatment arm completed the questionnaire at baseline and respective time point.</population>
          <units>Units on a scale</units>
          <param>Least Squares Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="146"/>
                <count group_id="O2" value="143"/>
                <count group_id="O3" value="148"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>24 hours PS (n=146, 142, 148)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="4.83" spread="0.202"/>
                    <measurement group_id="O2" value="4.92" spread="0.209"/>
                    <measurement group_id="O3" value="4.97" spread="0.207"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>48 hours PS (n=141, 143, 140)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3.22" spread="0.204"/>
                    <measurement group_id="O2" value="3.47" spread="0.205"/>
                    <measurement group_id="O3" value="3.46" spread="0.210"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>72 hours PS (n=83, 90, 74)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2.62" spread="0.242"/>
                    <measurement group_id="O2" value="2.69" spread="0.228"/>
                    <measurement group_id="O3" value="3.04" spread="0.263"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>96 hours PS (n=28, 31, 25)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.88" spread="0.465"/>
                    <measurement group_id="O2" value="3.05" spread="0.414"/>
                    <measurement group_id="O3" value="3.28" spread="0.487"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>120 hours PS (n=13, 14, 11)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.97" spread="0.685"/>
                    <measurement group_id="O2" value="2.10" spread="0.609"/>
                    <measurement group_id="O3" value="1.45" spread="0.740"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>144 hours PS (n=2, 5, 3)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3.67" spread="2.472"/>
                    <measurement group_id="O2" value="0.67" spread="1.453"/>
                    <measurement group_id="O3" value="1.67" spread="1.764"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <groups_desc>24 hours PS</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.5997</p_value>
            <method>ANOVA</method>
            <method_desc>LS Means from ANOVA model with terms of treatment, pooled center and salpingo-oophorectomy strata.</method_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O2</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <groups_desc>24 hours PS</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.8582</p_value>
            <method>ANOVA</method>
            <method_desc>LS Means from ANOVA model with terms of treatment, pooled center and salpingo-oophorectomy strata.</method_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <groups_desc>48 hours PS</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.3704</p_value>
            <method>ANOVA</method>
            <method_desc>LS Means from ANOVA model with terms of treatment, pooled center and salpingo-oophorectomy strata.</method_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O2</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <groups_desc>48 hours PS</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.9747</p_value>
            <method>ANOVA</method>
            <method_desc>LS Means from ANOVA model with terms of treatment, pooled center and salpingo-oophorectomy strata.</method_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <groups_desc>72 hours PS</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.2033</p_value>
            <method>ANOVA</method>
            <method_desc>LS Means from ANOVA model with terms of treatment, pooled center and salpingo-oophorectomy strata.</method_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O2</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <groups_desc>72 hours PS</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.2752</p_value>
            <method>ANOVA</method>
            <method_desc>LS Means from ANOVA model with terms of treatment, pooled center and salpingo-oophorectomy strata.</method_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <groups_desc>96 hours PS</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.0183</p_value>
            <method>ANOVA</method>
            <method_desc>LS Means from ANOVA model with terms of treatment, pooled center and salpingo-oophorectomy strata.</method_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O2</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <groups_desc>96 hours PS</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.6906</p_value>
            <method>ANOVA</method>
            <method_desc>LS Means from ANOVA model with terms of treatment, pooled center and salpingo-oophorectomy strata.</method_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <groups_desc>120 hours PS</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.5446</p_value>
            <method>ANOVA</method>
            <method_desc>LS Means from ANOVA model with terms of treatment, pooled center and salpingo-oophorectomy strata.</method_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O2</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <groups_desc>120 hours PS</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.4852</p_value>
            <method>ANOVA</method>
            <method_desc>LS Means from ANOVA model with terms of treatment, pooled center and salpingo-oophorectomy strata.</method_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <groups_desc>144 hours PS</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.5879</p_value>
            <method>ANOVA</method>
            <method_desc>LS Means from ANOVA model with terms of treatment, pooled center and salpingo-oophorectomy strata.</method_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O2</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <groups_desc>144 hours PS</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.7699</p_value>
            <method>ANOVA</method>
            <method_desc>LS Means from ANOVA model with terms of treatment, pooled center and salpingo-oophorectomy strata.</method_desc>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Area Under the Curve (AUC) Pain - Pain With Movement Caused by Sitting</title>
        <description>Time-normalized AUC of pain with movement caused by sitting reported by participants. Participant sat upright from supine position, followed by a 120sec rest period, during which the participant asked to rate pain with movement. Assessment performed 3 times each day of hospital stay, with 1 daily assessment at 24 (+/- 2) hour interval from end of surgery. Current pain reported on 11 point Likert scale 0 (no pain) to 10 (worst pain imaginable). LS Means adjusted for treatment, pooled center and salpingo-oophorectomy strata.</description>
        <time_frame>48 +/- 4 hours PS</time_frame>
        <population>mITT; N=number of evaluable participants analyzed</population>
        <group_list>
          <group group_id="O1">
            <title>Pregabalin 150mg</title>
            <description>Pregabalin 75 mg twice a day (150 mg/day total)</description>
          </group>
          <group group_id="O2">
            <title>Pregabalin 300 mg</title>
            <description>Pregabalin 150 mg twice a day (300 mg/day total)</description>
          </group>
          <group group_id="O3">
            <title>Placebo</title>
            <description>Matching placebo capsule</description>
          </group>
        </group_list>
        <measure>
          <title>Area Under the Curve (AUC) Pain - Pain With Movement Caused by Sitting</title>
          <description>Time-normalized AUC of pain with movement caused by sitting reported by participants. Participant sat upright from supine position, followed by a 120sec rest period, during which the participant asked to rate pain with movement. Assessment performed 3 times each day of hospital stay, with 1 daily assessment at 24 (+/- 2) hour interval from end of surgery. Current pain reported on 11 point Likert scale 0 (no pain) to 10 (worst pain imaginable). LS Means adjusted for treatment, pooled center and salpingo-oophorectomy strata.</description>
          <population>mITT; N=number of evaluable participants analyzed</population>
          <units>Units on a scale</units>
          <param>Least Squares Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="147"/>
                <count group_id="O2" value="140"/>
                <count group_id="O3" value="150"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="4.87" spread="0.155"/>
                    <measurement group_id="O2" value="5.01" spread="0.161"/>
                    <measurement group_id="O3" value="4.87" spread="0.157"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.9676</p_value>
            <method>ANOVA</method>
            <method_desc>LS Means from ANOVA model with terms of treatment, pooled center and salpingo-oophorectomy strata.</method_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O2</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.4944</p_value>
            <method>ANOVA</method>
            <method_desc>LS Means from ANOVA model with terms of treatment, pooled center and salpingo-oophorectomy strata.</method_desc>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Area Under the Curve (AUC) Pain - Pain With Movement Caused by Peak Expiratory Flow (PEF) Test</title>
        <description>Time-normalized AUC of pain reported by participants with movement caused by PEF test. Pain reported by participant on 11 point Likert scale 0 (no pain) to 10 (worst pain). PEF test performed 3 times, with 120sec rest periods in between. At beginning of each rest period, participant asked to rate pain caused by forced expiration. LS Means adjusted for treatment, pooled center and salpingo-oophorectomy strata.</description>
        <time_frame>48 +/- 4 hours PS</time_frame>
        <population>mITT; N=number of evaluable participants analyzed</population>
        <group_list>
          <group group_id="O1">
            <title>Pregabalin 150mg</title>
            <description>Pregabalin 75 mg twice a day (150 mg/day total)</description>
          </group>
          <group group_id="O2">
            <title>Pregabalin 300 mg</title>
            <description>Pregabalin 150 mg twice a day (300 mg/day total)</description>
          </group>
          <group group_id="O3">
            <title>Placebo</title>
            <description>Matching placebo capsule</description>
          </group>
        </group_list>
        <measure>
          <title>Area Under the Curve (AUC) Pain - Pain With Movement Caused by Peak Expiratory Flow (PEF) Test</title>
          <description>Time-normalized AUC of pain reported by participants with movement caused by PEF test. Pain reported by participant on 11 point Likert scale 0 (no pain) to 10 (worst pain). PEF test performed 3 times, with 120sec rest periods in between. At beginning of each rest period, participant asked to rate pain caused by forced expiration. LS Means adjusted for treatment, pooled center and salpingo-oophorectomy strata.</description>
          <population>mITT; N=number of evaluable participants analyzed</population>
          <units>Units on a scale</units>
          <param>Least Squares Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="148"/>
                <count group_id="O2" value="142"/>
                <count group_id="O3" value="146"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="4.45" spread="0.167"/>
                    <measurement group_id="O2" value="4.64" spread="0.174"/>
                    <measurement group_id="O3" value="4.61" spread="0.173"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.4801</p_value>
            <method>ANOVA</method>
            <method_desc>LS Means from ANOVA model with terms of treatment, pooled center and salpingo-oophorectomy strata.</method_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O2</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.8832</p_value>
            <method>ANOVA</method>
            <method_desc>LS Means from ANOVA model with terms of treatment, pooled center and salpingo-oophorectomy strata.</method_desc>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Current Pain at Rest</title>
        <description>Pain reported by participants at rest (numeric rating scale (NRS)  Current Pain) on an 11 point Likert scale 0 (no pain) - 10 (worst pain). Pain at rest during the hospital stay was assessed just before each Pain with Movement assessment. Assessment performed 3 times each day of hospital stay, with 1 of daily assessments at 24 (+/- 2 ) hour intervals from end of surgery. LS Means adjusted for treatment, pooled center and salpingo-oophorectomy strata.</description>
        <time_frame>8, 16, 24, 32, 40, 48 hours PS</time_frame>
        <population>mITT; n = number of evaluable participants analyzed for the given time point; N=number of evaluable participants analyzed</population>
        <group_list>
          <group group_id="O1">
            <title>Pregabalin 150mg</title>
            <description>Pregabalin 75 mg twice a day (150 mg/day total)</description>
          </group>
          <group group_id="O2">
            <title>Pregabalin 300 mg</title>
            <description>Pregabalin 150 mg twice a day (300 mg/day total)</description>
          </group>
          <group group_id="O3">
            <title>Placebo</title>
            <description>Matching placebo capsule</description>
          </group>
        </group_list>
        <measure>
          <title>Current Pain at Rest</title>
          <description>Pain reported by participants at rest (numeric rating scale (NRS)  Current Pain) on an 11 point Likert scale 0 (no pain) - 10 (worst pain). Pain at rest during the hospital stay was assessed just before each Pain with Movement assessment. Assessment performed 3 times each day of hospital stay, with 1 of daily assessments at 24 (+/- 2 ) hour intervals from end of surgery. LS Means adjusted for treatment, pooled center and salpingo-oophorectomy strata.</description>
          <population>mITT; n = number of evaluable participants analyzed for the given time point; N=number of evaluable participants analyzed</population>
          <units>Units on a scale</units>
          <param>Least Squares Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="151"/>
                <count group_id="O2" value="147"/>
                <count group_id="O3" value="154"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>8 Hours PS (n=123, 125, 126)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="5.13" spread="0.232"/>
                    <measurement group_id="O2" value="5.39" spread="0.231"/>
                    <measurement group_id="O3" value="5.47" spread="0.225"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>16 Hours PS (n=94, 88, 107)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="4.06" spread="0.256"/>
                    <measurement group_id="O2" value="4.55" spread="0.273"/>
                    <measurement group_id="O3" value="4.30" spread="0.245"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>24 Hours PS (n=151, 147, 154)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3.79" spread="0.179"/>
                    <measurement group_id="O2" value="3.76" spread="0.184"/>
                    <measurement group_id="O3" value="3.93" spread="0.180"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>32 Hours PS (n=127, 127, 136)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3.37" spread="0.207"/>
                    <measurement group_id="O2" value="3.31" spread="0.212"/>
                    <measurement group_id="O3" value="3.55" spread="0.204"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>40 Hours PS (n=93, 97, 100)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2.97" spread="0.265"/>
                    <measurement group_id="O2" value="2.71" spread="0.265"/>
                    <measurement group_id="O3" value="2.98" spread="0.263"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>48 Hours PS (n=142, 143, 140)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2.60" spread="0.173"/>
                    <measurement group_id="O2" value="2.26" spread="0.174"/>
                    <measurement group_id="O3" value="2.65" spread="0.179"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <groups_desc>8 Hours PS</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.2125</p_value>
            <method>ANOVA</method>
            <method_desc>LS Means from ANOVA model with terms of treatment, pooled center and salpingo-oophorectomy strata.</method_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O2</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <groups_desc>8 Hour PS</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.7602</p_value>
            <method>ANOVA</method>
            <method_desc>LS Means from ANOVA model with terms of treatment, pooled center and salpingo-oophorectomy strata.</method_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <groups_desc>16 Hours PS</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.4053</p_value>
            <method>ANOVA</method>
            <method_desc>LS Means from ANOVA model with terms of treatment, pooled center and salpingo-oophorectomy strata.</method_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O2</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <groups_desc>16 Hours PS</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.4147</p_value>
            <method>ANOVA</method>
            <method_desc>LS Means from ANOVA model with terms of treatment, pooled center and salpingo-oophorectomy strata.</method_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <groups_desc>24 Hours PS</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.5556</p_value>
            <method>ANOVA</method>
            <method_desc>LS Means from ANOVA model with terms of treatment, pooled center and salpingo-oophorectomy strata.</method_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O2</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <groups_desc>24 Hours PS</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.4820</p_value>
            <method>ANOVA</method>
            <method_desc>LS Means from ANOVA model with terms of treatment, pooled center and salpingo-oophorectomy strata.</method_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <groups_desc>32 Hours PS</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.5088</p_value>
            <method>ANOVA</method>
            <method_desc>LS Means from ANOVA model with terms of treatment, pooled center and salpingo-oophorectomy strata.</method_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O2</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <groups_desc>32 Hours PS</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.3900</p_value>
            <method>ANOVA</method>
            <method_desc>LS Means from ANOVA model with terms of treatment, pooled center and salpingo-oophorectomy strata.</method_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <groups_desc>40 Hours PS</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.9659</p_value>
            <method>ANOVA</method>
            <method_desc>LS Means from ANOVA model with terms of treatment, pooled center and salpingo-oophorectomy strata.</method_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O2</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <groups_desc>40 Hours PS</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.3968</p_value>
            <method>ANOVA</method>
            <method_desc>LS Means from ANOVA model with terms of treatment, pooled center and salpingo-oophorectomy strata.</method_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <groups_desc>48 Hours PS</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.8308</p_value>
            <method>ANOVA</method>
            <method_desc>LS Means from ANOVA model with terms of treatment, pooled center and salpingo-oophorectomy strata.</method_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O2</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <groups_desc>48 Hours PS</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.0902</p_value>
            <method>ANOVA</method>
            <method_desc>LS Means from ANOVA model with terms of treatment, pooled center and salpingo-oophorectomy strata.</method_desc>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Area Under the Curve (AUC) of Pain at Rest During the First Two Days of Hospital Stay</title>
        <description>Time-normalized AUC of pain reported by participants on 11 point Likert scale 0 (no pain) to 10 (worst pain). LS Means adjusted for treatment, pooled center and salpingo-oophorectomy strata.</description>
        <time_frame>48 +/- 4 hours PS</time_frame>
        <population>mITT; N=number of evaluable participants analyzed</population>
        <group_list>
          <group group_id="O1">
            <title>Pregabalin 150mg</title>
            <description>Pregabalin 75 mg twice a day (150 mg/day total)</description>
          </group>
          <group group_id="O2">
            <title>Pregabalin 300 mg</title>
            <description>Pregabalin 150 mg twice a day (300 mg/day total)</description>
          </group>
          <group group_id="O3">
            <title>Placebo</title>
            <description>Matching placebo capsule</description>
          </group>
        </group_list>
        <measure>
          <title>Area Under the Curve (AUC) of Pain at Rest During the First Two Days of Hospital Stay</title>
          <description>Time-normalized AUC of pain reported by participants on 11 point Likert scale 0 (no pain) to 10 (worst pain). LS Means adjusted for treatment, pooled center and salpingo-oophorectomy strata.</description>
          <population>mITT; N=number of evaluable participants analyzed</population>
          <units>Units on a scale</units>
          <param>Least Squares Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="151"/>
                <count group_id="O2" value="147"/>
                <count group_id="O3" value="154"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3.62" spread="0.143"/>
                    <measurement group_id="O2" value="3.58" spread="0.147"/>
                    <measurement group_id="O3" value="3.76" spread="0.144"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.4388</p_value>
            <method>ANOVA</method>
            <method_desc>LS Means from ANOVA model with terms of treatment, pooled center and salpingo-oophorectomy strata.</method_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O2</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.3364</p_value>
            <method>ANOVA</method>
            <method_desc>LS Means from ANOVA model with terms of treatment, pooled center and salpingo-oophorectomy strata.</method_desc>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Total Cumulative Dose of Opioids Following Surgery</title>
        <description>Total cumulative dose was calculated as milligram (mg) of morphine equivalent and included opioids administered by any route. LS Means adjusted for treatment, pooled center and salpingo-oophorectomy strata.</description>
        <time_frame>24, 48 Hours PS, Discharge (day 3 up to day 7 PS)</time_frame>
        <population>mITT; n = number of evaluable participants analyzed for the given time point; N=number of evaluable participants analyzed</population>
        <group_list>
          <group group_id="O1">
            <title>Pregabalin 150mg</title>
            <description>Pregabalin 75 mg twice a day (150 mg/day total)</description>
          </group>
          <group group_id="O2">
            <title>Pregabalin 300 mg</title>
            <description>Pregabalin 150 mg twice a day (300 mg/day total)</description>
          </group>
          <group group_id="O3">
            <title>Placebo</title>
            <description>Matching placebo capsule</description>
          </group>
        </group_list>
        <measure>
          <title>Total Cumulative Dose of Opioids Following Surgery</title>
          <description>Total cumulative dose was calculated as milligram (mg) of morphine equivalent and included opioids administered by any route. LS Means adjusted for treatment, pooled center and salpingo-oophorectomy strata.</description>
          <population>mITT; n = number of evaluable participants analyzed for the given time point; N=number of evaluable participants analyzed</population>
          <units>milligram (mg)</units>
          <param>Least Squares Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="150"/>
                <count group_id="O2" value="147"/>
                <count group_id="O3" value="153"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>24 hours PS (n=150, 147, 153)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="113.38" spread="7.078"/>
                    <measurement group_id="O2" value="111.27" spread="7.211"/>
                    <measurement group_id="O3" value="124.44" spread="7.160"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>48 hours PS (n=150, 147, 151)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="148.67" spread="9.218"/>
                    <measurement group_id="O2" value="144.95" spread="9.391"/>
                    <measurement group_id="O3" value="168.31" spread="9.372"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Till Discharge (n=147, 143, 144)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="164.28" spread="11.161"/>
                    <measurement group_id="O2" value="167.01" spread="11.410"/>
                    <measurement group_id="O3" value="195.32" spread="11.569"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <groups_desc>24 hours PS</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.2409</p_value>
            <method>ANOVA</method>
            <method_desc>LS Means from ANOVA model with terms of treatment, pooled center and salpingo-oophorectomy strata.</method_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O2</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <groups_desc>24 hours PS</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.1654</p_value>
            <method>ANOVA</method>
            <method_desc>LS Means from ANOVA model with terms of treatment, pooled center and salpingo-oophorectomy strata.</method_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <groups_desc>48 hours PS</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.1110</p_value>
            <method>ANOVA</method>
            <method_desc>LS Means from ANOVA model with terms of treatment, pooled center and salpingo-oophorectomy strata.</method_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O2</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <groups_desc>48 hours PS</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.0598</p_value>
            <method>ANOVA</method>
            <method_desc>LS Means from ANOVA model with terms of treatment, pooled center and salpingo-oophorectomy strata.</method_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <groups_desc>Till Discharge</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.0398</p_value>
            <method>ANOVA</method>
            <method_desc>LS Means from ANOVA model with terms of treatment, pooled center and salpingo-oophorectomy strata.</method_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O2</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <groups_desc>Till Discharge</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.0623</p_value>
            <method>ANOVA</method>
            <method_desc>LS Means from ANOVA model with terms of treatment, pooled center and salpingo-oophorectomy strata.</method_desc>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Integrated Analgesic Score</title>
        <description>The integrated analgesic score (a combination of opioid use and either worst pain, or pain at rest, or pain caused by sitting, or pain caused by forced expiration as defined by Silverman et al 1993) was the sum of percent differences from mean rank for pain and opioids and ranged from -200 to 200 where lower values represent improvement. LS Means adjusted for treatment, pooled center and salpingo-oophorectomy strata.</description>
        <time_frame>0-24, 24-48, 48-72 hours PS</time_frame>
        <population>mITT; n = number of evaluable participants analyzed for the given time point; N=number of evaluable participants analyzed</population>
        <group_list>
          <group group_id="O1">
            <title>Pregabalin 150mg</title>
            <description>Pregabalin 75 mg twice a day (150 mg/day total)</description>
          </group>
          <group group_id="O2">
            <title>Pregabalin 300 mg</title>
            <description>Pregabalin 150 mg twice a day (300 mg/day total)</description>
          </group>
          <group group_id="O3">
            <title>Placebo</title>
            <description>Matching placebo capsule</description>
          </group>
        </group_list>
        <measure>
          <title>Integrated Analgesic Score</title>
          <description>The integrated analgesic score (a combination of opioid use and either worst pain, or pain at rest, or pain caused by sitting, or pain caused by forced expiration as defined by Silverman et al 1993) was the sum of percent differences from mean rank for pain and opioids and ranged from -200 to 200 where lower values represent improvement. LS Means adjusted for treatment, pooled center and salpingo-oophorectomy strata.</description>
          <population>mITT; n = number of evaluable participants analyzed for the given time point; N=number of evaluable participants analyzed</population>
          <units>Units on a scale</units>
          <param>Least Squares Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="150"/>
                <count group_id="O2" value="145"/>
                <count group_id="O3" value="151"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>0-24 Hours PS (n=150, 145, 151)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-6.58" spread="6.795"/>
                    <measurement group_id="O2" value="-11.66" spread="6.991"/>
                    <measurement group_id="O3" value="3.36" spread="6.906"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>24-48 Hours PS (n=141, 142, 139)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-5.51" spread="6.979"/>
                    <measurement group_id="O2" value="-18.84" spread="7.051"/>
                    <measurement group_id="O3" value="5.48" spread="7.210"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>48-72 Hours PS (n=81, 89, 74)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3.23" spread="9.884"/>
                    <measurement group_id="O2" value="-6.93" spread="9.271"/>
                    <measurement group_id="O3" value="19.85" spread="10.568"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <groups_desc>0-24 Hours PS</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.2730</p_value>
            <method>ANOVA</method>
            <method_desc>LS Means from ANOVA model with terms of treatment, pooled center and salpingo-oophorectomy strata.</method_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O2</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <groups_desc>0-24 Hours PS</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.1015</p_value>
            <method>ANOVA</method>
            <method_desc>LS Means from ANOVA model with terms of treatment, pooled center and salpingo-oophorectomy strata.</method_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <groups_desc>24-48 Hours PS</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.2438</p_value>
            <method>ANOVA</method>
            <method_desc>LS Means from ANOVA model with terms of treatment, pooled center and salpingo-oophorectomy strata.</method_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O2</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <groups_desc>24-48 Hours PS</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.0102</p_value>
            <method>ANOVA</method>
            <method_desc>LS Means from ANOVA model with terms of treatment, pooled center and salpingo-oophorectomy strata.</method_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <groups_desc>48-72 Hours PS</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.2063</p_value>
            <method>ANOVA</method>
            <method_desc>LS Means from ANOVA model with terms of treatment, pooled center and salpingo-oophorectomy strata.</method_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O2</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <groups_desc>48-72 Hours PS</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.0387</p_value>
            <method>ANOVA</method>
            <method_desc>LS Means from ANOVA model with terms of treatment, pooled center and salpingo-oophorectomy strata.</method_desc>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Non-opioid Rescue Medication - Paracetamol</title>
        <description>The amounts of non-opioid rescue medications, paracetamol, used by the participants during the study, including anti-emetic medications.</description>
        <time_frame>24, 48, 72 hours PS, Discharge (day 3 up to day 7 PS), Week 1, 2, 3, 4 PS,</time_frame>
        <population>mITT; n = number of evaluable participants analyzed for the given time point; N=number of evaluable participants analyzed</population>
        <group_list>
          <group group_id="O1">
            <title>Pregabalin 150mg</title>
            <description>Pregabalin 75 mg twice a day (150 mg/day total)</description>
          </group>
          <group group_id="O2">
            <title>Pregabalin 300 mg</title>
            <description>Pregabalin 150 mg twice a day (300 mg/day total)</description>
          </group>
          <group group_id="O3">
            <title>Placebo</title>
            <description>Matching placebo capsule</description>
          </group>
        </group_list>
        <measure>
          <title>Non-opioid Rescue Medication - Paracetamol</title>
          <description>The amounts of non-opioid rescue medications, paracetamol, used by the participants during the study, including anti-emetic medications.</description>
          <population>mITT; n = number of evaluable participants analyzed for the given time point; N=number of evaluable participants analyzed</population>
          <units>Grams (g)</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="150"/>
                <count group_id="O2" value="147"/>
                <count group_id="O3" value="155"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>24 Hours PS (n=150, 147, 155)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.16" spread="0.098"/>
                    <measurement group_id="O2" value="1.21" spread="0.100"/>
                    <measurement group_id="O3" value="1.22" spread="0.098"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>48 Hours PS (n=150, 147, 154)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3.23" spread="0.195"/>
                    <measurement group_id="O2" value="3.20" spread="0.199"/>
                    <measurement group_id="O3" value="3.55" spread="0.195"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>72 Hours PS (n=150, 147,149)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="5.07" spread="0.294"/>
                    <measurement group_id="O2" value="5.08" spread="0.300"/>
                    <measurement group_id="O3" value="5.68" spread="0.301"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>1st Week PS (n=142, 142, 145)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="10.76" spread="0.732"/>
                    <measurement group_id="O2" value="10.57" spread="0.739"/>
                    <measurement group_id="O3" value="12.63" spread="0.740"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>2nd Week PS (n=139, 135, 143)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="17.89" spread="1.711"/>
                    <measurement group_id="O2" value="16.79" spread="1.747"/>
                    <measurement group_id="O3" value="19.70" spread="1.731"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>3rd Week PS (n=131, 124, 134)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="23.56" spread="2.654"/>
                    <measurement group_id="O2" value="22.12" spread="2.748"/>
                    <measurement group_id="O3" value="24.35" spread="2.695"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>4th Week PS (n=95, 94, 103)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="27.10" spread="3.313"/>
                    <measurement group_id="O2" value="25.62" spread="3.437"/>
                    <measurement group_id="O3" value="25.63" spread="3.301"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Till Discharge (n=147, 143, 147)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="5.45" spread="0.390"/>
                    <measurement group_id="O2" value="5.78" spread="0.399"/>
                    <measurement group_id="O3" value="6.05" spread="0.399"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <groups_desc>24 hours PS</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.5995</p_value>
            <method>ANOVA</method>
            <method_desc>LS Means from ANOVA model with terms of treatment, pooled center and salpingo-oophorectomy strata.</method_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O2</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <groups_desc>24 Hours PS</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.9104</p_value>
            <method>ANOVA</method>
            <method_desc>LS Means from ANOVA model with terms of treatment, pooled center and salpingo-oophorectomy strata.</method_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <groups_desc>48 Hours PS</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.2177</p_value>
            <method>ANOVA</method>
            <method_desc>LS Means from ANOVA model with terms of treatment, pooled center and salpingo-oophorectomy strata.</method_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O2</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <groups_desc>48 hours PS</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.1770</p_value>
            <method>ANOVA</method>
            <method_desc>LS Means from ANOVA model with terms of treatment, pooled center and salpingo-oophorectomy strata.</method_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <groups_desc>72 hours PS</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.1229</p_value>
            <method>ANOVA</method>
            <method_desc>LS Means from ANOVA model with terms of treatment, pooled center and salpingo-oophorectomy strata.</method_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O2</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <groups_desc>72 hours PS</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.1274</p_value>
            <method>ANOVA</method>
            <method_desc>LS Means from ANOVA model with terms of treatment, pooled center and salpingo-oophorectomy strata.</method_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <groups_desc>1st Week PS</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.0568</p_value>
            <method>ANOVA</method>
            <method_desc>LS Means from ANOVA model with terms of treatment, pooled center and salpingo-oophorectomy strata.</method_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O2</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <groups_desc>1st Week PS</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.0354</p_value>
            <method>ANOVA</method>
            <method_desc>LS Means from ANOVA model with terms of treatment, pooled center and salpingo-oophorectomy strata.</method_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <groups_desc>2nd Week PS</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.4269</p_value>
            <method>ANOVA</method>
            <method_desc>LS Means from ANOVA model with terms of treatment, pooled center and salpingo-oophorectomy strata.</method_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O2</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <groups_desc>2nd Week PS</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.2058</p_value>
            <method>ANOVA</method>
            <method_desc>LS Means from ANOVA model with terms of treatment, pooled center and salpingo-oophorectomy strata.</method_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <groups_desc>3rd Week PS</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.8215</p_value>
            <method>ANOVA</method>
            <method_desc>LS Means from ANOVA model with terms of treatment, pooled center and salpingo-oophorectomy strata.</method_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O2</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <groups_desc>3rd Week PS</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.5331</p_value>
            <method>ANOVA</method>
            <method_desc>LS Means from ANOVA model with terms of treatment, pooled center and salpingo-oophorectomy strata.</method_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <groups_desc>4th Week PS</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.7365</p_value>
            <method>ANOVA</method>
            <method_desc>LS Means from ANOVA model with terms of treatment, pooled center and salpingo-oophorectomy strata.</method_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O2</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <groups_desc>4th Week PS</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.9989</p_value>
            <method>ANOVA</method>
            <method_desc>LS Means from ANOVA model with terms of treatment, pooled center and salpingo-oophorectomy strata.</method_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <groups_desc>Till Discharge</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.2501</p_value>
            <method>ANOVA</method>
            <method_desc>LS Means from ANOVA model with terms of treatment, pooled center and salpingo-oophorectomy strata.</method_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O2</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <groups_desc>Till Discharge</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.6021</p_value>
            <method>ANOVA</method>
            <method_desc>LS Means from ANOVA model with terms of treatment, pooled center and salpingo-oophorectomy strata.</method_desc>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Anxiety Before and After Surgery</title>
        <description>Participant anxiety reported on Visual Anxiety Scale (VAS), 0 (not at all anxious) to 100 (extremely anxious). LS Means adjusted for treatment, pooled center and salpingo-oophorectomy strata</description>
        <time_frame>Surgery day before first dose and 1 hour after first dose, Day 1, 2, 3, 4, 5 PS and Discharge (day 3 up to day 7 PS)</time_frame>
        <population>mITT; n = number of evaluable participants analyzed for the given time point; N=number of evaluable participants analyzed</population>
        <group_list>
          <group group_id="O1">
            <title>Pregabalin 150mg</title>
            <description>Pregabalin 75 mg twice a day (150 mg/day total)</description>
          </group>
          <group group_id="O2">
            <title>Pregabalin 300 mg</title>
            <description>Pregabalin 150 mg twice a day (300 mg/day total)</description>
          </group>
          <group group_id="O3">
            <title>Placebo</title>
            <description>Matching placebo capsule</description>
          </group>
        </group_list>
        <measure>
          <title>Anxiety Before and After Surgery</title>
          <description>Participant anxiety reported on Visual Anxiety Scale (VAS), 0 (not at all anxious) to 100 (extremely anxious). LS Means adjusted for treatment, pooled center and salpingo-oophorectomy strata</description>
          <population>mITT; n = number of evaluable participants analyzed for the given time point; N=number of evaluable participants analyzed</population>
          <units>Units on a scale</units>
          <param>Least Squares Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="150"/>
                <count group_id="O2" value="149"/>
                <count group_id="O3" value="154"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Surgery Day (prior to first dose)(n=149, 144, 151)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="31.9" spread="2.38"/>
                    <measurement group_id="O2" value="28.4" spread="2.45"/>
                    <measurement group_id="O3" value="33.3" spread="2.40"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Surgery Day (1 hour after dosing)(n=138, 139, 146)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="29.5" spread="2.39"/>
                    <measurement group_id="O2" value="29.7" spread="2.39"/>
                    <measurement group_id="O3" value="30.9" spread="2.38"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 1 PS (n=150, 149, 154)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="15.6" spread="1.75"/>
                    <measurement group_id="O2" value="16.1" spread="1.78"/>
                    <measurement group_id="O3" value="18.6" spread="1.77"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 2 PS (n=112, 120, 118)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="12.6" spread="2.05"/>
                    <measurement group_id="O2" value="13.4" spread="1.98"/>
                    <measurement group_id="O3" value="13.8" spread="2.03"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 3 PS (n=44, 40, 35)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="17.2" spread="3.17"/>
                    <measurement group_id="O2" value="11.2" spread="2.93"/>
                    <measurement group_id="O3" value="13.9" spread="3.20"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 4 PS (n=17, 20, 15)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="9.0" spread="3.22"/>
                    <measurement group_id="O2" value="4.2" spread="2.72"/>
                    <measurement group_id="O3" value="9.3" spread="3.51"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 5 PS (n=7, 13, 7)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="11.6" spread="8.31"/>
                    <measurement group_id="O2" value="4.5" spread="5.39"/>
                    <measurement group_id="O3" value="15.1" spread="8.46"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Discharge (n=143, 144, 148)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="10.2" spread="1.50"/>
                    <measurement group_id="O2" value="8.3" spread="1.50"/>
                    <measurement group_id="O3" value="8.8" spread="1.50"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <groups_desc>Surgery day (prior to first dose)</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.6613</p_value>
            <method>ANOVA</method>
            <method_desc>LS Means from ANOVA model with terms of treatment, pooled center and salpingo-oophorectomy strata.</method_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O2</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <groups_desc>Surgery day (prior to first dose)</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.1311</p_value>
            <method>ANOVA</method>
            <method_desc>LS Means from ANOVA model with terms of treatment, pooled center and salpingo-oophorectomy strata.</method_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <groups_desc>Surgery day (1 hour after dosing)</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.6574</p_value>
            <method>ANOVA</method>
            <method_desc>LS Means from ANOVA model with terms of treatment, pooled center and salpingo-oophorectomy strata.</method_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O2</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <groups_desc>Surgery day (1 hour after dosing)</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.6949</p_value>
            <method>ANOVA</method>
            <method_desc>LS Means from ANOVA model with terms of treatment, pooled center and salpingo-oophorectomy strata.</method_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <groups_desc>Day 1 PS</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.2008</p_value>
            <method>ANOVA</method>
            <method_desc>LS Means from ANOVA model with terms of treatment, pooled center and salpingo-oophorectomy strata.</method_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O2</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <groups_desc>Day 1 PS</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.3022</p_value>
            <method>ANOVA</method>
            <method_desc>LS Means from ANOVA model with terms of treatment, pooled center and salpingo-oophorectomy strata.</method_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <groups_desc>Day 2 PS</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.6382</p_value>
            <method>ANOVA</method>
            <method_desc>LS Means from ANOVA model with terms of treatment, pooled center and salpingo-oophorectomy strata.</method_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O2</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <groups_desc>Day 2 PS</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.8624</p_value>
            <method>ANOVA</method>
            <method_desc>LS Means from ANOVA model with terms of treatment, pooled center and salpingo-oophorectomy strata.</method_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <groups_desc>Day 3 PS</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.3858</p_value>
            <method>ANOVA</method>
            <method_desc>LS Means from ANOVA model with terms of treatment, pooled center and salpingo-oophorectomy strata.</method_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O2</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <groups_desc>Day 3 PS</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.4814</p_value>
            <method>ANOVA</method>
            <method_desc>LS Means from ANOVA model with terms of treatment, pooled center and salpingo-oophorectomy strata.</method_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <groups_desc>Day 4 PS</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.9520</p_value>
            <method>ANOVA</method>
            <method_desc>LS Means from ANOVA model with terms of treatment, pooled center and salpingo-oophorectomy strata.</method_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O2</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <groups_desc>Day 4 PS</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.2315</p_value>
            <method>ANOVA</method>
            <method_desc>LS Means from ANOVA model with terms of treatment, pooled center and salpingo-oophorectomy strata.</method_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <groups_desc>Day 5 PS</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.7061</p_value>
            <method>ANOVA</method>
            <method_desc>LS Means from ANOVA model with terms of treatment, pooled center and salpingo-oophorectomy strata.</method_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O2</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <groups_desc>Day 5 PS</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.2908</p_value>
            <method>ANOVA</method>
            <method_desc>LS Means from ANOVA model with terms of treatment, pooled center and salpingo-oophorectomy strata.</method_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <groups_desc>Discharge</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.4782</p_value>
            <method>ANOVA</method>
            <method_desc>LS Means from ANOVA model with terms of treatment, pooled center and salpingo-oophorectomy strata.</method_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O2</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <groups_desc>Discharge</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.8130</p_value>
            <method>ANOVA</method>
            <method_desc>LS Means from ANOVA model with terms of treatment, pooled center and salpingo-oophorectomy strata.</method_desc>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Non-opioid Rescue Medication - Ibuprofen</title>
        <description>The amounts of non-opioid rescue medications, ibuprofen, used by the participants during the study, including anti-emetic medications.</description>
        <time_frame>24, 48, 72 hours PS, Discharge (day 3 up to day 7 PS), Week 1, 2, 3, 4 PS</time_frame>
        <population>mITT; n = number of evaluable participants analyzed for the given time point; N=number of evaluable participants analyzed</population>
        <group_list>
          <group group_id="O1">
            <title>Pregabalin 150mg</title>
            <description>Pregabalin 75 mg twice a day (150 mg/day total)</description>
          </group>
          <group group_id="O2">
            <title>Pregabalin 300 mg</title>
            <description>Pregabalin 150 mg twice a day (300 mg/day total)</description>
          </group>
          <group group_id="O3">
            <title>Placebo</title>
            <description>Matching placebo capsule</description>
          </group>
        </group_list>
        <measure>
          <title>Non-opioid Rescue Medication - Ibuprofen</title>
          <description>The amounts of non-opioid rescue medications, ibuprofen, used by the participants during the study, including anti-emetic medications.</description>
          <population>mITT; n = number of evaluable participants analyzed for the given time point; N=number of evaluable participants analyzed</population>
          <units>Grams (g)</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="150"/>
                <count group_id="O2" value="147"/>
                <count group_id="O3" value="155"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>24 Hours PS (n=150, 147, 155)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.01" spread="0.014"/>
                    <measurement group_id="O2" value="0.03" spread="0.014"/>
                    <measurement group_id="O3" value="0.01" spread="0.014"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>48 Hours PS (n=150, 147, 154)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.08" spread="0.037"/>
                    <measurement group_id="O2" value="0.15" spread="0.038"/>
                    <measurement group_id="O3" value="0.12" spread="0.038"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>72 Hours PS (n=150, 147, 149)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.14" spread="0.064"/>
                    <measurement group_id="O2" value="0.27" spread="0.065"/>
                    <measurement group_id="O3" value="0.24" spread="0.066"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>1st Week PS (n=142, 142, 145)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.51" spread="0.208"/>
                    <measurement group_id="O2" value="0.87" spread="0.210"/>
                    <measurement group_id="O3" value="0.97" spread="0.211"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>2nd Week PS (n=140, 135, 143)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.22" spread="0.413"/>
                    <measurement group_id="O2" value="1.94" spread="0.423"/>
                    <measurement group_id="O3" value="1.88" spread="0.420"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>3rd Week PS (n=132, 124, 134)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.95" spread="0.665"/>
                    <measurement group_id="O2" value="2.99" spread="0.692"/>
                    <measurement group_id="O3" value="2.83" spread="0.679"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>4th Week PS (n=95, 94, 103)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2.42" spread="1.041"/>
                    <measurement group_id="O2" value="4.30" spread="1.080"/>
                    <measurement group_id="O3" value="3.84" spread="1.038"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Till Discharge (n=147, 143, 147)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.18" spread="0.074"/>
                    <measurement group_id="O2" value="0.38" spread="0.076"/>
                    <measurement group_id="O3" value="0.26" spread="0.076"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <groups_desc>24 hours PS</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.8940</p_value>
            <method>ANOVA</method>
            <method_desc>LS Means from ANOVA model with terms of treatment, pooled center and salpingo-oophorectomy strata.</method_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O2</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <groups_desc>24 hours PS</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.5938</p_value>
            <method>ANOVA</method>
            <method_desc>LS Means from ANOVA model with terms of treatment, pooled center and salpingo-oophorectomy strata.</method_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <groups_desc>48 hours PS</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.4306</p_value>
            <method>ANOVA</method>
            <method_desc>LS Means from ANOVA model with terms of treatment, pooled center and salpingo-oophorectomy strata.</method_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O2</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <groups_desc>48 hours PS</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.5899</p_value>
            <method>ANOVA</method>
            <method_desc>LS Means from ANOVA model with terms of treatment, pooled center and salpingo-oophorectomy strata.</method_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <groups_desc>72 hours PS</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.2209</p_value>
            <method>ANOVA</method>
            <method_desc>LS Means from ANOVA model with terms of treatment, pooled center and salpingo-oophorectomy strata.</method_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O2</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <groups_desc>72 hours PS</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.7145</p_value>
            <method>ANOVA</method>
            <method_desc>LS Means from ANOVA model with terms of treatment, pooled center and salpingo-oophorectomy strata.</method_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <groups_desc>1st Week PS</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.1022</p_value>
            <method>ANOVA</method>
            <method_desc>LS Means from ANOVA model with terms of treatment, pooled center and salpingo-oophorectomy strata.</method_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O2</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <groups_desc>1st Week PS</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.7243</p_value>
            <method>ANOVA</method>
            <method_desc>LS Means from ANOVA model with terms of treatment, pooled center and salpingo-oophorectomy strata.</method_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <groups_desc>2nd Week PS</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.2310</p_value>
            <method>ANOVA</method>
            <method_desc>LS Means from ANOVA model with terms of treatment, pooled center and salpingo-oophorectomy strata.</method_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O2</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <groups_desc>2nd Week PS</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.9192</p_value>
            <method>ANOVA</method>
            <method_desc>LS Means from ANOVA model with terms of treatment, pooled center and salpingo-oophorectomy strata.</method_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <groups_desc>3rd Week PS</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.3214</p_value>
            <method>ANOVA</method>
            <method_desc>LS Means from ANOVA model with terms of treatment, pooled center and salpingo-oophorectomy strata.</method_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O2</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <groups_desc>3rd Week PS</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.8641</p_value>
            <method>ANOVA</method>
            <method_desc>LS Means from ANOVA model with terms of treatment, pooled center and salpingo-oophorectomy strata.</method_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <groups_desc>4th Week PS</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.3024</p_value>
            <method>ANOVA</method>
            <method_desc>LS Means from ANOVA model with terms of treatment, pooled center and salpingo-oophorectomy strata.</method_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O2</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <groups_desc>4th Week PS</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.7359</p_value>
            <method>ANOVA</method>
            <method_desc>LS Means from ANOVA model with terms of treatment, pooled center and salpingo-oophorectomy strata.</method_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <groups_desc>Till Discharge</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.4303</p_value>
            <method>ANOVA</method>
            <method_desc>LS Means from ANOVA model with terms of treatment, pooled center and salpingo-oophorectomy strata.</method_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O2</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <groups_desc>Till Discharge</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.2133</p_value>
            <method>ANOVA</method>
            <method_desc>LS Means from ANOVA model with terms of treatment, pooled center and salpingo-oophorectomy strata.</method_desc>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Percent Change From Baseline in Peak Expiratory Flow</title>
        <description>Change from baseline= PEF at x hours minus PEF at baseline; possible values ranged from 0-900 liters/minute (higher values indicated better lung function). LS Means adjusted for treatment, pooled center and salpingo-oophorectomy strata.</description>
        <time_frame>Baseline, every 8 hours (up to 232 hours) PS, and Discharge (Day 3-7 PS flexible)</time_frame>
        <population>mITT; n = number of evaluable participants analyzed for the given time point; N=number of evaluable participants analyzed; Results presented for only those timepoints PS where at least 4 participants in each treatment arm completed the questionnaire at baseline and respective time point.</population>
        <group_list>
          <group group_id="O1">
            <title>Pregabalin 150mg</title>
            <description>Pregabalin 75 mg twice a day (150 mg/day total)</description>
          </group>
          <group group_id="O2">
            <title>Pregabalin 300 mg</title>
            <description>Pregabalin 150 mg twice a day (300 mg/day total)</description>
          </group>
          <group group_id="O3">
            <title>Placebo</title>
            <description>Matching placebo capsule</description>
          </group>
        </group_list>
        <measure>
          <title>Percent Change From Baseline in Peak Expiratory Flow</title>
          <description>Change from baseline= PEF at x hours minus PEF at baseline; possible values ranged from 0-900 liters/minute (higher values indicated better lung function). LS Means adjusted for treatment, pooled center and salpingo-oophorectomy strata.</description>
          <population>mITT; n = number of evaluable participants analyzed for the given time point; N=number of evaluable participants analyzed; Results presented for only those timepoints PS where at least 4 participants in each treatment arm completed the questionnaire at baseline and respective time point.</population>
          <units>L/min</units>
          <param>Least Squares Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="116"/>
                <count group_id="O2" value="114"/>
                <count group_id="O3" value="121"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Baseline (n=116, 114, 121)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0" spread="0"/>
                    <measurement group_id="O2" value="0" spread="0"/>
                    <measurement group_id="O3" value="0" spread="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>8 Hours PS (n=84, 79, 83)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-39.25" spread="3.081"/>
                    <measurement group_id="O2" value="-35.35" spread="3.307"/>
                    <measurement group_id="O3" value="-41.29" spread="3.242"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>16 Hours PS (n=72, 62, 76)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-37.37" spread="3.454"/>
                    <measurement group_id="O2" value="-36.49" spread="3.764"/>
                    <measurement group_id="O3" value="-36.48" spread="3.395"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>24 Hours PS (n=115, 112, 117)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-28.92" spread="3.084"/>
                    <measurement group_id="O2" value="-26.53" spread="3.212"/>
                    <measurement group_id="O3" value="-29.46" spread="3.058"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>32 Hours PS (n=104, 105, 106)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-24.53" spread="3.510"/>
                    <measurement group_id="O2" value="-25.66" spread="3.644"/>
                    <measurement group_id="O3" value="-28.92" spread="3.632"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>40 Hours PS (n=70, 73, 79)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-24.18" spread="3.575"/>
                    <measurement group_id="O2" value="-25.70" spread="3.663"/>
                    <measurement group_id="O3" value="-25.07" spread="3.449"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>48 Hours PS (n=108, 112, 111)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-16.71" spread="3.203"/>
                    <measurement group_id="O2" value="-13.62" spread="3.255"/>
                    <measurement group_id="O3" value="-21.70" spread="3.162"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>56 Hours PS (n=78, 85, 82)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-17.11" spread="3.760"/>
                    <measurement group_id="O2" value="-15.40" spread="3.771"/>
                    <measurement group_id="O3" value="-21.12" spread="3.726"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>64 Hours PS (n=52, 51, 54)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-15.04" spread="4.672"/>
                    <measurement group_id="O2" value="-14.20" spread="5.028"/>
                    <measurement group_id="O3" value="-17.18" spread="4.392"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>72 Hours PS (n=61, 68, 60)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-18.12" spread="5.270"/>
                    <measurement group_id="O2" value="-12.97" spread="4.792"/>
                    <measurement group_id="O3" value="-20.81" spread="5.059"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>80 Hours PS (n=30, 24, 24)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-17.23" spread="7.290"/>
                    <measurement group_id="O2" value="-3.01" spread="7.750"/>
                    <measurement group_id="O3" value="-8.17" spread="7.443"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>88 Hours PS (n=18, 15, 19)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-10.08" spread="8.257"/>
                    <measurement group_id="O2" value="-2.30" spread="8.818"/>
                    <measurement group_id="O3" value="-9.71" spread="6.636"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>96 Hours PS (n=20, 22, 21)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-1.45" spread="9.063"/>
                    <measurement group_id="O2" value="5.26" spread="8.585"/>
                    <measurement group_id="O3" value="2.36" spread="9.110"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>104 Hours PS (n=9, 12, 12)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-12.79" spread="10.574"/>
                    <measurement group_id="O2" value="0.69" spread="9.428"/>
                    <measurement group_id="O3" value="-4.94" spread="10.210"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>112 Hours PS (n=5, 10, 9)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-15.61" spread="15.629"/>
                    <measurement group_id="O2" value="8.49" spread="10.863"/>
                    <measurement group_id="O3" value="-11.61" spread="10.700"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>120 Hours PS (n=10, 12, 10)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-12.36" spread="11.386"/>
                    <measurement group_id="O2" value="-8.14" spread="10.307"/>
                    <measurement group_id="O3" value="-6.98" spread="12.201"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>128 Hours PS (n=4, 9, 7)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-6.72" spread="13.735"/>
                    <measurement group_id="O2" value="-4.76" spread="8.166"/>
                    <measurement group_id="O3" value="-14.32" spread="10.711"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <groups_desc>8 hours PS</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.5682</p_value>
            <method>ANOVA</method>
            <method_desc>LS Means from ANOVA model with terms of treatment, pooled center and salpingo-oophorectomy strata.</method_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O2</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <groups_desc>8 hours PS</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.1005</p_value>
            <method>ANOVA</method>
            <method_desc>LS Means from ANOVA model with terms of treatment, pooled center and salpingo-oophorectomy strata.</method_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <groups_desc>16 hours PS</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.8261</p_value>
            <method>ANOVA</method>
            <method_desc>LS Means from ANOVA model with terms of treatment, pooled center and salpingo-oophorectomy strata.</method_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O2</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <groups_desc>16 hours PS</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.9981</p_value>
            <method>ANOVA</method>
            <method_desc>LS Means from ANOVA model with terms of treatment, pooled center and salpingo-oophorectomy strata.</method_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <groups_desc>24 hours PS</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.8884</p_value>
            <method>ANOVA</method>
            <method_desc>LS Means from ANOVA model with terms of treatment, pooled center and salpingo-oophorectomy strata.</method_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O2</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <groups_desc>24 hours PS</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.4507</p_value>
            <method>ANOVA</method>
            <method_desc>LS Means from ANOVA model with terms of treatment, pooled center and salpingo-oophorectomy strata.</method_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <groups_desc>32 hours PS</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.2994</p_value>
            <method>ANOVA</method>
            <method_desc>LS Means from ANOVA model with terms of treatment, pooled center and salpingo-oophorectomy strata.</method_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O2</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <groups_desc>32 hours PS</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.4371</p_value>
            <method>ANOVA</method>
            <method_desc>LS Means from ANOVA model with terms of treatment, pooled center and salpingo-oophorectomy strata.</method_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <groups_desc>40 hours PS</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.8295</p_value>
            <method>ANOVA</method>
            <method_desc>LS Means from ANOVA model with terms of treatment, pooled center and salpingo-oophorectomy strata.</method_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O2</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <groups_desc>40 hours PS</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.8783</p_value>
            <method>ANOVA</method>
            <method_desc>LS Means from ANOVA model with terms of treatment, pooled center and salpingo-oophorectomy strata.</method_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <groups_desc>48 hours PS</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.2161</p_value>
            <method>ANOVA</method>
            <method_desc>LS Means from ANOVA model with terms of treatment, pooled center and salpingo-oophorectomy strata.</method_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O2</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <groups_desc>48 hours PS</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.0440</p_value>
            <method>ANOVA</method>
            <method_desc>LS Means from ANOVA model with terms of treatment, pooled center and salpingo-oophorectomy strata.</method_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <groups_desc>56 hours PS</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.3855</p_value>
            <method>ANOVA</method>
            <method_desc>LS Means from ANOVA model with terms of treatment, pooled center and salpingo-oophorectomy strata.</method_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O2</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <groups_desc>56 hours PS</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.2010</p_value>
            <method>ANOVA</method>
            <method_desc>LS Means from ANOVA model with terms of treatment, pooled center and salpingo-oophorectomy strata.</method_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <groups_desc>64 hours PS</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.7104</p_value>
            <method>ANOVA</method>
            <method_desc>LS Means from ANOVA model with terms of treatment, pooled center and salpingo-oophorectomy strata.</method_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O2</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <groups_desc>64 hours PS</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.6107</p_value>
            <method>ANOVA</method>
            <method_desc>LS Means from ANOVA model with terms of treatment, pooled center and salpingo-oophorectomy strata.</method_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <groups_desc>72 hours PS</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.6705</p_value>
            <method>ANOVA</method>
            <method_desc>LS Means from ANOVA model with terms of treatment, pooled center and salpingo-oophorectomy strata.</method_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O2</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <groups_desc>72 hours PS</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.2083</p_value>
            <method>ANOVA</method>
            <method_desc>LS Means from ANOVA model with terms of treatment, pooled center and salpingo-oophorectomy strata.</method_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <groups_desc>80 hours PS</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.3234</p_value>
            <method>ANOVA</method>
            <method_desc>LS Means from ANOVA model with terms of treatment, pooled center and salpingo-oophorectomy strata.</method_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O2</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <groups_desc>80 hours PS</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.5938</p_value>
            <method>ANOVA</method>
            <method_desc>LS Means from ANOVA model with terms of treatment, pooled center and salpingo-oophorectomy strata.</method_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <groups_desc>88 hours PS</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.9711</p_value>
            <method>ANOVA</method>
            <method_desc>LS Means from ANOVA model with terms of treatment, pooled center and salpingo-oophorectomy strata.</method_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O2</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <groups_desc>88 hours PS</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.4869</p_value>
            <method>ANOVA</method>
            <method_desc>LS Means from ANOVA model with terms of treatment, pooled center and salpingo-oophorectomy strata.</method_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <groups_desc>96 hours PS</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.7439</p_value>
            <method>ANOVA</method>
            <method_desc>LS Means from ANOVA model with terms of treatment, pooled center and salpingo-oophorectomy strata.</method_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O2</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <groups_desc>96 hours PS</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.8045</p_value>
            <method>ANOVA</method>
            <method_desc>LS Means from ANOVA model with terms of treatment, pooled center and salpingo-oophorectomy strata.</method_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <groups_desc>104 hours PS</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.5925</p_value>
            <method>ANOVA</method>
            <method_desc>LS Means from ANOVA model with terms of treatment, pooled center and salpingo-oophorectomy strata.</method_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O2</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <groups_desc>104 hours PS</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.6830</p_value>
            <method>ANOVA</method>
            <method_desc>LS Means from ANOVA model with terms of treatment, pooled center and salpingo-oophorectomy strata.</method_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <groups_desc>112 hours PS</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.8266</p_value>
            <method>ANOVA</method>
            <method_desc>LS Means from ANOVA model with terms of treatment, pooled center and salpingo-oophorectomy strata.</method_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O2</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <groups_desc>112 hours PS</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.1929</p_value>
            <method>ANOVA</method>
            <method_desc>LS Means from ANOVA model with terms of treatment, pooled center and salpingo-oophorectomy strata.</method_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <groups_desc>120 hours PS</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.7071</p_value>
            <method>ANOVA</method>
            <method_desc>LS Means from ANOVA model with terms of treatment, pooled center and salpingo-oophorectomy strata.</method_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O2</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <groups_desc>120 hours PS</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.9367</p_value>
            <method>ANOVA</method>
            <method_desc>LS Means from ANOVA model with terms of treatment, pooled center and salpingo-oophorectomy strata.</method_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <groups_desc>128 hours PS</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.6046</p_value>
            <method>ANOVA</method>
            <method_desc>LS Means from ANOVA model with terms of treatment, pooled center and salpingo-oophorectomy strata.</method_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O2</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <groups_desc>128 hours PS</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.5119</p_value>
            <method>ANOVA</method>
            <method_desc>LS Means from ANOVA model with terms of treatment, pooled center and salpingo-oophorectomy strata.</method_desc>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Timed Up-and-Go (TUG)</title>
        <description>Functional mobility test performed once a day at 24 hour intervals from surgery after the pain with movement assessment. LS Means adjusted for treatment, pooled center and salpingo-oophorectomy strata.</description>
        <time_frame>Day 1, 2, 3, 4, 5 PS and Discharge (day 3 up to day 7 PS)</time_frame>
        <population>mITT; n = number of evaluable participants analyzed for the given time point; N=number of evaluable participants analyzed</population>
        <group_list>
          <group group_id="O1">
            <title>Pregabalin 150mg</title>
            <description>Pregabalin 75 mg twice a day (150 mg/day total)</description>
          </group>
          <group group_id="O2">
            <title>Pregabalin 300 mg</title>
            <description>Pregabalin 150 mg twice a day (300 mg/day total)</description>
          </group>
          <group group_id="O3">
            <title>Placebo</title>
            <description>Matching placebo capsule</description>
          </group>
        </group_list>
        <measure>
          <title>Timed Up-and-Go (TUG)</title>
          <description>Functional mobility test performed once a day at 24 hour intervals from surgery after the pain with movement assessment. LS Means adjusted for treatment, pooled center and salpingo-oophorectomy strata.</description>
          <population>mITT; n = number of evaluable participants analyzed for the given time point; N=number of evaluable participants analyzed</population>
          <units>Seconds</units>
          <param>Least Squares Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="130"/>
                <count group_id="O2" value="134"/>
                <count group_id="O3" value="134"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Day 1 PS (n=85, 85, 93)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="39.77" spread="2.558"/>
                    <measurement group_id="O2" value="42.79" spread="2.769"/>
                    <measurement group_id="O3" value="38.54" spread="2.611"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 2 PS (n=107, 105, 105)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="31.82" spread="1.776"/>
                    <measurement group_id="O2" value="33.06" spread="1.878"/>
                    <measurement group_id="O3" value="29.25" spread="1.845"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 3 PS (n=43, 35, 31)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="34.07" spread="2.779"/>
                    <measurement group_id="O2" value="33.48" spread="2.781"/>
                    <measurement group_id="O3" value="31.38" spread="2.960"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 4 PS (n=16, 18, 13)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="42.26" spread="4.591"/>
                    <measurement group_id="O2" value="37.31" spread="4.065"/>
                    <measurement group_id="O3" value="40.43" spread="5.275"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 5 PS (n=7, 10, 7)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="31.27" spread="5.295"/>
                    <measurement group_id="O2" value="23.06" spread="3.704"/>
                    <measurement group_id="O3" value="32.18" spread="5.326"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Discharge (n=130, 134, 134)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="28.11" spread="1.604"/>
                    <measurement group_id="O2" value="30.05" spread="1.569"/>
                    <measurement group_id="O3" value="26.40" spread="1.582"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <groups_desc>Day 1 PS</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.6966</p_value>
            <method>ANOVA</method>
            <method_desc>LS Means from ANOVA model with terms of treatment, pooled center and salpingo-oophorectomy strata.</method_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O2</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <groups_desc>Day 1 PS</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.1808</p_value>
            <method>ANOVA</method>
            <method_desc>LS Means from ANOVA model with terms of treatment, pooled center and salpingo-oophorectomy strata.</method_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <groups_desc>Day 2 PS</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.2616</p_value>
            <method>ANOVA</method>
            <method_desc>LS Means from ANOVA model with terms of treatment, pooled center and salpingo-oophorectomy strata.</method_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O2</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <groups_desc>Day 2 PS</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.1014</p_value>
            <method>ANOVA</method>
            <method_desc>LS Means from ANOVA model with terms of treatment, pooled center and salpingo-oophorectomy strata.</method_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <groups_desc>Day 3 PS</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.4401</p_value>
            <method>ANOVA</method>
            <method_desc>LS Means from ANOVA model with terms of treatment, pooled center and salpingo-oophorectomy strata.</method_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O2</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <groups_desc>Day 3 PS</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.5615</p_value>
            <method>ANOVA</method>
            <method_desc>LS Means from ANOVA model with terms of treatment, pooled center and salpingo-oophorectomy strata.</method_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <groups_desc>Day 4 PS</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.7615</p_value>
            <method>ANOVA</method>
            <method_desc>LS Means from ANOVA model with terms of treatment, pooled center and salpingo-oophorectomy strata.</method_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O2</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <groups_desc>Day 4 PS</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.6204</p_value>
            <method>ANOVA</method>
            <method_desc>LS Means from ANOVA model with terms of treatment, pooled center and salpingo-oophorectomy strata.</method_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <groups_desc>Day 5 PS</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.8766</p_value>
            <method>ANOVA</method>
            <method_desc>LS Means from ANOVA model with terms of treatment, pooled center and salpingo-oophorectomy strata.</method_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O2</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <groups_desc>Day 5 PS</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.1717</p_value>
            <method>ANOVA</method>
            <method_desc>LS Means from ANOVA model with terms of treatment, pooled center and salpingo-oophorectomy strata.</method_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <groups_desc>Discharge</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.4065</p_value>
            <method>ANOVA</method>
            <method_desc>LS Means from ANOVA model with terms of treatment, pooled center and salpingo-oophorectomy strata.</method_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O2</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <groups_desc>Discharge</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.0746</p_value>
            <method>ANOVA</method>
            <method_desc>LS Means from ANOVA model with terms of treatment, pooled center and salpingo-oophorectomy strata.</method_desc>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Average Daily Pain</title>
        <description>Post-discharge average pain as measured in daily participant diaries NRS an 11 point Likert scale ranged from 0 (no pain) to 10 (worst pain). LS Means adjusted for treatment, pooled center and salpingo-oophorectomy strata.</description>
        <time_frame>Day 2, 3, 4, 5, 6, 7, PS; week 2, 3, 4 PS</time_frame>
        <population>mITT; n = number of evaluable participants analyzed for the given time point; N=number of evaluable participants analyzed</population>
        <group_list>
          <group group_id="O1">
            <title>Pregabalin 150mg</title>
            <description>Pregabalin 75 mg twice a day (150 mg/day total)</description>
          </group>
          <group group_id="O2">
            <title>Pregabalin 300 mg</title>
            <description>Pregabalin 150 mg twice a day (300 mg/day total)</description>
          </group>
          <group group_id="O3">
            <title>Placebo</title>
            <description>Matching placebo capsule</description>
          </group>
        </group_list>
        <measure>
          <title>Average Daily Pain</title>
          <description>Post-discharge average pain as measured in daily participant diaries NRS an 11 point Likert scale ranged from 0 (no pain) to 10 (worst pain). LS Means adjusted for treatment, pooled center and salpingo-oophorectomy strata.</description>
          <population>mITT; n = number of evaluable participants analyzed for the given time point; N=number of evaluable participants analyzed</population>
          <units>Units on a scale</units>
          <param>Least Squares Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="134"/>
                <count group_id="O2" value="131"/>
                <count group_id="O3" value="139"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Day 2 PS (n=29, 21, 25)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3.9" spread="0.48"/>
                    <measurement group_id="O2" value="4.3" spread="0.55"/>
                    <measurement group_id="O3" value="3.1" spread="0.59"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 3 PS (n=97, 94, 98)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3.0" spread="0.22"/>
                    <measurement group_id="O2" value="3.2" spread="0.23"/>
                    <measurement group_id="O3" value="2.8" spread="0.23"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 4 PS (n=126, 114, 125)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2.7" spread="0.19"/>
                    <measurement group_id="O2" value="2.9" spread="0.21"/>
                    <measurement group_id="O3" value="2.8" spread="0.20"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 5 PS (n=133, 117, 133)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2.5" spread="0.18"/>
                    <measurement group_id="O2" value="2.6" spread="0.20"/>
                    <measurement group_id="O3" value="2.6" spread="0.19"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 6 PS (n=133, 125, 138)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2.3" spread="0.18"/>
                    <measurement group_id="O2" value="2.5" spread="0.19"/>
                    <measurement group_id="O3" value="2.4" spread="0.18"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 7 PS (n=132, 130, 135)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2.1" spread="0.17"/>
                    <measurement group_id="O2" value="2.3" spread="0.17"/>
                    <measurement group_id="O3" value="2.2" spread="0.17"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>2nd Week PS (Average) (n=134, 131, 139)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.7" spread="0.14"/>
                    <measurement group_id="O2" value="2.0" spread="0.14"/>
                    <measurement group_id="O3" value="1.7" spread="0.14"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>3rd Week PS (Average) (n=114, 110, 114)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.3" spread="0.15"/>
                    <measurement group_id="O2" value="1.7" spread="0.15"/>
                    <measurement group_id="O3" value="1.3" spread="0.16"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>4th Week PS (Average) (n=87, 87, 82)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.2" spread="0.18"/>
                    <measurement group_id="O2" value="1.6" spread="0.19"/>
                    <measurement group_id="O3" value="1.2" spread="0.20"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <groups_desc>Day 2 PS</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.2201</p_value>
            <method>ANOVA</method>
            <method_desc>LS Means from ANOVA model with terms of treatment, pooled center and salpingo-oophorectomy strata.</method_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O2</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <groups_desc>Day 2 PS</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.0606</p_value>
            <method>ANOVA</method>
            <method_desc>LS Means from ANOVA model with terms of treatment, pooled center and salpingo-oophorectomy strata.</method_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <groups_desc>Day 3 PS</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.5303</p_value>
            <method>ANOVA</method>
            <method_desc>LS Means from ANOVA model with terms of treatment, pooled center and salpingo-oophorectomy strata.</method_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O2</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <groups_desc>Day 3 PS</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.2227</p_value>
            <method>ANOVA</method>
            <method_desc>LS Means from ANOVA model with terms of treatment, pooled center and salpingo-oophorectomy strata.</method_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <groups_desc>Day 4 PS</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.8237</p_value>
            <method>ANOVA</method>
            <method_desc>LS Means from ANOVA model with terms of treatment, pooled center and salpingo-oophorectomy strata.</method_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O2</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <groups_desc>Day 4 PS</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.7476</p_value>
            <method>ANOVA</method>
            <method_desc>LS Means from ANOVA model with terms of treatment, pooled center and salpingo-oophorectomy strata.</method_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <groups_desc>Day 5 PS</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.6882</p_value>
            <method>ANOVA</method>
            <method_desc>LS Means from ANOVA model with terms of treatment, pooled center and salpingo-oophorectomy strata.</method_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O2</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <groups_desc>Day 5 PS</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.9689</p_value>
            <method>ANOVA</method>
            <method_desc>LS Means from ANOVA model with terms of treatment, pooled center and salpingo-oophorectomy strata.</method_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <groups_desc>Day 6 PS</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.5010</p_value>
            <method>ANOVA</method>
            <method_desc>LS Means from ANOVA model with terms of treatment, pooled center and salpingo-oophorectomy strata.</method_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O2</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <groups_desc>Day 6 PS</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.9143</p_value>
            <method>ANOVA</method>
            <method_desc>LS Means from ANOVA model with terms of treatment, pooled center and salpingo-oophorectomy strata.</method_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <groups_desc>Day 7 PS</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.7381</p_value>
            <method>ANOVA</method>
            <method_desc>LS Means from ANOVA model with terms of treatment, pooled center and salpingo-oophorectomy strata.</method_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O2</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <groups_desc>Day 7 PS</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.5336</p_value>
            <method>ANOVA</method>
            <method_desc>LS Means from ANOVA model with terms of treatment, pooled center and salpingo-oophorectomy strata.</method_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <groups_desc>2nd Week PS (Average)</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.6479</p_value>
            <method>ANOVA</method>
            <method_desc>LS Means from ANOVA model with terms of treatment, pooled center and salpingo-oophorectomy strata.</method_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O2</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <groups_desc>2nd Week PS (Average)</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.1133</p_value>
            <method>ANOVA</method>
            <method_desc>LS Means from ANOVA model with terms of treatment, pooled center and salpingo-oophorectomy strata.</method_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <groups_desc>3rd Week PS (Average)</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.7637</p_value>
            <method>ANOVA</method>
            <method_desc>LS Means from ANOVA model with terms of treatment, pooled center and salpingo-oophorectomy strata.</method_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O2</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <groups_desc>3rd Week PS (Average)</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.1056</p_value>
            <method>ANOVA</method>
            <method_desc>LS Means from ANOVA model with terms of treatment, pooled center and salpingo-oophorectomy strata.</method_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <groups_desc>4th Week PS (Average)</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.8079</p_value>
            <method>ANOVA</method>
            <method_desc>LS Means from ANOVA model with terms of treatment, pooled center and salpingo-oophorectomy strata.</method_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O2</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <groups_desc>4th Week PS (Average)</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.0917</p_value>
            <method>ANOVA</method>
            <method_desc>LS Means from ANOVA model with terms of treatment, pooled center and salpingo-oophorectomy strata.</method_desc>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Worst Daily Pain</title>
        <description>Post-discharge worst pain as measured in daily participant diaries NRS an 11 point Likert scale that ranged from 0 (no pain) to 10 (pain as bad as you can imagine). LS Means from ANOVA model with terms of treatment, pooled center, salpingo-oophorectomy strata and baseline worst pain score.</description>
        <time_frame>Discharge (day 3 up to day 7 PS), Day 7, 14, 28 PS</time_frame>
        <population>mITT; n = number of evaluable participants analyzed for the given time point; N=number of evaluable participants analyzed</population>
        <group_list>
          <group group_id="O1">
            <title>Pregabalin 150mg</title>
            <description>Pregabalin 75 mg twice a day (150 mg/day total)</description>
          </group>
          <group group_id="O2">
            <title>Pregabalin 300 mg</title>
            <description>Pregabalin 150 mg twice a day (300 mg/day total)</description>
          </group>
          <group group_id="O3">
            <title>Placebo</title>
            <description>Matching placebo capsule</description>
          </group>
        </group_list>
        <measure>
          <title>Worst Daily Pain</title>
          <description>Post-discharge worst pain as measured in daily participant diaries NRS an 11 point Likert scale that ranged from 0 (no pain) to 10 (pain as bad as you can imagine). LS Means from ANOVA model with terms of treatment, pooled center, salpingo-oophorectomy strata and baseline worst pain score.</description>
          <population>mITT; n = number of evaluable participants analyzed for the given time point; N=number of evaluable participants analyzed</population>
          <units>Units on a scale</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="141"/>
                <count group_id="O2" value="143"/>
                <count group_id="O3" value="143"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Discharge (n=140, 143, 138)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="4.3" spread="0.22"/>
                    <measurement group_id="O2" value="4.4" spread="0.22"/>
                    <measurement group_id="O3" value="4.2" spread="0.22"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 7 (n=123, 121, 125)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3.2" spread="0.24"/>
                    <measurement group_id="O2" value="3.4" spread="0.24"/>
                    <measurement group_id="O3" value="3.5" spread="0.23"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 14 (n=129, 125, 130)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.8" spread="0.19"/>
                    <measurement group_id="O2" value="2.4" spread="0.19"/>
                    <measurement group_id="O3" value="2.5" spread="0.19"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 28 (n=141, 142, 143)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.2" spread="0.15"/>
                    <measurement group_id="O2" value="1.7" spread="0.15"/>
                    <measurement group_id="O3" value="1.4" spread="0.15"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <groups_desc>Discharge</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.7511</p_value>
            <method>ANOVA</method>
            <method_desc>LS Means from ANOVA model with terms of treatment, pooled center and salpingo-oophorectomy strata.</method_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O2</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <groups_desc>Discharge</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.6742</p_value>
            <method>ANOVA</method>
            <method_desc>LS Means from ANOVA model with terms of treatment, pooled center and salpingo-oophorectomy strata.</method_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <groups_desc>Day 7</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.3808</p_value>
            <method>ANOVA</method>
            <method_desc>LS Means from ANOVA model with terms of treatment, pooled center and salpingo-oophorectomy strata.</method_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O2</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <groups_desc>Day 7</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.7021</p_value>
            <method>ANOVA</method>
            <method_desc>LS Means from ANOVA model with terms of treatment, pooled center and salpingo-oophorectomy strata.</method_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <groups_desc>Day 14</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.0045</p_value>
            <method>ANOVA</method>
            <method_desc>LS Means from ANOVA model with terms of treatment, pooled center and salpingo-oophorectomy strata.</method_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O2</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <groups_desc>Day 14</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.7916</p_value>
            <method>ANOVA</method>
            <method_desc>LS Means from ANOVA model with terms of treatment, pooled center and salpingo-oophorectomy strata.</method_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <groups_desc>Day 28</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.3682</p_value>
            <method>ANOVA</method>
            <method_desc>LS Means from ANOVA model with terms of treatment, pooled center and salpingo-oophorectomy strata.</method_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O2</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <groups_desc>Day 28</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.1419</p_value>
            <method>ANOVA</method>
            <method_desc>LS Means from ANOVA model with terms of treatment, pooled center and salpingo-oophorectomy strata.</method_desc>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Sleep Interference</title>
        <description>Sleep interference post surgery measured daily in participant diaries; NRS of how pain interfered with sleep during the last 24 hours, ranged from 0 (does not interfere) to 10 (completely interferes). LS Means adjusted for treatment, pooled center and salpingo-oophorectomy strata.</description>
        <time_frame>Daily post hospital discharge ( Day 2-7 PS), Week 2, 3, 4 PS</time_frame>
        <population>mITT; n = number of evaluable participants analyzed for the given time point; N=number of evaluable participants analyzed</population>
        <group_list>
          <group group_id="O1">
            <title>Pregabalin 150mg</title>
            <description>Pregabalin 75 mg twice a day (150 mg/day total)</description>
          </group>
          <group group_id="O2">
            <title>Pregabalin 300 mg</title>
            <description>Pregabalin 150 mg twice a day (300 mg/day total)</description>
          </group>
          <group group_id="O3">
            <title>Placebo</title>
            <description>Matching placebo capsule</description>
          </group>
        </group_list>
        <measure>
          <title>Sleep Interference</title>
          <description>Sleep interference post surgery measured daily in participant diaries; NRS of how pain interfered with sleep during the last 24 hours, ranged from 0 (does not interfere) to 10 (completely interferes). LS Means adjusted for treatment, pooled center and salpingo-oophorectomy strata.</description>
          <population>mITT; n = number of evaluable participants analyzed for the given time point; N=number of evaluable participants analyzed</population>
          <units>Units on a scale</units>
          <param>Least Squares Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="134"/>
                <count group_id="O2" value="131"/>
                <count group_id="O3" value="139"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Day 2 PS (n=21, 18, 20)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2.4" spread="0.65"/>
                    <measurement group_id="O2" value="3.6" spread="0.67"/>
                    <measurement group_id="O3" value="3.2" spread="0.77"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 3 PS (n=88, 89, 87)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2.6" spread="0.32"/>
                    <measurement group_id="O2" value="2.3" spread="0.33"/>
                    <measurement group_id="O3" value="2.6" spread="0.33"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 4 PS (n=122, 111, 119)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2.3" spread="0.24"/>
                    <measurement group_id="O2" value="2.5" spread="0.27"/>
                    <measurement group_id="O3" value="2.5" spread="0.26"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 5 PS (n=133, 117, 132)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2.1" spread="0.22"/>
                    <measurement group_id="O2" value="2.2" spread="0.24"/>
                    <measurement group_id="O3" value="2.5" spread="0.22"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 6 PS (n=133, 127, 138)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.7" spread="0.22"/>
                    <measurement group_id="O2" value="1.9" spread="0.23"/>
                    <measurement group_id="O3" value="2.1" spread="0.22"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 7 PS (n=132, 131, 138)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.7" spread="0.22"/>
                    <measurement group_id="O2" value="2.0" spread="0.22"/>
                    <measurement group_id="O3" value="2.1" spread="0.22"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>2nd Week PS (Average) (n=134, 131, 139)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.3" spread="0.16"/>
                    <measurement group_id="O2" value="1.7" spread="0.17"/>
                    <measurement group_id="O3" value="1.5" spread="0.16"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>3rd Week PS (Average) (n=115, 112, 113)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.0" spread="0.16"/>
                    <measurement group_id="O2" value="1.3" spread="0.16"/>
                    <measurement group_id="O3" value="1.0" spread="0.17"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>4th Week PS (Average) (n=87, 87, 81)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.0" spread="0.21"/>
                    <measurement group_id="O2" value="1.4" spread="0.21"/>
                    <measurement group_id="O3" value="0.9" spread="0.22"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <groups_desc>Day 2 PS</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.3323</p_value>
            <method>ANOVA</method>
            <method_desc>LS Means from ANOVA model with terms of treatment, pooled center and salpingo-oophorectomy strata.</method_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O2</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <groups_desc>Day 2 PS</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.5662</p_value>
            <method>ANOVA</method>
            <method_desc>LS Means from ANOVA model with terms of treatment, pooled center and salpingo-oophorectomy strata.</method_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <groups_desc>Day 3 PS</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.9538</p_value>
            <method>ANOVA</method>
            <method_desc>LS Means from ANOVA model with terms of treatment, pooled center and salpingo-oophorectomy strata.</method_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O2</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <groups_desc>Day 3 PS</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.4592</p_value>
            <method>ANOVA</method>
            <method_desc>LS Means from ANOVA model with terms of treatment, pooled center and salpingo-oophorectomy strata.</method_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <groups_desc>Day 4 PS</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.4793</p_value>
            <method>ANOVA</method>
            <method_desc>LS Means from ANOVA model with terms of treatment, pooled center and salpingo-oophorectomy strata.</method_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O2</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <groups_desc>Day 4 PS</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.8517</p_value>
            <method>ANOVA</method>
            <method_desc>LS Means from ANOVA model with terms of treatment, pooled center and salpingo-oophorectomy strata.</method_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <groups_desc>Day 5 PS</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.1829</p_value>
            <method>ANOVA</method>
            <method_desc>LS Means from ANOVA model with terms of treatment, pooled center and salpingo-oophorectomy strata.</method_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O2</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <groups_desc>Day 5 PS</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.3544</p_value>
            <method>ANOVA</method>
            <method_desc>LS Means from ANOVA model with terms of treatment, pooled center and salpingo-oophorectomy strata.</method_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <groups_desc>Day 6 PS</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.1718</p_value>
            <method>ANOVA</method>
            <method_desc>LS Means from ANOVA model with terms of treatment, pooled center and salpingo-oophorectomy strata.</method_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O2</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <groups_desc>Day 6 PS</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.5078</p_value>
            <method>ANOVA</method>
            <method_desc>LS Means from ANOVA model with terms of treatment, pooled center and salpingo-oophorectomy strata.</method_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <groups_desc>Day 7 PS</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.2443</p_value>
            <method>ANOVA</method>
            <method_desc>LS Means from ANOVA model with terms of treatment, pooled center and salpingo-oophorectomy strata.</method_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O2</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <groups_desc>Day 7 PS</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.8296</p_value>
            <method>ANOVA</method>
            <method_desc>LS Means from ANOVA model with terms of treatment, pooled center and salpingo-oophorectomy strata.</method_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <groups_desc>2nd Week PS (Average)</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.3243</p_value>
            <method>ANOVA</method>
            <method_desc>LS Means from ANOVA model with terms of treatment, pooled center and salpingo-oophorectomy strata.</method_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O2</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <groups_desc>2nd Week PS (Average)</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.3755</p_value>
            <method>ANOVA</method>
            <method_desc>LS Means from ANOVA model with terms of treatment, pooled center and salpingo-oophorectomy strata.</method_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <groups_desc>3rd Week PS (Average)</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.9584</p_value>
            <method>ANOVA</method>
            <method_desc>LS Means from ANOVA model with terms of treatment, pooled center and salpingo-oophorectomy strata.</method_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O2</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <groups_desc>3rd Week PS (Average)</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.1187</p_value>
            <method>ANOVA</method>
            <method_desc>LS Means from ANOVA model with terms of treatment, pooled center and salpingo-oophorectomy strata.</method_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <groups_desc>4th Week PS (Average)</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.7915</p_value>
            <method>ANOVA</method>
            <method_desc>LS Means from ANOVA model with terms of treatment, pooled center and salpingo-oophorectomy strata.</method_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O2</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <groups_desc>4th Week PS (Average)</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.0703</p_value>
            <method>ANOVA</method>
            <method_desc>LS Means from ANOVA model with terms of treatment, pooled center and salpingo-oophorectomy strata.</method_desc>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Brief Pain Inventory-Short Form (m-BPI-sf): Pain Interference Index Scores</title>
        <description>m-BPI-sf: participant-rated 11 point Likert rating scale ranging from 0 (does not interfere) to 10 (completely interferes) with functional activities (general activity, mood, walking ability, relations with other people, sleep, normal work, and enjoyment of life) in past 24 hours. LS Means adjusted for treatment, pooled center and salpingo-oophorectomy strata.</description>
        <time_frame>Baseline, Discharge (day 3 up to day 7 PS), Day 7, 14, 28 PS</time_frame>
        <population>mITT; n = number of evaluable participants analyzed for the given time point; N=number of evaluable participants analyzed</population>
        <group_list>
          <group group_id="O1">
            <title>Pregabalin 150mg</title>
            <description>Pregabalin 75 mg twice a day (150 mg/day total)</description>
          </group>
          <group group_id="O2">
            <title>Pregabalin 300 mg</title>
            <description>Pregabalin 150 mg twice a day (300 mg/day total)</description>
          </group>
          <group group_id="O3">
            <title>Placebo</title>
            <description>Matching placebo capsule</description>
          </group>
        </group_list>
        <measure>
          <title>Brief Pain Inventory-Short Form (m-BPI-sf): Pain Interference Index Scores</title>
          <description>m-BPI-sf: participant-rated 11 point Likert rating scale ranging from 0 (does not interfere) to 10 (completely interferes) with functional activities (general activity, mood, walking ability, relations with other people, sleep, normal work, and enjoyment of life) in past 24 hours. LS Means adjusted for treatment, pooled center and salpingo-oophorectomy strata.</description>
          <population>mITT; n = number of evaluable participants analyzed for the given time point; N=number of evaluable participants analyzed</population>
          <units>Units on a scale</units>
          <param>Least Squares Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="149"/>
                <count group_id="O2" value="147"/>
                <count group_id="O3" value="154"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Baseline (n=149, 147, 154)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0" spread="0"/>
                    <measurement group_id="O2" value="0" spread="0"/>
                    <measurement group_id="O3" value="0" spread="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Discharge (n=133, 131, 130)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2.57" spread="0.194"/>
                    <measurement group_id="O2" value="2.62" spread="0.198"/>
                    <measurement group_id="O3" value="2.90" spread="0.200"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 7 (n=121, 119, 123)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.96" spread="0.201"/>
                    <measurement group_id="O2" value="2.09" spread="0.206"/>
                    <measurement group_id="O3" value="2.52" spread="0.198"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 28 (n=140, 141, 142)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.85" spread="0.122"/>
                    <measurement group_id="O2" value="1.01" spread="0.122"/>
                    <measurement group_id="O3" value="1.07" spread="0.123"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 14 (n=129, 123, 126)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.20" spread="0.148"/>
                    <measurement group_id="O2" value="1.41" spread="0.152"/>
                    <measurement group_id="O3" value="1.68" spread="0.152"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <groups_desc>Discharge;</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.1975</p_value>
            <method>ANOVA</method>
            <method_desc>LS Means from ANOVA model with terms of treatment, pooled center and salpingo-oophorectomy strata.</method_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O2</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <groups_desc>Discharge;</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.2784</p_value>
            <method>ANOVA</method>
            <method_desc>LS Means from ANOVA model with terms of treatment, pooled center and salpingo-oophorectomy strata.</method_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <groups_desc>Day 7</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.0271</p_value>
            <method>ANOVA</method>
            <method_desc>LS Means from ANOVA model with terms of treatment, pooled center and salpingo-oophorectomy strata.</method_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O2</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <groups_desc>Day 7</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.0881</p_value>
            <method>ANOVA</method>
            <method_desc>LS Means from ANOVA model with terms of treatment, pooled center and salpingo-oophorectomy strata.</method_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <groups_desc>Day 14</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.0159</p_value>
            <method>ANOVA</method>
            <method_desc>LS Means from ANOVA model with terms of treatment, pooled center and salpingo-oophorectomy strata.</method_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O2</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <groups_desc>Day 14</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.1870</p_value>
            <method>ANOVA</method>
            <method_desc>LS Means from ANOVA model with terms of treatment, pooled center and salpingo-oophorectomy strata.</method_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <groups_desc>Day 28</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.1752</p_value>
            <method>ANOVA</method>
            <method_desc>LS Means from ANOVA model with terms of treatment, pooled center and salpingo-oophorectomy strata.</method_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O2</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <groups_desc>Day 28</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.6923</p_value>
            <method>ANOVA</method>
            <method_desc>LS Means from ANOVA model with terms of treatment, pooled center and salpingo-oophorectomy strata.</method_desc>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Other Pre-specified</type>
        <title>Percentage of Participants With Wound Healing Complications - Discharge</title>
        <description>Pre-specified adverse events of wound healing complications based on Center for Disease Control and Prevention, 1999, guidelines for prevention of surgical site infection (SSI) wound healing complications included: superficial incisional SSI, deep incisional SSI, organ/space SSI or non-infections wound healing complication.</description>
        <time_frame>Discharge (day 3 up to day 7 PS)</time_frame>
        <population>Safety population all participants who were administered at least one dose of double blind medication, and for whom at least one post-baseline safety evaluation was obtained were included.</population>
        <group_list>
          <group group_id="O1">
            <title>Pregabalin 150mg</title>
            <description>Pregabalin 75 mg twice a day (150 mg/day total)</description>
          </group>
          <group group_id="O2">
            <title>Pregabalin 300 mg</title>
            <description>Pregabalin 150 mg twice a day (300 mg/day total)</description>
          </group>
          <group group_id="O3">
            <title>Placebo</title>
            <description>Matching placebo capsule</description>
          </group>
        </group_list>
        <measure>
          <title>Percentage of Participants With Wound Healing Complications - Discharge</title>
          <description>Pre-specified adverse events of wound healing complications based on Center for Disease Control and Prevention, 1999, guidelines for prevention of surgical site infection (SSI) wound healing complications included: superficial incisional SSI, deep incisional SSI, organ/space SSI or non-infections wound healing complication.</description>
          <population>Safety population all participants who were administered at least one dose of double blind medication, and for whom at least one post-baseline safety evaluation was obtained were included.</population>
          <units>Percentage of participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="161"/>
                <count group_id="O2" value="166"/>
                <count group_id="O3" value="167"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Superficial Incision SSI</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3.1"/>
                    <measurement group_id="O2" value="1.2"/>
                    <measurement group_id="O3" value="0.6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Deep Incision SSI</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Organ/space SSI</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Non-infectious Wound Healing</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="1.2"/>
                    <measurement group_id="O3" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Other Pre-specified</type>
        <title>Percentage of Participants With Wound Healing Complications - Day 7 PS</title>
        <description>Pre-specified adverse events of wound healing complications based on Center for Disease Control and Prevention, 1999, guidelines for prevention of surgical site infection (SSI) wound healing complications included: superficial incisional SSI, deep incisional SSI, organ/space SSI or non-infections wound healing complication.</description>
        <time_frame>Day 7 PS</time_frame>
        <population>Safety population</population>
        <group_list>
          <group group_id="O1">
            <title>Pregabalin 150mg</title>
            <description>Pregabalin 75 mg twice a day (150 mg/day total)</description>
          </group>
          <group group_id="O2">
            <title>Pregabalin 300 mg</title>
            <description>Pregabalin 150 mg twice a day (300 mg/day total)</description>
          </group>
          <group group_id="O3">
            <title>Placebo</title>
            <description>Matching placebo capsule</description>
          </group>
        </group_list>
        <measure>
          <title>Percentage of Participants With Wound Healing Complications - Day 7 PS</title>
          <description>Pre-specified adverse events of wound healing complications based on Center for Disease Control and Prevention, 1999, guidelines for prevention of surgical site infection (SSI) wound healing complications included: superficial incisional SSI, deep incisional SSI, organ/space SSI or non-infections wound healing complication.</description>
          <population>Safety population</population>
          <units>Percentage of participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="161"/>
                <count group_id="O2" value="166"/>
                <count group_id="O3" value="167"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Superficial Incision SSI</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.9"/>
                    <measurement group_id="O2" value="2.5"/>
                    <measurement group_id="O3" value="0.6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Deep Incision SSI</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.6"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Organ/space SSI</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Non-infectious Wound Healing</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3.8"/>
                    <measurement group_id="O2" value="1.9"/>
                    <measurement group_id="O3" value="0.6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Brief Pain Inventory-Short Form (m-BPI-sf): Pain Severity Index Scores</title>
        <description>m-BPI-sf: participant rated 11-point Likert rating scale ranging from 0 (no pain) to 10 (worst pain possible). Pain severity index is the mean of item scores 2, 3, and 4 (pain right now, worst pain, and average pain level).
LS Means adjusted for treatment, pooled center and salpingo-oophorectomy strata.</description>
        <time_frame>Baseline, Discharge (day 3 up to day 7 PS), Day 7, 14, 28 PS</time_frame>
        <population>mITT; n = number of evaluable participants analyzed for the given time point; N=number of evaluable participants analyzed</population>
        <group_list>
          <group group_id="O1">
            <title>Pregabalin 150mg</title>
            <description>Pregabalin 75 mg twice a day (150 mg/day total)</description>
          </group>
          <group group_id="O2">
            <title>Pregabalin 300 mg</title>
            <description>Pregabalin 150 mg twice a day (300 mg/day total)</description>
          </group>
          <group group_id="O3">
            <title>Placebo</title>
            <description>Matching placebo capsule</description>
          </group>
        </group_list>
        <measure>
          <title>Brief Pain Inventory-Short Form (m-BPI-sf): Pain Severity Index Scores</title>
          <description>m-BPI-sf: participant rated 11-point Likert rating scale ranging from 0 (no pain) to 10 (worst pain possible). Pain severity index is the mean of item scores 2, 3, and 4 (pain right now, worst pain, and average pain level).
LS Means adjusted for treatment, pooled center and salpingo-oophorectomy strata.</description>
          <population>mITT; n = number of evaluable participants analyzed for the given time point; N=number of evaluable participants analyzed</population>
          <units>Units on a scale</units>
          <param>Least Squares Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="149"/>
                <count group_id="O2" value="147"/>
                <count group_id="O3" value="155"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Baseline (n=149, 147, 155)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0" spread="0"/>
                    <measurement group_id="O2" value="0" spread="0"/>
                    <measurement group_id="O3" value="0" spread="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Discharge (n=140, 141, 138)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2.62" spread="0.137"/>
                    <measurement group_id="O2" value="2.60" spread="0.137"/>
                    <measurement group_id="O3" value="2.53" spread="0.141"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 7 (n=122, 121, 125)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2.05" spread="0.172"/>
                    <measurement group_id="O2" value="2.16" spread="0.177"/>
                    <measurement group_id="O3" value="2.20" spread="0.169"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 14 (n=129, 124, 130)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.19" spread="0.137"/>
                    <measurement group_id="O2" value="1.63" spread="0.142"/>
                    <measurement group_id="O3" value="1.61" spread="0.138"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 28 (n=141, 142, 143)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.79" spread="0.110"/>
                    <measurement group_id="O2" value="0.98" spread="0.110"/>
                    <measurement group_id="O3" value="0.83" spread="0.110"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <groups_desc>Discharge</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.6295</p_value>
            <method>ANOVA</method>
            <method_desc>LS Means from ANOVA model with terms of treatment, pooled center and salpingo-oophorectomy strata.</method_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O2</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <groups_desc>Discharge</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.6890</p_value>
            <method>ANOVA</method>
            <method_desc>LS Means from ANOVA model with terms of treatment, pooled center and salpingo-oophorectomy strata.</method_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <groups_desc>Day 7</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.5094</p_value>
            <method>ANOVA</method>
            <method_desc>LS Means from ANOVA model with terms of treatment, pooled center and salpingo-oophorectomy strata.</method_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O2</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <groups_desc>Day 7</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.8741</p_value>
            <method>ANOVA</method>
            <method_desc>LS Means from ANOVA model with terms of treatment, pooled center and salpingo-oophorectomy strata.</method_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <groups_desc>Day 14</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.0214</p_value>
            <method>ANOVA</method>
            <method_desc>LS Means from ANOVA model with terms of treatment, pooled center and salpingo-oophorectomy strata.</method_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O2</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <groups_desc>Day 14</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.9366</p_value>
            <method>ANOVA</method>
            <method_desc>LS Means from ANOVA model with terms of treatment, pooled center and salpingo-oophorectomy strata.</method_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <groups_desc>Day 28</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.7833</p_value>
            <method>ANOVA</method>
            <method_desc>LS Means from ANOVA model with terms of treatment, pooled center and salpingo-oophorectomy strata.</method_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O2</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <groups_desc>Day 28</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.2983</p_value>
            <method>ANOVA</method>
            <method_desc>LS Means from ANOVA model with terms of treatment, pooled center and salpingo-oophorectomy strata.</method_desc>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Other Pre-specified</type>
        <title>Percentage of Participants With Wound Healing Complications - Day 14 PS</title>
        <description>Pre-specified adverse events of wound healing complications based on Center for Disease Control and Prevention, 1999, guidelines for prevention of surgical site infection (SSI) wound healing complications included: superficial incisional SSI, deep incisional SSI, organ/space SSI or non-infections wound healing complication.</description>
        <time_frame>Day 14 PS</time_frame>
        <population>Safety population</population>
        <group_list>
          <group group_id="O1">
            <title>Pregabalin 150mg</title>
            <description>Pregabalin 75 mg twice a day (150 mg/day total)</description>
          </group>
          <group group_id="O2">
            <title>Pregabalin 300 mg</title>
            <description>Pregabalin 150 mg twice a day (300 mg/day total)</description>
          </group>
          <group group_id="O3">
            <title>Placebo</title>
            <description>Matching placebo capsule</description>
          </group>
        </group_list>
        <measure>
          <title>Percentage of Participants With Wound Healing Complications - Day 14 PS</title>
          <description>Pre-specified adverse events of wound healing complications based on Center for Disease Control and Prevention, 1999, guidelines for prevention of surgical site infection (SSI) wound healing complications included: superficial incisional SSI, deep incisional SSI, organ/space SSI or non-infections wound healing complication.</description>
          <population>Safety population</population>
          <units>Percentage of participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="161"/>
                <count group_id="O2" value="166"/>
                <count group_id="O3" value="167"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Superficial Incision SSI</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="5.0"/>
                    <measurement group_id="O2" value="2.5"/>
                    <measurement group_id="O3" value="2.4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Deep Incision SSI</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.6"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Organ/space SSI</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.6"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Non-infectious Wound Healing</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="4.4"/>
                    <measurement group_id="O2" value="2.5"/>
                    <measurement group_id="O3" value="0.6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Other Pre-specified</type>
        <title>Percentage of Participants With Wound Healing Complications - Day 28 PS</title>
        <description>Pre-specified adverse events of wound healing complications based on Center for Disease Control and Prevention, 1999, guidelines for prevention of surgical site infection (SSI) wound healing complications included: superficial incisional SSI, deep incisional SSI, organ/space SSI or non-infections wound healing complication.</description>
        <time_frame>Day 28 PS</time_frame>
        <population>Safety population</population>
        <group_list>
          <group group_id="O1">
            <title>Pregabalin 150mg</title>
            <description>Pregabalin 75 mg twice a day (150 mg/day total)</description>
          </group>
          <group group_id="O2">
            <title>Pregabalin 300 mg</title>
            <description>Pregabalin 150 mg twice a day (300 mg/day total)</description>
          </group>
          <group group_id="O3">
            <title>Placebo</title>
            <description>Matching placebo capsule</description>
          </group>
        </group_list>
        <measure>
          <title>Percentage of Participants With Wound Healing Complications - Day 28 PS</title>
          <description>Pre-specified adverse events of wound healing complications based on Center for Disease Control and Prevention, 1999, guidelines for prevention of surgical site infection (SSI) wound healing complications included: superficial incisional SSI, deep incisional SSI, organ/space SSI or non-infections wound healing complication.</description>
          <population>Safety population</population>
          <units>Percentage of participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="161"/>
                <count group_id="O2" value="166"/>
                <count group_id="O3" value="167"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Superficial Incision SSI</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.9"/>
                    <measurement group_id="O2" value="1.9"/>
                    <measurement group_id="O3" value="1.2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Deep Incision SSI</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Organ/space SSI</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="0.6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Non-infectious Wound Healing</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2.5"/>
                    <measurement group_id="O2" value="2.5"/>
                    <measurement group_id="O3" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Participant Satisfaction With Study Medication - Surgery Day</title>
        <description>Participant satisfaction with study medication using the Global Evaluation of Study Medication questionaire. Participants overall impression (global evaluation) of the study medication was recorded by the participant by answering the following question: How would you rate the study medication you received for pain? Excellent 4; Good 3; Fair 2; Poor 1.</description>
        <time_frame>Day 1</time_frame>
        <population>mITT; N=number of evaluable participants analyzed</population>
        <group_list>
          <group group_id="O1">
            <title>Pregabalin 150mg</title>
            <description>Pregabalin 75 mg twice a day (150 mg/day total)</description>
          </group>
          <group group_id="O2">
            <title>Pregabalin 300 mg</title>
            <description>Pregabalin 150 mg twice a day (300 mg/day total)</description>
          </group>
          <group group_id="O3">
            <title>Placebo</title>
            <description>Matching placebo capsule</description>
          </group>
        </group_list>
        <measure>
          <title>Participant Satisfaction With Study Medication - Surgery Day</title>
          <description>Participant satisfaction with study medication using the Global Evaluation of Study Medication questionaire. Participants overall impression (global evaluation) of the study medication was recorded by the participant by answering the following question: How would you rate the study medication you received for pain? Excellent 4; Good 3; Fair 2; Poor 1.</description>
          <population>mITT; N=number of evaluable participants analyzed</population>
          <units>Percentage of participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="28"/>
                <count group_id="O2" value="32"/>
                <count group_id="O3" value="40"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Excellent</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="14.3"/>
                    <measurement group_id="O2" value="3.1"/>
                    <measurement group_id="O3" value="20.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Good</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="42.9"/>
                    <measurement group_id="O2" value="62.5"/>
                    <measurement group_id="O3" value="35.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Fair</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="39.3"/>
                    <measurement group_id="O2" value="31.3"/>
                    <measurement group_id="O3" value="30.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Poor</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3.6"/>
                    <measurement group_id="O2" value="3.1"/>
                    <measurement group_id="O3" value="15.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <groups_desc>Surgery Day</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.6861</p_value>
            <method>Cochran-Mantel-Haenszel</method>
            <method_desc>Cochran-Mantel-Haenszel (CMH) test adjusted for pooled centers and salpingo-oophorectomy strata.</method_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O2</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <groups_desc>Surgery Day</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.9905</p_value>
            <method>Cochran-Mantel-Haenszel</method>
            <method_desc>CMH test adjusted for pooled centers and salpingo-oophorectomy strata.</method_desc>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Participant Satisfaction With Study Medication - Day 1 PS</title>
        <description>Participant satisfaction with study medication using the Global Evaluation of Study Medication questionaire. Participants overall impression (global evaluation) of the study medication was recorded by the participant by answering the following question: How would you rate the study medication you received for pain? Excellent 4; Good 3; Fair 2; Poor 1.</description>
        <time_frame>Day 1 PS</time_frame>
        <population>mITT; N=number of evaluable participants analyzed</population>
        <group_list>
          <group group_id="O1">
            <title>Pregabalin 150mg</title>
            <description>Pregabalin 75 mg twice a day (150 mg/day total)</description>
          </group>
          <group group_id="O2">
            <title>Pregabalin 300 mg</title>
            <description>Pregabalin 150 mg twice a day (300 mg/day total)</description>
          </group>
          <group group_id="O3">
            <title>Placebo</title>
            <description>Matching placebo capsule</description>
          </group>
        </group_list>
        <measure>
          <title>Participant Satisfaction With Study Medication - Day 1 PS</title>
          <description>Participant satisfaction with study medication using the Global Evaluation of Study Medication questionaire. Participants overall impression (global evaluation) of the study medication was recorded by the participant by answering the following question: How would you rate the study medication you received for pain? Excellent 4; Good 3; Fair 2; Poor 1.</description>
          <population>mITT; N=number of evaluable participants analyzed</population>
          <units>Percentage of participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="150"/>
                <count group_id="O2" value="148"/>
                <count group_id="O3" value="154"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Excellent</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="13.3"/>
                    <measurement group_id="O2" value="17.6"/>
                    <measurement group_id="O3" value="16.2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Good</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="56.0"/>
                    <measurement group_id="O2" value="47.3"/>
                    <measurement group_id="O3" value="45.5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Fair</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="26.7"/>
                    <measurement group_id="O2" value="29.1"/>
                    <measurement group_id="O3" value="30.5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Poor</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="4.0"/>
                    <measurement group_id="O2" value="6.1"/>
                    <measurement group_id="O3" value="7.8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <groups_desc>Day 1 PS</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.4264</p_value>
            <method>Cochran-Mantel-Haenszel</method>
            <method_desc>CMH test adjusted for pooled centers and salpingo-oophorectomy strata.</method_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O2</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <groups_desc>Day 1 PS</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.3045</p_value>
            <method>Cochran-Mantel-Haenszel</method>
            <method_desc>CMH test adjusted for pooled centers and salpingo-oophorectomy strata.</method_desc>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Participant Satisfaction With Study Medication - Day 2 PS</title>
        <description>Participant satisfaction with study medication using the Global Evaluation of Study Medication questionaire. Participants overall impression (global evaluation) of the study medication was recorded by the participant by answering the following question: How would you rate the study medication you received for pain? Excellent 4; Good 3; Fair 2; Poor 1.</description>
        <time_frame>Day 2 PS</time_frame>
        <population>mITT; N=number of evaluable participants analyzed;</population>
        <group_list>
          <group group_id="O1">
            <title>Pregabalin 150mg</title>
            <description>Pregabalin 75 mg twice a day (150 mg/day total)</description>
          </group>
          <group group_id="O2">
            <title>Pregabalin 300 mg</title>
            <description>Pregabalin 150 mg twice a day (300 mg/day total)</description>
          </group>
          <group group_id="O3">
            <title>Placebo</title>
            <description>Matching placebo capsule</description>
          </group>
        </group_list>
        <measure>
          <title>Participant Satisfaction With Study Medication - Day 2 PS</title>
          <description>Participant satisfaction with study medication using the Global Evaluation of Study Medication questionaire. Participants overall impression (global evaluation) of the study medication was recorded by the participant by answering the following question: How would you rate the study medication you received for pain? Excellent 4; Good 3; Fair 2; Poor 1.</description>
          <population>mITT; N=number of evaluable participants analyzed;</population>
          <units>Percentage of participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="114"/>
                <count group_id="O2" value="119"/>
                <count group_id="O3" value="117"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Excellent</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="21.9"/>
                    <measurement group_id="O2" value="17.6"/>
                    <measurement group_id="O3" value="16.2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Good</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="49.1"/>
                    <measurement group_id="O2" value="54.6"/>
                    <measurement group_id="O3" value="47.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Fair</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="25.4"/>
                    <measurement group_id="O2" value="21.8"/>
                    <measurement group_id="O3" value="29.1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Poor</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3.5"/>
                    <measurement group_id="O2" value="5.9"/>
                    <measurement group_id="O3" value="7.7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <groups_desc>Day 2 PS</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.0714</p_value>
            <method>Cochran-Mantel-Haenszel</method>
            <method_desc>CMH test adjusted for pooled centers and salpingo-oophorectomy strata.</method_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O2</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <groups_desc>Day 2 PS</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.4455</p_value>
            <method>Cochran-Mantel-Haenszel</method>
            <method_desc>CMH test adjusted for pooled centers and salpingo-oophorectomy strata.</method_desc>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Participant Satisfaction With Study Medication - Day 3 PS</title>
        <description>Participant satisfaction with study medication using the Global Evaluation of Study Medication questionaire. Participants overall impression (global evaluation) of the study medication was recorded by the participant by answering the following question: How would you rate the study medication you received for pain? Excellent 4; Good 3; Fair 2; Poor 1.</description>
        <time_frame>Day 3 PS</time_frame>
        <population>mITT; N=number of evaluable participants analyzed</population>
        <group_list>
          <group group_id="O1">
            <title>Pregabalin 150mg</title>
            <description>Pregabalin 75 mg twice a day (150 mg/day total)</description>
          </group>
          <group group_id="O2">
            <title>Pregabalin 300 mg</title>
            <description>Pregabalin 150 mg twice a day (300 mg/day total)</description>
          </group>
          <group group_id="O3">
            <title>Placebo</title>
            <description>Matching placebo capsule</description>
          </group>
        </group_list>
        <measure>
          <title>Participant Satisfaction With Study Medication - Day 3 PS</title>
          <description>Participant satisfaction with study medication using the Global Evaluation of Study Medication questionaire. Participants overall impression (global evaluation) of the study medication was recorded by the participant by answering the following question: How would you rate the study medication you received for pain? Excellent 4; Good 3; Fair 2; Poor 1.</description>
          <population>mITT; N=number of evaluable participants analyzed</population>
          <units>Percentage of participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="44"/>
                <count group_id="O2" value="40"/>
                <count group_id="O3" value="34"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Excellent</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="15.9"/>
                    <measurement group_id="O2" value="17.5"/>
                    <measurement group_id="O3" value="17.6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Good</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="52.3"/>
                    <measurement group_id="O2" value="47.5"/>
                    <measurement group_id="O3" value="50.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Fair</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="31.8"/>
                    <measurement group_id="O2" value="30.0"/>
                    <measurement group_id="O3" value="29.4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Poor</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="5.0"/>
                    <measurement group_id="O3" value="2.9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <groups_desc>Day 3 PS</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.7418</p_value>
            <method>Cochran-Mantel-Haenszel</method>
            <method_desc>CMH test adjusted for pooled centers and salpingo-oophorectomy strata.</method_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O2</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <groups_desc>Day 3 PS</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.5154</p_value>
            <method>Cochran-Mantel-Haenszel</method>
            <method_desc>CMH test adjusted for pooled centers and salpingo-oophorectomy strata.</method_desc>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Participant Satisfaction With Study Medication - Day 4 PS</title>
        <description>Participant satisfaction with study medication using the Global Evaluation of Study Medication questionaire. Participants overall impression (global evaluation) of the study medication was recorded by the participant by answering the following question: How would you rate the study medication you received for pain? Excellent 4; Good 3; Fair 2; Poor 1.</description>
        <time_frame>Day 4 PS</time_frame>
        <population>mITT; N=number of evaluable participants analyzed</population>
        <group_list>
          <group group_id="O1">
            <title>Pregabalin 150mg</title>
            <description>Pregabalin 75 mg twice a day (150 mg/day total)</description>
          </group>
          <group group_id="O2">
            <title>Pregabalin 300 mg</title>
            <description>Pregabalin 150 mg twice a day (300 mg/day total)</description>
          </group>
          <group group_id="O3">
            <title>Placebo</title>
            <description>Matching placebo capsule</description>
          </group>
        </group_list>
        <measure>
          <title>Participant Satisfaction With Study Medication - Day 4 PS</title>
          <description>Participant satisfaction with study medication using the Global Evaluation of Study Medication questionaire. Participants overall impression (global evaluation) of the study medication was recorded by the participant by answering the following question: How would you rate the study medication you received for pain? Excellent 4; Good 3; Fair 2; Poor 1.</description>
          <population>mITT; N=number of evaluable participants analyzed</population>
          <units>Percentage of participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="17"/>
                <count group_id="O2" value="19"/>
                <count group_id="O3" value="14"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Excellent</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="17.6"/>
                    <measurement group_id="O2" value="5.3"/>
                    <measurement group_id="O3" value="14.3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Good</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="52.9"/>
                    <measurement group_id="O2" value="57.9"/>
                    <measurement group_id="O3" value="42.9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Fair</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="29.4"/>
                    <measurement group_id="O2" value="31.6"/>
                    <measurement group_id="O3" value="28.6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Poor</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="5.3"/>
                    <measurement group_id="O3" value="14.3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <groups_desc>Day 4 PS</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.6715</p_value>
            <method>Cochran-Mantel-Haenszel</method>
            <method_desc>CMH test adjusted for pooled centers and salpingo-oophorectomy strata.</method_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O2</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <groups_desc>Day 4 PS</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.9013</p_value>
            <method>Cochran-Mantel-Haenszel</method>
            <method_desc>CMH test adjusted for pooled centers and salpingo-oophorectomy strata.</method_desc>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Participant Satisfaction With Study Medication - Day 5 PS</title>
        <description>Participant satisfaction with study medication using the Global Evaluation of Study Medication questionaire. Participants overall impression (global evaluation) of the study medication was recorded by the participant by answering the following question: How would you rate the study medication you received for pain? Excellent 4; Good 3; Fair 2; Poor 1.</description>
        <time_frame>Day 5 PS</time_frame>
        <population>mITT; N=number of evaluable participants analyzed</population>
        <group_list>
          <group group_id="O1">
            <title>Pregabalin 150mg</title>
            <description>Pregabalin 75 mg twice a day (150 mg/day total)</description>
          </group>
          <group group_id="O2">
            <title>Pregabalin 300 mg</title>
            <description>Pregabalin 150 mg twice a day (300 mg/day total)</description>
          </group>
          <group group_id="O3">
            <title>Placebo</title>
            <description>Matching placebo capsule</description>
          </group>
        </group_list>
        <measure>
          <title>Participant Satisfaction With Study Medication - Day 5 PS</title>
          <description>Participant satisfaction with study medication using the Global Evaluation of Study Medication questionaire. Participants overall impression (global evaluation) of the study medication was recorded by the participant by answering the following question: How would you rate the study medication you received for pain? Excellent 4; Good 3; Fair 2; Poor 1.</description>
          <population>mITT; N=number of evaluable participants analyzed</population>
          <units>Percentage of participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="7"/>
                <count group_id="O2" value="13"/>
                <count group_id="O3" value="7"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Excellent</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="7.7"/>
                    <measurement group_id="O3" value="14.3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Good</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="71.4"/>
                    <measurement group_id="O2" value="53.8"/>
                    <measurement group_id="O3" value="42.9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Fair</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="28.6"/>
                    <measurement group_id="O2" value="38.5"/>
                    <measurement group_id="O3" value="28.6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Poor</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="14.3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <groups_desc>Day 5 PS</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.9126</p_value>
            <method>Cochran-Mantel-Haenszel</method>
            <method_desc>CMH test adjusted for pooled centers and salpingo-oophorectomy strata.</method_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O2</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <groups_desc>Day 5 PS</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>1.0000</p_value>
            <method>Cochran-Mantel-Haenszel</method>
            <method_desc>CMH test adjusted for pooled centers and salpingo-oophorectomy strata.</method_desc>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Participant Satisfaction With Study Medication - Discharge</title>
        <description>Participant satisfaction with study medication using the Global Evaluation of Study Medication questionaire. Participants overall impression (global evaluation) of the study medication was recorded by the participant by answering the following question: How would you rate the study medication you received for pain? Excellent 4; Good 3; Fair 2; Poor 1.</description>
        <time_frame>Discharge (day 3 up to day 7 PS)</time_frame>
        <population>mITT; N=number of evaluable participants analyzed</population>
        <group_list>
          <group group_id="O1">
            <title>Pregabalin 150mg</title>
            <description>Pregabalin 75 mg twice a day (150 mg/day total)</description>
          </group>
          <group group_id="O2">
            <title>Pregabalin 300 mg</title>
            <description>Pregabalin 150 mg twice a day (300 mg/day total)</description>
          </group>
          <group group_id="O3">
            <title>Placebo</title>
            <description>Matching placebo capsule</description>
          </group>
        </group_list>
        <measure>
          <title>Participant Satisfaction With Study Medication - Discharge</title>
          <description>Participant satisfaction with study medication using the Global Evaluation of Study Medication questionaire. Participants overall impression (global evaluation) of the study medication was recorded by the participant by answering the following question: How would you rate the study medication you received for pain? Excellent 4; Good 3; Fair 2; Poor 1.</description>
          <population>mITT; N=number of evaluable participants analyzed</population>
          <units>Percentage of participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="142"/>
                <count group_id="O2" value="145"/>
                <count group_id="O3" value="148"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Excellent</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="29.6"/>
                    <measurement group_id="O2" value="26.2"/>
                    <measurement group_id="O3" value="26.4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Good</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="48.6"/>
                    <measurement group_id="O2" value="51.0"/>
                    <measurement group_id="O3" value="39.9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Fair</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="16.9"/>
                    <measurement group_id="O2" value="17.9"/>
                    <measurement group_id="O3" value="25.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Poor</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="4.9"/>
                    <measurement group_id="O2" value="4.8"/>
                    <measurement group_id="O3" value="8.8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <groups_desc>Discharge</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.1233</p_value>
            <method>Cochran-Mantel-Haenszel</method>
            <method_desc>CMH test adjusted for pooled centers and salpingo-oophorectomy strata.</method_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O2</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <groups_desc>Discharge</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.1666</p_value>
            <method>Cochran-Mantel-Haenszel</method>
            <method_desc>CMH test adjusted for pooled centers and salpingo-oophorectomy strata.</method_desc>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Participant Satisfaction With Study Medication - Day 7 PS</title>
        <description>Participant satisfaction with study medication using the Global Evaluation of Study Medication questionaire. Participants overall impression (global evaluation) of the study medication was recorded by the participant by answering the following question: How would you rate the study medication you received for pain? Excellent 4; Good 3; Fair 2; Poor 1.</description>
        <time_frame>Day 7 PS</time_frame>
        <population>mITT; N=number of evaluable participants analyzed</population>
        <group_list>
          <group group_id="O1">
            <title>Pregabalin 150mg</title>
            <description>Pregabalin 75 mg twice a day (150 mg/day total)</description>
          </group>
          <group group_id="O2">
            <title>Pregabalin 300 mg</title>
            <description>Pregabalin 150 mg twice a day (300 mg/day total)</description>
          </group>
          <group group_id="O3">
            <title>Placebo</title>
            <description>Matching placebo capsule</description>
          </group>
        </group_list>
        <measure>
          <title>Participant Satisfaction With Study Medication - Day 7 PS</title>
          <description>Participant satisfaction with study medication using the Global Evaluation of Study Medication questionaire. Participants overall impression (global evaluation) of the study medication was recorded by the participant by answering the following question: How would you rate the study medication you received for pain? Excellent 4; Good 3; Fair 2; Poor 1.</description>
          <population>mITT; N=number of evaluable participants analyzed</population>
          <units>Percentage of participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="123"/>
                <count group_id="O2" value="122"/>
                <count group_id="O3" value="127"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Excellent</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="36.6"/>
                    <measurement group_id="O2" value="36.9"/>
                    <measurement group_id="O3" value="25.2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Good</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="38.2"/>
                    <measurement group_id="O2" value="37.7"/>
                    <measurement group_id="O3" value="39.4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Fair</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="15.4"/>
                    <measurement group_id="O2" value="17.2"/>
                    <measurement group_id="O3" value="26.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Poor</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="9.8"/>
                    <measurement group_id="O2" value="8.2"/>
                    <measurement group_id="O3" value="9.4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <groups_desc>Day 7</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.0361</p_value>
            <method>Cochran-Mantel-Haenszel</method>
            <method_desc>CMH test adjusted for pooled centers and salpingo-oophorectomy strata.</method_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O2</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <groups_desc>Day 7</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.0797</p_value>
            <method>Cochran-Mantel-Haenszel</method>
            <method_desc>CMH test adjusted for pooled centers and salpingo-oophorectomy strata.</method_desc>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Participant Satisfaction With Study Medication - Day 14 PS</title>
        <description>Participant satisfaction with study medication using the Global Evaluation of Study Medication questionaire. Participants overall impression (global evaluation) of the study medication was recorded by the participant by answering the following question: How would you rate the study medication you received for pain? Excellent 4; Good 3; Fair 2; Poor 1.</description>
        <time_frame>Day 14 PS</time_frame>
        <population>mITT; N=number of evaluable participants analyzed</population>
        <group_list>
          <group group_id="O1">
            <title>Pregabalin 150mg</title>
            <description>Pregabalin 75 mg twice a day (150 mg/day total)</description>
          </group>
          <group group_id="O2">
            <title>Pregabalin 300 mg</title>
            <description>Pregabalin 150 mg twice a day (300 mg/day total)</description>
          </group>
          <group group_id="O3">
            <title>Placebo</title>
            <description>Matching placebo capsule</description>
          </group>
        </group_list>
        <measure>
          <title>Participant Satisfaction With Study Medication - Day 14 PS</title>
          <description>Participant satisfaction with study medication using the Global Evaluation of Study Medication questionaire. Participants overall impression (global evaluation) of the study medication was recorded by the participant by answering the following question: How would you rate the study medication you received for pain? Excellent 4; Good 3; Fair 2; Poor 1.</description>
          <population>mITT; N=number of evaluable participants analyzed</population>
          <units>Percentage of participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="130"/>
                <count group_id="O2" value="126"/>
                <count group_id="O3" value="131"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Excellent</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="40.0"/>
                    <measurement group_id="O2" value="42.9"/>
                    <measurement group_id="O3" value="31.3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Good</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="42.3"/>
                    <measurement group_id="O2" value="37.3"/>
                    <measurement group_id="O3" value="33.6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Fair</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="11.5"/>
                    <measurement group_id="O2" value="16.7"/>
                    <measurement group_id="O3" value="24.4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Poor</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="6.2"/>
                    <measurement group_id="O2" value="3.2"/>
                    <measurement group_id="O3" value="10.7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <groups_desc>Day 14</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.0206</p_value>
            <method>Cochran-Mantel-Haenszel</method>
            <method_desc>CMH test adjusted for pooled centers and salpingo-oophorectomy strata.</method_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O2</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <groups_desc>Day 14</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.0011</p_value>
            <method>Cochran-Mantel-Haenszel</method>
            <method_desc>CMH test adjusted for pooled centers and salpingo-oophorectomy strata.</method_desc>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Other Pre-specified</type>
        <title>Percentage of Participants With Wound Healing Complications - End of Treatment</title>
        <description>Pre-specified adverse events of wound healing complications based on Center for Disease Control and Prevention, 1999, guidelines for prevention of surgical site infection (SSI) wound healing complications included: superficial incisional SSI, deep incisional SSI, organ/space SSI or non-infections wound healing complication.</description>
        <time_frame>Day 1 up to Day 28 PS</time_frame>
        <population>Safety population</population>
        <group_list>
          <group group_id="O1">
            <title>Pregabalin 150mg</title>
            <description>Pregabalin 75 mg twice a day (150 mg/day total)</description>
          </group>
          <group group_id="O2">
            <title>Pregabalin 300 mg</title>
            <description>Pregabalin 150 mg twice a day (300 mg/day total)</description>
          </group>
          <group group_id="O3">
            <title>Placebo</title>
            <description>Matching placebo capsule</description>
          </group>
        </group_list>
        <measure>
          <title>Percentage of Participants With Wound Healing Complications - End of Treatment</title>
          <description>Pre-specified adverse events of wound healing complications based on Center for Disease Control and Prevention, 1999, guidelines for prevention of surgical site infection (SSI) wound healing complications included: superficial incisional SSI, deep incisional SSI, organ/space SSI or non-infections wound healing complication.</description>
          <population>Safety population</population>
          <units>Percentage of participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="161"/>
                <count group_id="O2" value="166"/>
                <count group_id="O3" value="167"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Superficial Incision SSI</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="1.2"/>
                    <measurement group_id="O3" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Deep Incision SSI</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Organ/space SSI</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Non-infectious Wound Healing</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Other Pre-specified</type>
        <title>Incision Length Correlated With Worst Pain</title>
        <description>Incision length (cm) correlated with worst pain. Worst pain ranged from 0 (no pain) to 10 (worst pain imaginable). LS Means adjusted for treatment, pooled center, salpingo-oophorectomy strata.</description>
        <time_frame>Day 1</time_frame>
        <population>mITT</population>
        <group_list>
          <group group_id="O1">
            <title>Pregabalin 150mg</title>
            <description>Pregabalin 75 mg twice a day (150 mg/day total)</description>
          </group>
          <group group_id="O2">
            <title>Pregabalin 300 mg</title>
            <description>Pregabalin 150 mg twice a day (300 mg/day total)</description>
          </group>
          <group group_id="O3">
            <title>Placebo</title>
            <description>Matching placebo capsule</description>
          </group>
        </group_list>
        <measure>
          <title>Incision Length Correlated With Worst Pain</title>
          <description>Incision length (cm) correlated with worst pain. Worst pain ranged from 0 (no pain) to 10 (worst pain imaginable). LS Means adjusted for treatment, pooled center, salpingo-oophorectomy strata.</description>
          <population>mITT</population>
          <units>Centimeter (cm)</units>
          <param>Least Squares Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="151"/>
                <count group_id="O2" value="149"/>
                <count group_id="O3" value="156"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="7.1074" spread="0.2010"/>
                    <measurement group_id="O2" value="7.2324" spread="0.1966"/>
                    <measurement group_id="O3" value="7.4437" spread="0.1977"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <groups_desc>24 hours</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.3506</p_value>
            <method>ANOVA</method>
            <method_desc>LS Means from ANOVA model with terms of treatment, pooled center and salpingo-oophorectomy strata.</method_desc>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Participant Satisfaction With Study Medication - Day 28 PS</title>
        <description>Participant satisfaction with study medication using the Global Evaluation of Study Medication questionaire. Participants overall impression (global evaluation) of the study medication was recorded by the participant by answering the following question: How would you rate the study medication you received for pain? Excellent 4; Good 3; Fair 2; Poor 1.</description>
        <time_frame>Day 28 PS</time_frame>
        <population>mITT; N=number of evaluable participants analyzed</population>
        <group_list>
          <group group_id="O1">
            <title>Pregabalin 150mg</title>
            <description>Pregabalin 75 mg twice a day (150 mg/day total)</description>
          </group>
          <group group_id="O2">
            <title>Pregabalin 300 mg</title>
            <description>Pregabalin 150 mg twice a day (300 mg/day total)</description>
          </group>
          <group group_id="O3">
            <title>Placebo</title>
            <description>Matching placebo capsule</description>
          </group>
        </group_list>
        <measure>
          <title>Participant Satisfaction With Study Medication - Day 28 PS</title>
          <description>Participant satisfaction with study medication using the Global Evaluation of Study Medication questionaire. Participants overall impression (global evaluation) of the study medication was recorded by the participant by answering the following question: How would you rate the study medication you received for pain? Excellent 4; Good 3; Fair 2; Poor 1.</description>
          <population>mITT; N=number of evaluable participants analyzed</population>
          <units>Percentage of participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="139"/>
                <count group_id="O2" value="142"/>
                <count group_id="O3" value="143"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Excellent</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="42.4"/>
                    <measurement group_id="O2" value="40.1"/>
                    <measurement group_id="O3" value="34.3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Good</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="41.7"/>
                    <measurement group_id="O2" value="34.5"/>
                    <measurement group_id="O3" value="35.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Fair</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="9.4"/>
                    <measurement group_id="O2" value="16.2"/>
                    <measurement group_id="O3" value="23.8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Poor</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="6.5"/>
                    <measurement group_id="O2" value="9.2"/>
                    <measurement group_id="O3" value="7.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <groups_desc>Day 28</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.0287</p_value>
            <method>Cochran-Mantel-Haenszel</method>
            <method_desc>CMH test adjusted for pooled centers and salpingo-oophorectomy strata.</method_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O2</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <groups_desc>Day 28</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.2270</p_value>
            <method>Cochran-Mantel-Haenszel</method>
            <method_desc>CMH test adjusted for pooled centers and salpingo-oophorectomy strata.</method_desc>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Pain Treatment Satisfaction Scale (PTSS): Satisfaction With Current Pain Medication</title>
        <description>Satisfaction with current pain medication ranged from 0 (worst possible response) to100 (best possible response). LS Means adjusted for treatment, pooled center and salpingo-oophorectomy strata.</description>
        <time_frame>Discharge (day 3 up to day 7 PS), Day 28 PS</time_frame>
        <population>mITT; n = number of evaluable participants analyzed for the given time point; N=number of evaluable participants analyzed</population>
        <group_list>
          <group group_id="O1">
            <title>Pregabalin 150mg</title>
            <description>Pregabalin 75 mg twice a day (150 mg/day total)</description>
          </group>
          <group group_id="O2">
            <title>Pregabalin 300 mg</title>
            <description>Pregabalin 150 mg twice a day (300 mg/day total)</description>
          </group>
          <group group_id="O3">
            <title>Placebo</title>
            <description>Matching placebo capsule</description>
          </group>
        </group_list>
        <measure>
          <title>Pain Treatment Satisfaction Scale (PTSS): Satisfaction With Current Pain Medication</title>
          <description>Satisfaction with current pain medication ranged from 0 (worst possible response) to100 (best possible response). LS Means adjusted for treatment, pooled center and salpingo-oophorectomy strata.</description>
          <population>mITT; n = number of evaluable participants analyzed for the given time point; N=number of evaluable participants analyzed</population>
          <units>Units on a scale</units>
          <param>Least Squares Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="138"/>
                <count group_id="O2" value="137"/>
                <count group_id="O3" value="139"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Medication Subscale/Discharge (n=138, 137, 139)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="79.43" spread="1.717"/>
                    <measurement group_id="O2" value="78.45" spread="1.747"/>
                    <measurement group_id="O3" value="76.71" spread="1.776"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Medication Subscale/Day 28 (n=133, 134, 137)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="82.52" spread="1.619"/>
                    <measurement group_id="O2" value="80.16" spread="1.601"/>
                    <measurement group_id="O3" value="78.26" spread="1.615"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Characteristic Subscale/Discharge (n=138,136,138)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="82.15" spread="1.565"/>
                    <measurement group_id="O2" value="81.88" spread="1.597"/>
                    <measurement group_id="O3" value="79.58" spread="1.623"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Characteristic Subscale/Day 28 (n=133, 133, 137)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="84.82" spread="1.448"/>
                    <measurement group_id="O2" value="83.16" spread="1.438"/>
                    <measurement group_id="O3" value="81.69" spread="1.445"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Efficacy Subscale/Discharge (n=138, 137, 139)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="76.68" spread="2.264"/>
                    <measurement group_id="O2" value="75.04" spread="2.304"/>
                    <measurement group_id="O3" value="73.77" spread="2.342"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Efficacy Subscale/Day 28 (n=133, 134, 136)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="80.20" spread="2.161"/>
                    <measurement group_id="O2" value="76.92" spread="2.138"/>
                    <measurement group_id="O3" value="74.82" spread="2.166"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <groups_desc>Medication Subscale at Discharge</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.1872</p_value>
            <method>ANOVA</method>
            <method_desc>LS Means from ANOVA model with terms of treatment, pooled center and salpingo-oophorectomy strata.</method_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O2</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <groups_desc>Medication Subscale at Discharge</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.3994</p_value>
            <method>ANOVA</method>
            <method_desc>LS Means from ANOVA model with terms of treatment, pooled center and salpingo-oophorectomy strata.</method_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <groups_desc>Medication Subscale at Day 28</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.0422</p_value>
            <method>ANOVA</method>
            <method_desc>LS Means from ANOVA model with terms of treatment, pooled center and salpingo-oophorectomy strata.</method_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O2</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <groups_desc>Medication Subscale at Day 28</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.3647</p_value>
            <method>ANOVA</method>
            <method_desc>LS Means from ANOVA model with terms of treatment, pooled center and salpingo-oophorectomy strata.</method_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <groups_desc>Characteristics at Discharge</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.1729</p_value>
            <method>ANOVA</method>
            <method_desc>LS Means from ANOVA model with terms of treatment, pooled center and salpingo-oophorectomy strata.</method_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O2</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <groups_desc>Characteristics at Discharge</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.2234</p_value>
            <method>ANOVA</method>
            <method_desc>LS Means from ANOVA model with terms of treatment, pooled center and salpingo-oophorectomy strata.</method_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <groups_desc>Characteristics at Day 28</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.0950</p_value>
            <method>ANOVA</method>
            <method_desc>LS Means from ANOVA model with terms of treatment, pooled center and salpingo-oophorectomy strata.</method_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O2</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <groups_desc>Characteristics at Day 28</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.4345</p_value>
            <method>ANOVA</method>
            <method_desc>LS Means from ANOVA model with terms of treatment, pooled center and salpingo-oophorectomy strata.</method_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <groups_desc>Efficacy at Discharge</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.2840</p_value>
            <method>ANOVA</method>
            <method_desc>LS Means from ANOVA model with terms of treatment, pooled center and salpingo-oophorectomy strata.</method_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O2</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <groups_desc>Efficacy at Discharge</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.6404</p_value>
            <method>ANOVA</method>
            <method_desc>LS Means from ANOVA model with terms of treatment, pooled center and salpingo-oophorectomy strata.</method_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <groups_desc>Efficacy at Day 28</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.0550</p_value>
            <method>ANOVA</method>
            <method_desc>LS Means from ANOVA model with terms of treatment, pooled center and salpingo-oophorectomy strata.</method_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O2</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <groups_desc>Efficacy at Day 28</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.4531</p_value>
            <method>ANOVA</method>
            <method_desc>LS Means from ANOVA model with terms of treatment, pooled center and salpingo-oophorectomy strata.</method_desc>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Pain Treatment Satisfaction Scale (PTSS): Impact of Current Pain Medication</title>
        <description>Impact of current pain medication response scale: 0 (worst possible response) to 100 (best possible response). LS Means adjusted for treatment, pooled center and salpingo-oophorectomy strata.</description>
        <time_frame>Discharge (day 3 up to day 7 PS), Day 28 PS</time_frame>
        <population>mITT; n = number of evaluable participants analyzed for the given time point; N=number of evaluable participants analyzed</population>
        <group_list>
          <group group_id="O1">
            <title>Pregabalin 150mg</title>
            <description>Pregabalin 75 mg twice a day (150 mg/day total)</description>
          </group>
          <group group_id="O2">
            <title>Pregabalin 300 mg</title>
            <description>Pregabalin 150 mg twice a day (300 mg/day total)</description>
          </group>
          <group group_id="O3">
            <title>Placebo</title>
            <description>Matching placebo capsule</description>
          </group>
        </group_list>
        <measure>
          <title>Pain Treatment Satisfaction Scale (PTSS): Impact of Current Pain Medication</title>
          <description>Impact of current pain medication response scale: 0 (worst possible response) to 100 (best possible response). LS Means adjusted for treatment, pooled center and salpingo-oophorectomy strata.</description>
          <population>mITT; n = number of evaluable participants analyzed for the given time point; N=number of evaluable participants analyzed</population>
          <units>Units on a scale</units>
          <param>Least Squares Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="139"/>
                <count group_id="O2" value="141"/>
                <count group_id="O3" value="141"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Discharge (n=139, 141, 140)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="72.73" spread="2.080"/>
                    <measurement group_id="O2" value="66.28" spread="2.099"/>
                    <measurement group_id="O3" value="72.82" spread="2.159"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 28 (n=133, 135, 141)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="76.41" spread="2.180"/>
                    <measurement group_id="O2" value="69.53" spread="2.181"/>
                    <measurement group_id="O3" value="69.05" spread="2.156"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <groups_desc>Discharge</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.9712</p_value>
            <method>ANOVA</method>
            <method_desc>LS Means from ANOVA model with terms of treatment, pooled center and salpingo-oophorectomy strata.</method_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O2</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <groups_desc>Discharge</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.0112</p_value>
            <method>ANOVA</method>
            <method_desc>LS Means from ANOVA model with terms of treatment, pooled center and salpingo-oophorectomy strata.</method_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <groups_desc>Day 28</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.0090</p_value>
            <method>ANOVA</method>
            <method_desc>LS Means from ANOVA model with terms of treatment, pooled center and salpingo-oophorectomy strata.</method_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O2</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <groups_desc>Day 28</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.8650</p_value>
            <method>ANOVA</method>
            <method_desc>LS Means from ANOVA model with terms of treatment, pooled center and salpingo-oophorectomy strata.</method_desc>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Quality of Life Using EuroQol (EQ-5D) Health State Profile</title>
        <description>Participant rated questionnaire assessed current health for 6 domains: mobility/self-care/ usual activities/pain/discomfort/anxiety and depression. Scoring developed by EuroQol Group assigned a utility value for each domain in the profile. Scores ranged from 1 better health (no problems) to 3 worst health (eg, &quot;confined to bed&quot;). Score transformed and resulted in a total score range -0.594 to 1.000; higher score=better health state. Health profile scores estimated using Dolan computational algorithms 1997 and 2001. LS Means adjusted for treatment/pooled center/salpingo-oophorectomy strata.</description>
        <time_frame>Discharge (day 3 up to day 7 PS) and day 28 PS</time_frame>
        <population>mITT; n = number of evaluable participants analyzed for the given time point; N=number of evaluable participants analyzed</population>
        <group_list>
          <group group_id="O1">
            <title>Pregabalin 150mg</title>
            <description>Pregabalin 75 mg twice a day (150 mg/day total)</description>
          </group>
          <group group_id="O2">
            <title>Pregabalin 300 mg</title>
            <description>Pregabalin 150 mg twice a day (300 mg/day total)</description>
          </group>
          <group group_id="O3">
            <title>Placebo</title>
            <description>Matching placebo capsule</description>
          </group>
        </group_list>
        <measure>
          <title>Quality of Life Using EuroQol (EQ-5D) Health State Profile</title>
          <description>Participant rated questionnaire assessed current health for 6 domains: mobility/self-care/ usual activities/pain/discomfort/anxiety and depression. Scoring developed by EuroQol Group assigned a utility value for each domain in the profile. Scores ranged from 1 better health (no problems) to 3 worst health (eg, &quot;confined to bed&quot;). Score transformed and resulted in a total score range -0.594 to 1.000; higher score=better health state. Health profile scores estimated using Dolan computational algorithms 1997 and 2001. LS Means adjusted for treatment/pooled center/salpingo-oophorectomy strata.</description>
          <population>mITT; n = number of evaluable participants analyzed for the given time point; N=number of evaluable participants analyzed</population>
          <units>Units on a scale</units>
          <param>Least Squares Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="140"/>
                <count group_id="O2" value="143"/>
                <count group_id="O3" value="142"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>EQ-5D 1997, Discharge (n=138, 141, 138)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.57" spread="0.021"/>
                    <measurement group_id="O2" value="0.61" spread="0.021"/>
                    <measurement group_id="O3" value="0.58" spread="0.022"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>EQ-5D 1997, Day 28 (n=140, 143, 142)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.81" spread="0.014"/>
                    <measurement group_id="O2" value="0.78" spread="0.014"/>
                    <measurement group_id="O3" value="0.78" spread="0.014"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>EQ-5D 2001, Discharge (n=138, 141, 138)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.59" spread="0.018"/>
                    <measurement group_id="O2" value="0.62" spread="0.018"/>
                    <measurement group_id="O3" value="0.60" spread="0.019"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>EQ-5D 2001, Day 28 (n=140, 143, 142)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.81" spread="0.014"/>
                    <measurement group_id="O2" value="0.78" spread="0.014"/>
                    <measurement group_id="O3" value="0.78" spread="0.014"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <groups_desc>EQ-5D 1997 Discharge</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.8914</p_value>
            <method>ANOVA</method>
            <method_desc>LS Means from ANOVA model with terms of treatment, pooled center and salpingo-oophorectomy strata.</method_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O2</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <groups_desc>EQ-5D 1997 Discharge</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.2214</p_value>
            <method>ANOVA</method>
            <method_desc>LS Means from ANOVA model with terms of treatment, pooled center and salpingo-oophorectomy strata.</method_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <groups_desc>EQ-5D 1997 Day 28</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.1008</p_value>
            <method>ANOVA</method>
            <method_desc>LS Means from ANOVA model with terms of treatment, pooled center and salpingo-oophorectomy strata.</method_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O2</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <groups_desc>EQ-5D 1997 Day 28</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.9135</p_value>
            <method>ANOVA</method>
            <method_desc>LS Means from ANOVA model with terms of treatment, pooled center and salpingo-oophorectomy strata.</method_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <groups_desc>EQ-5D 2001 Discharge</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.5609</p_value>
            <method>ANOVA</method>
            <method_desc>LS Means from ANOVA model with terms of treatment, pooled center and salpingo-oophorectomy strata.</method_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O2</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <groups_desc>EQ-5D 2001 Discharge</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.4047</p_value>
            <method>ANOVA</method>
            <method_desc>LS Means from ANOVA model with terms of treatment, pooled center and salpingo-oophorectomy strata.</method_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <groups_desc>EQ-5D 2001 Day 28</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.1663</p_value>
            <method>ANOVA</method>
            <method_desc>LS Means from ANOVA model with terms of treatment, pooled center and salpingo-oophorectomy strata.</method_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O2</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <groups_desc>EQ-5D 2001 Day 28</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.8364</p_value>
            <method>ANOVA</method>
            <method_desc>LS Means from ANOVA model with terms of treatment, pooled center and salpingo-oophorectomy strata.</method_desc>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Time to Meet Hospital Discharge Criteria</title>
        <description>Mean time from end of surgery to meet protocol defined hospital discharge criteria: participant no longer received parental opioids, was able to dress and mobilize without assistance, and had normal intake of food and fluids.</description>
        <time_frame>Day 1 up to Day 7 PS</time_frame>
        <population>mITT</population>
        <group_list>
          <group group_id="O1">
            <title>Pregabalin 150mg</title>
            <description>Pregabalin 75 mg twice a day (150 mg/day total)</description>
          </group>
          <group group_id="O2">
            <title>Pregabalin 300 mg</title>
            <description>Pregabalin 150 mg twice a day (300 mg/day total)</description>
          </group>
          <group group_id="O3">
            <title>Placebo</title>
            <description>Matching placebo capsule</description>
          </group>
        </group_list>
        <measure>
          <title>Time to Meet Hospital Discharge Criteria</title>
          <description>Mean time from end of surgery to meet protocol defined hospital discharge criteria: participant no longer received parental opioids, was able to dress and mobilize without assistance, and had normal intake of food and fluids.</description>
          <population>mITT</population>
          <units>Hours</units>
          <param>Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="151"/>
                <count group_id="O2" value="149"/>
                <count group_id="O3" value="156"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="57.670" spread="2.829"/>
                    <measurement group_id="O2" value="60.751" spread="2.678"/>
                    <measurement group_id="O3" value="58.745" spread="2.786"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <groups_desc>Kaplan-Meier method was used for survival distribution estimation;</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.7218</p_value>
            <method>Log Rank</method>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O2</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <groups_desc>Kaplan-Meier method was used for survival distribution estimation;</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.4425</p_value>
            <method>Log Rank</method>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Time to Actual Discharge</title>
        <description>Mean time from end of surgery to actual hospital discharge. Participant was expected to remain at the hospital for a minimum of 2 days following surgery.</description>
        <time_frame>Day 1 up to Day 7 PS</time_frame>
        <population>mITT</population>
        <group_list>
          <group group_id="O1">
            <title>Pregabalin 150mg</title>
            <description>Pregabalin 75 mg twice a day (150 mg/day total)</description>
          </group>
          <group group_id="O2">
            <title>Pregabalin 300 mg</title>
            <description>Pregabalin 150 mg twice a day (300 mg/day total)</description>
          </group>
          <group group_id="O3">
            <title>Placebo</title>
            <description>Matching placebo capsule</description>
          </group>
        </group_list>
        <measure>
          <title>Time to Actual Discharge</title>
          <description>Mean time from end of surgery to actual hospital discharge. Participant was expected to remain at the hospital for a minimum of 2 days following surgery.</description>
          <population>mITT</population>
          <units>Hours</units>
          <param>Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="151"/>
                <count group_id="O2" value="149"/>
                <count group_id="O3" value="156"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="79.339" spread="2.547"/>
                    <measurement group_id="O2" value="85.221" spread="3.935"/>
                    <measurement group_id="O3" value="78.740" spread="2.441"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <groups_desc>Kaplan-Meier method was used for survival distribution estimation;</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.7889</p_value>
            <method>Log Rank</method>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O2</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <groups_desc>Kaplan-Meier method was used for survival distribution estimation;</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.1565</p_value>
            <method>Log Rank</method>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Other Pre-specified</type>
        <title>Neuropathic Pain Symptom Inventory (NPSI)</title>
        <description>Pain characteristics in participants who reported pain (mBPI-sf, NPSI); NPSI a participant rated questionnaire to evaluate different symptoms of neuropathic pain, burning spontaneous pain, pressing spontaneous pain, paroxysmal pain, evoked pain, and paresthesia/dysesthesia at discharge. NPSI Total Score ranged from 0 to 0.5; NPSI subscales pain ranged from 0 (no pain) to 10 (worst pain). LS Means adjusted for treatment, pooled center and salpingo-oophorectomy strata.</description>
        <time_frame>Discharge (day 3 up to day 7 PS)</time_frame>
        <population>mITT; n = number of evaluable participants analyzed for the given time point; N=number of evaluable participants analyzed</population>
        <group_list>
          <group group_id="O1">
            <title>Pregabalin 150mg</title>
            <description>Pregabalin 75 mg twice a day (150 mg/day total)</description>
          </group>
          <group group_id="O2">
            <title>Pregabalin 300 mg</title>
            <description>Pregabalin 150 mg twice a day (300 mg/day total)</description>
          </group>
          <group group_id="O3">
            <title>Placebo</title>
            <description>Matching placebo capsule</description>
          </group>
        </group_list>
        <measure>
          <title>Neuropathic Pain Symptom Inventory (NPSI)</title>
          <description>Pain characteristics in participants who reported pain (mBPI-sf, NPSI); NPSI a participant rated questionnaire to evaluate different symptoms of neuropathic pain, burning spontaneous pain, pressing spontaneous pain, paroxysmal pain, evoked pain, and paresthesia/dysesthesia at discharge. NPSI Total Score ranged from 0 to 0.5; NPSI subscales pain ranged from 0 (no pain) to 10 (worst pain). LS Means adjusted for treatment, pooled center and salpingo-oophorectomy strata.</description>
          <population>mITT; n = number of evaluable participants analyzed for the given time point; N=number of evaluable participants analyzed</population>
          <units>Units on a scale</units>
          <param>Least Squares Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="139"/>
                <count group_id="O2" value="145"/>
                <count group_id="O3" value="143"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Total subscale(n=132, 131, 136)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.073" spread="0.0057"/>
                    <measurement group_id="O2" value="0.070" spread="0.0057"/>
                    <measurement group_id="O3" value="0.076" spread="0.0058"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Burning Spontaneous subscale (n=139, 145, 143)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.86" spread="0.235"/>
                    <measurement group_id="O2" value="1.80" spread="0.231"/>
                    <measurement group_id="O3" value="1.75" spread="0.235"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Pressing Spontaneous subscale (n=139, 145, 143)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.74" spread="0.166"/>
                    <measurement group_id="O2" value="1.60" spread="0.164"/>
                    <measurement group_id="O3" value="1.57" spread="0.168"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Paroxysmal pain subscale (n=138, 140, 143)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.08" spread="0.155"/>
                    <measurement group_id="O2" value="0.95" spread="0.154"/>
                    <measurement group_id="O3" value="1.18" spread="0.156"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Evoked Pain subscale (n=134, 135, 142)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2.14" spread="0.177"/>
                    <measurement group_id="O2" value="2.27" spread="0.177"/>
                    <measurement group_id="O3" value="2.27" spread="0.175"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Paresthesia/dysesthesia (n=136, 140, 141)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.46" spread="0.129"/>
                    <measurement group_id="O2" value="0.67" spread="0.127"/>
                    <measurement group_id="O3" value="0.91" spread="0.128"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <groups_desc>Total subscale</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.6211</p_value>
            <method>ANOVA</method>
            <method_desc>LS Means from ANOVA model with terms of treatment, pooled center and salpingo-oophorectomy strata.</method_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O2</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <groups_desc>Total subscale</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.3687</p_value>
            <method>ANOVA</method>
            <method_desc>LS Means from ANOVA model with terms of treatment, pooled center and salpingo-oophorectomy strata.</method_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <groups_desc>Burning Spontaneous subscale</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.7078</p_value>
            <method>ANOVA</method>
            <method_desc>LS Means from ANOVA model with terms of treatment, pooled center and salpingo-oophorectomy strata.</method_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O2</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <groups_desc>Burning Spontaneous subscale</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.8696</p_value>
            <method>ANOVA</method>
            <method_desc>LS Means from ANOVA model with terms of treatment, pooled center and salpingo-oophorectomy strata.</method_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <groups_desc>Pressing Spontaneous subscale</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.4320</p_value>
            <method>ANOVA</method>
            <method_desc>LS Means from ANOVA model with terms of treatment, pooled center and salpingo-oophorectomy strata.</method_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O2</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <groups_desc>Pressing Spontaneous subscale</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.8843</p_value>
            <method>ANOVA</method>
            <method_desc>LS Means from ANOVA model with terms of treatment, pooled center and salpingo-oophorectomy strata.</method_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <groups_desc>Paroxysmal pain subscale</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.6215</p_value>
            <method>ANOVA</method>
            <method_desc>LS Means from ANOVA model with terms of treatment, pooled center and salpingo-oophorectomy strata.</method_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O2</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <groups_desc>Paroxysmal pain subscale</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.2722</p_value>
            <method>ANOVA</method>
            <method_desc>LS Means from ANOVA model with terms of treatment, pooled center and salpingo-oophorectomy strata.</method_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <groups_desc>Evoked Pain subscale</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.5500</p_value>
            <method>ANOVA</method>
            <method_desc>LS Means from ANOVA model with terms of treatment, pooled center and salpingo-oophorectomy strata.</method_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O2</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <groups_desc>Evoked Pain subscale</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.9942</p_value>
            <method>ANOVA</method>
            <method_desc>LS Means from ANOVA model with terms of treatment, pooled center and salpingo-oophorectomy strata.</method_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <groups_desc>Paresthesia/dysesthesia</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.0075</p_value>
            <method>ANOVA</method>
            <method_desc>LS Means from ANOVA model with terms of treatment, pooled center and salpingo-oophorectomy strata.</method_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O2</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <groups_desc>Paresthesia/dysesthesia</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.1464</p_value>
            <method>ANOVA</method>
            <method_desc>LS Means from ANOVA model with terms of treatment, pooled center and salpingo-oophorectomy strata.</method_desc>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Incidence of Chronic Post-operative Pain</title>
        <description>Chronic post-operative pain as a result of abdominal hysterectomy as reported by participants on PS questionaire of pain within last 24 hours in area affected by surgery.</description>
        <time_frame>3 and 6 Months PS</time_frame>
        <population>mITT; n = number of evaluable participants analyzed for the given time point; N=number of evaluable participants analyzed. Participants reported as no chronic pain in the 3 month visit were carried over to the missing data at 6 month visit.</population>
        <group_list>
          <group group_id="O1">
            <title>Pregabalin 150mg</title>
            <description>Pregabalin 75 mg twice a day (150 mg/day total)</description>
          </group>
          <group group_id="O2">
            <title>Pregabalin 300 mg</title>
            <description>Pregabalin 150 mg twice a day (300 mg/day total)</description>
          </group>
          <group group_id="O3">
            <title>Placebo</title>
            <description>Matching placebo capsule</description>
          </group>
        </group_list>
        <measure>
          <title>Incidence of Chronic Post-operative Pain</title>
          <description>Chronic post-operative pain as a result of abdominal hysterectomy as reported by participants on PS questionaire of pain within last 24 hours in area affected by surgery.</description>
          <population>mITT; n = number of evaluable participants analyzed for the given time point; N=number of evaluable participants analyzed. Participants reported as no chronic pain in the 3 month visit were carried over to the missing data at 6 month visit.</population>
          <units>Percentage of participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="138"/>
                <count group_id="O2" value="127"/>
                <count group_id="O3" value="141"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Months 3 PS (n =136, 127, 138)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="12.5"/>
                    <measurement group_id="O2" value="17.3"/>
                    <measurement group_id="O3" value="10.1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Months 6 PS (n =138, 127, 141)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="6.5"/>
                    <measurement group_id="O2" value="6.3"/>
                    <measurement group_id="O3" value="4.3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <groups_desc>Incidence of chronic PS pain at Month 3 PS.</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.9877</p_value>
            <method>Cochran-Mantel-Haenszel</method>
            <method_desc>p-values are derived from CMH test adjusted for pooled centers and salpingo-oophorectomy strata</method_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O2</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <groups_desc>Incidence of chronic PS pain at Month 3 PS.</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.1334</p_value>
            <method>Cochran-Mantel-Haenszel</method>
            <method_desc>p-values are derived from CMH test adjusted for pooled centers and salpingo-oophorectomy strata</method_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <groups_desc>Incidence of chronic PS pain at Month 6 PS.</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.3566</p_value>
            <method>Cochran-Mantel-Haenszel</method>
            <method_desc>p-values are derived from CMH test adjusted for pooled centers and salpingo-oophorectomy strata</method_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O2</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <groups_desc>Incidence of chronic PS pain at Month 6 PS.</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.6262</p_value>
            <method>Cochran-Mantel-Haenszel</method>
            <method_desc>p-values are derived from CMH test adjusted for pooled centers and salpingo-oophorectomy strata</method_desc>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Total Clinically Meaningful Event (CME) Score</title>
        <description>Total CME score calculated by summing the number of Clinically Meaningful Events (CMEs) across symptoms. CME for each symptom will be defined using the Opioid-Related Symptom Distress Scale (OR-SDS) a participant rated scale of symptoms within the last 24 hours. Total CME score could range from 0 to 9. LS Means adjusted for treatment, pooled center and salpingo-oophorectomy strata.</description>
        <time_frame>Surgery Day, Day 1, 2, 3, 4, 5 PS, Discharge (day 3 up to day 7 PS), Day 7, 14, 28 PS</time_frame>
        <population>mITT; n = number of evaluable participants analyzed for the given time point; N=number of evaluable participants analyzed</population>
        <group_list>
          <group group_id="O1">
            <title>Pregabalin 150mg</title>
            <description>Pregabalin 75 mg twice a day (150 mg/day total)</description>
          </group>
          <group group_id="O2">
            <title>Pregabalin 300 mg</title>
            <description>Pregabalin 150 mg twice a day (300 mg/day total)</description>
          </group>
          <group group_id="O3">
            <title>Placebo</title>
            <description>Matching placebo capsule</description>
          </group>
        </group_list>
        <measure>
          <title>Total Clinically Meaningful Event (CME) Score</title>
          <description>Total CME score calculated by summing the number of Clinically Meaningful Events (CMEs) across symptoms. CME for each symptom will be defined using the Opioid-Related Symptom Distress Scale (OR-SDS) a participant rated scale of symptoms within the last 24 hours. Total CME score could range from 0 to 9. LS Means adjusted for treatment, pooled center and salpingo-oophorectomy strata.</description>
          <population>mITT; n = number of evaluable participants analyzed for the given time point; N=number of evaluable participants analyzed</population>
          <units>Units on a scale</units>
          <param>Least Squares Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="148"/>
                <count group_id="O2" value="147"/>
                <count group_id="O3" value="154"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Surgery Day (n=26, 25, 32)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.9" spread="0.29"/>
                    <measurement group_id="O2" value="0.8" spread="0.30"/>
                    <measurement group_id="O3" value="0.9" spread="0.26"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 1 PS (n=148, 147, 154)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.1" spread="0.13"/>
                    <measurement group_id="O2" value="1.1" spread="0.13"/>
                    <measurement group_id="O3" value="1.2" spread="0.13"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 2 PS (n=108, 116, 114)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.6" spread="0.12"/>
                    <measurement group_id="O2" value="0.6" spread="0.12"/>
                    <measurement group_id="O3" value="0.7" spread="0.12"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 3 PS (n=38, 36, 32)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.5" spread="0.19"/>
                    <measurement group_id="O2" value="0.7" spread="0.17"/>
                    <measurement group_id="O3" value="0.3" spread="0.19"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 4 PS (n=14, 16, 11)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.0" spread="0.19"/>
                    <measurement group_id="O2" value="0.4" spread="0.15"/>
                    <measurement group_id="O3" value="0.3" spread="0.22"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 5 PS (n=5, 9, 6)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.4" spread="0.19"/>
                    <measurement group_id="O2" value="0.1" spread="0.13"/>
                    <measurement group_id="O3" value="0.3" spread="0.18"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Discharge (n=133, 132, 133)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.4" spread="0.09"/>
                    <measurement group_id="O2" value="0.4" spread="0.09"/>
                    <measurement group_id="O3" value="0.3" spread="0.09"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 7 PS (n=119, 117, 120)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.2" spread="0.06"/>
                    <measurement group_id="O2" value="0.4" spread="0.06"/>
                    <measurement group_id="O3" value="0.2" spread="0.06"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 14 PS (n=119, 116, 124)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.1" spread="0.06"/>
                    <measurement group_id="O2" value="0.2" spread="0.06"/>
                    <measurement group_id="O3" value="0.1" spread="0.06"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 28 PS (n=129, 135, 136)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.0" spread="0.06"/>
                    <measurement group_id="O2" value="0.2" spread="0.06"/>
                    <measurement group_id="O3" value="0.2" spread="0.06"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <groups_desc>Surgery day;</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.9463</p_value>
            <method>ANOVA</method>
            <method_desc>LS Means from ANOVA model with terms of treatment, pooled center and salpingo-oophorectomy strata.</method_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O2</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <groups_desc>Surgery day;</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.7347</p_value>
            <method>ANOVA</method>
            <method_desc>LS Means from ANOVA model with terms of treatment, pooled center and salpingo-oophorectomy strata.</method_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <groups_desc>Day 1 PS;</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.4132</p_value>
            <method>ANOVA</method>
            <method_desc>LS Means from ANOVA model with terms of treatment, pooled center and salpingo-oophorectomy strata.</method_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O2</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <groups_desc>Day 1 PS;</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.4929</p_value>
            <method>ANOVA</method>
            <method_desc>LS Means from ANOVA model with terms of treatment, pooled center and salpingo-oophorectomy strata.</method_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <groups_desc>Day 2 PS;</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.6003</p_value>
            <method>ANOVA</method>
            <method_desc>LS Means from ANOVA model with terms of treatment, pooled center and salpingo-oophorectomy strata.</method_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O2</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <groups_desc>Day 2 PS;</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.9343</p_value>
            <method>ANOVA</method>
            <method_desc>LS Means from ANOVA model with terms of treatment, pooled center and salpingo-oophorectomy strata.</method_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <groups_desc>Day 3 PS;</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.3838</p_value>
            <method>ANOVA</method>
            <method_desc>LS Means from ANOVA model with terms of treatment, pooled center and salpingo-oophorectomy strata.</method_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O2</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <groups_desc>Day 3 PS;</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.1351</p_value>
            <method>ANOVA</method>
            <method_desc>LS Means from ANOVA model with terms of treatment, pooled center and salpingo-oophorectomy strata.</method_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <groups_desc>Day 4 PS;</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.3343</p_value>
            <method>ANOVA</method>
            <method_desc>LS Means from ANOVA model with terms of treatment, pooled center and salpingo-oophorectomy strata.</method_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O2</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <groups_desc>Day 4 PS;</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.7948</p_value>
            <method>ANOVA</method>
            <method_desc>LS Means from ANOVA model with terms of treatment, pooled center and salpingo-oophorectomy strata.</method_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <groups_desc>Day 5 PS;</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.8090</p_value>
            <method>ANOVA</method>
            <method_desc>LS Means from ANOVA model with terms of treatment, pooled center and salpingo-oophorectomy strata.</method_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O2</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <groups_desc>Day 5 PS;</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.4035</p_value>
            <method>ANOVA</method>
            <method_desc>LS Means from ANOVA model with terms of treatment, pooled center and salpingo-oophorectomy strata.</method_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <groups_desc>Discharge</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.6009</p_value>
            <method>ANOVA</method>
            <method_desc>LS Means from ANOVA model with terms of treatment, pooled center and salpingo-oophorectomy strata.</method_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O2</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <groups_desc>Discharge</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.7597</p_value>
            <method>ANOVA</method>
            <method_desc>LS Means from ANOVA model with terms of treatment, pooled center and salpingo-oophorectomy strata.</method_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <groups_desc>Day 7</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.7804</p_value>
            <method>ANOVA</method>
            <method_desc>LS Means from ANOVA model with terms of treatment, pooled center and salpingo-oophorectomy strata.</method_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O2</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <groups_desc>Day 7</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.0463</p_value>
            <method>ANOVA</method>
            <method_desc>LS Means from ANOVA model with terms of treatment, pooled center and salpingo-oophorectomy strata.</method_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <groups_desc>Day 14</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.4951</p_value>
            <method>ANOVA</method>
            <method_desc>LS Means from ANOVA model with terms of treatment, pooled center and salpingo-oophorectomy strata.</method_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O2</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <groups_desc>Day 14</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.3030</p_value>
            <method>ANOVA</method>
            <method_desc>LS Means from ANOVA model with terms of treatment, pooled center and salpingo-oophorectomy strata.</method_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <groups_desc>Day 28</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.0104</p_value>
            <method>ANOVA</method>
            <method_desc>LS Means from ANOVA model with terms of treatment, pooled center and salpingo-oophorectomy strata.</method_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O2</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <groups_desc>Day 28</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.6978</p_value>
            <method>ANOVA</method>
            <method_desc>LS Means from ANOVA model with terms of treatment, pooled center and salpingo-oophorectomy strata.</method_desc>
          </analysis>
        </analysis_list>
      </outcome>
    </outcome_list>

    <reported_events>
      <group_list>
        <group group_id="E1">
          <title>Pregabalin 150mg</title>
          <description>Pregabalin 75 mg twice a day (150 mg/day total)</description>
        </group>
        <group group_id="E2">
          <title>Pregabalin 300 mg</title>
          <description>Pregabalin 150 mg twice a day (300 mg/day total)</description>
        </group>
        <group group_id="E3">
          <title>Placebo</title>
          <description>Matching placebo capsule</description>
        </group>
      </group_list>
      <serious_events>
        <default_vocab>MedDRA 13.1</default_vocab>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="9" subjects_at_risk="161"/>
                <counts group_id="E2" subjects_affected="11" subjects_at_risk="166"/>
                <counts group_id="E3" subjects_affected="15" subjects_at_risk="167"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Blood and lymphatic system disorders</title>
            <event_list>
              <event>
                <sub_title>Anaemia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="161"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="166"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="167"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Cardiac disorders</title>
            <event_list>
              <event>
                <sub_title>Atrioventricular block complete</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="161"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="166"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="167"/>
              </event>
              <event>
                <sub_title>Tachycardia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="161"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="166"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="167"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Abdominal distension</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="161"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="166"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="167"/>
              </event>
              <event>
                <sub_title>Abdominal pain</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="161"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="166"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="167"/>
              </event>
              <event>
                <sub_title>Abdominal pain lower</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="161"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="166"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="167"/>
              </event>
              <event>
                <sub_title>Constipation</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="161"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="166"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="167"/>
              </event>
              <event>
                <sub_title>Gastritis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="161"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="166"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="167"/>
              </event>
              <event>
                <sub_title>Ileus</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="161"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="166"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="167"/>
              </event>
              <event>
                <sub_title>Intestinal obstruction</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="161"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="166"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="167"/>
              </event>
              <event>
                <sub_title>Rectal perforation</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="161"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="166"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="167"/>
              </event>
              <event>
                <sub_title>Umbilical hernia</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="161"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="166"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="167"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>Chest pain</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="161"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="166"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="167"/>
              </event>
              <event>
                <sub_title>Impaired healing</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="161"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="166"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="167"/>
              </event>
              <event>
                <sub_title>Pyrexia</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="161"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="166"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="167"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>Incision site infection</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="161"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="166"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="167"/>
              </event>
              <event>
                <sub_title>Pneumonia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="161"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="166"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="167"/>
              </event>
              <event>
                <sub_title>Postoperative wound infection</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="161"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="166"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="167"/>
              </event>
              <event>
                <sub_title>Pyelonephritis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="161"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="166"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="167"/>
              </event>
              <event>
                <sub_title>Sepsis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="161"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="166"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="167"/>
              </event>
              <event>
                <sub_title>Urinary tract infection</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="161"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="166"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="167"/>
              </event>
              <event>
                <sub_title>Wound infection</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="161"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="166"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="167"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Injury, poisoning and procedural complications</title>
            <event_list>
              <event>
                <sub_title>Abdominal wound dehiscence</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="161"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="166"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="167"/>
              </event>
              <event>
                <sub_title>Post procedural haematoma</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="161"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="166"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="167"/>
              </event>
              <event>
                <sub_title>Postoperative ileus</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="161"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="166"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="167"/>
              </event>
              <event>
                <sub_title>Ureteric injury</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="161"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="166"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="167"/>
              </event>
              <event>
                <sub_title>Wound complication</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="161"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="166"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="167"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Investigations</title>
            <event_list>
              <event>
                <sub_title>Liver function test abnormal</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="161"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="166"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="167"/>
              </event>
              <event>
                <sub_title>Oxygen saturation decreased</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="161"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="166"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="167"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Neoplasms benign, malignant and unspecified (incl cysts and polyps)</title>
            <event_list>
              <event>
                <sub_title>Cervix carcinoma</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="161"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="166"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="167"/>
              </event>
              <event>
                <sub_title>Endometrial cancer</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="161"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="166"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="167"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Renal and urinary disorders</title>
            <event_list>
              <event>
                <sub_title>Dysuria</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="161"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="166"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="167"/>
              </event>
              <event>
                <sub_title>Ureteric stenosis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="161"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="166"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="167"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Reproductive system and breast disorders</title>
            <event_list>
              <event>
                <sub_title>Pelvic haematoma</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="161"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="166"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="167"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Respiratory, thoracic and mediastinal disorders</title>
            <event_list>
              <event>
                <sub_title>Dyspnoea</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="161"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="166"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="167"/>
              </event>
              <event>
                <sub_title>Hypoxia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="161"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="166"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="167"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Vascular disorders</title>
            <event_list>
              <event>
                <sub_title>Haematoma</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="161"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="166"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="167"/>
              </event>
              <event>
                <sub_title>Hypertension</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="161"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="166"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="167"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>2</frequency_threshold>
        <default_vocab>MedDRA 13.1</default_vocab>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="125" subjects_at_risk="161"/>
                <counts group_id="E2" subjects_affected="128" subjects_at_risk="166"/>
                <counts group_id="E3" subjects_affected="124" subjects_at_risk="167"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Blood and lymphatic system disorders</title>
            <event_list>
              <event>
                <sub_title>Anaemia</sub_title>
                <counts group_id="E1" subjects_affected="9" subjects_at_risk="161"/>
                <counts group_id="E2" subjects_affected="5" subjects_at_risk="166"/>
                <counts group_id="E3" subjects_affected="5" subjects_at_risk="167"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Cardiac disorders</title>
            <event_list>
              <event>
                <sub_title>Tachycardia</sub_title>
                <counts group_id="E1" subjects_affected="4" subjects_at_risk="161"/>
                <counts group_id="E2" subjects_affected="6" subjects_at_risk="166"/>
                <counts group_id="E3" subjects_affected="3" subjects_at_risk="167"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Eye disorders</title>
            <event_list>
              <event>
                <sub_title>Vision blurred</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="161"/>
                <counts group_id="E2" subjects_affected="4" subjects_at_risk="166"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="167"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Abdominal distension</sub_title>
                <counts group_id="E1" subjects_affected="6" subjects_at_risk="161"/>
                <counts group_id="E2" subjects_affected="5" subjects_at_risk="166"/>
                <counts group_id="E3" subjects_affected="3" subjects_at_risk="167"/>
              </event>
              <event>
                <sub_title>Abdominal pain</sub_title>
                <counts group_id="E1" subjects_affected="6" subjects_at_risk="161"/>
                <counts group_id="E2" subjects_affected="4" subjects_at_risk="166"/>
                <counts group_id="E3" subjects_affected="10" subjects_at_risk="167"/>
              </event>
              <event>
                <sub_title>Constipation</sub_title>
                <counts group_id="E1" subjects_affected="46" subjects_at_risk="161"/>
                <counts group_id="E2" subjects_affected="49" subjects_at_risk="166"/>
                <counts group_id="E3" subjects_affected="45" subjects_at_risk="167"/>
              </event>
              <event>
                <sub_title>Diarrhoea</sub_title>
                <counts group_id="E1" subjects_affected="4" subjects_at_risk="161"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="166"/>
                <counts group_id="E3" subjects_affected="7" subjects_at_risk="167"/>
              </event>
              <event>
                <sub_title>Dyspepsia</sub_title>
                <counts group_id="E1" subjects_affected="5" subjects_at_risk="161"/>
                <counts group_id="E2" subjects_affected="6" subjects_at_risk="166"/>
                <counts group_id="E3" subjects_affected="6" subjects_at_risk="167"/>
              </event>
              <event>
                <sub_title>Flatulence</sub_title>
                <counts group_id="E1" subjects_affected="16" subjects_at_risk="161"/>
                <counts group_id="E2" subjects_affected="10" subjects_at_risk="166"/>
                <counts group_id="E3" subjects_affected="13" subjects_at_risk="167"/>
              </event>
              <event>
                <sub_title>Nausea</sub_title>
                <counts group_id="E1" subjects_affected="67" subjects_at_risk="161"/>
                <counts group_id="E2" subjects_affected="60" subjects_at_risk="166"/>
                <counts group_id="E3" subjects_affected="76" subjects_at_risk="167"/>
              </event>
              <event>
                <sub_title>Retching</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="161"/>
                <counts group_id="E2" subjects_affected="6" subjects_at_risk="166"/>
                <counts group_id="E3" subjects_affected="4" subjects_at_risk="167"/>
              </event>
              <event>
                <sub_title>Vomiting</sub_title>
                <counts group_id="E1" subjects_affected="33" subjects_at_risk="161"/>
                <counts group_id="E2" subjects_affected="20" subjects_at_risk="166"/>
                <counts group_id="E3" subjects_affected="30" subjects_at_risk="167"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>Chills</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="161"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="166"/>
                <counts group_id="E3" subjects_affected="4" subjects_at_risk="167"/>
              </event>
              <event>
                <sub_title>Fatigue</sub_title>
                <counts group_id="E1" subjects_affected="38" subjects_at_risk="161"/>
                <counts group_id="E2" subjects_affected="46" subjects_at_risk="166"/>
                <counts group_id="E3" subjects_affected="34" subjects_at_risk="167"/>
              </event>
              <event>
                <sub_title>Oedema peripheral</sub_title>
                <counts group_id="E1" subjects_affected="4" subjects_at_risk="161"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="166"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="167"/>
              </event>
              <event>
                <sub_title>Pain</sub_title>
                <counts group_id="E1" subjects_affected="4" subjects_at_risk="161"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="166"/>
                <counts group_id="E3" subjects_affected="3" subjects_at_risk="167"/>
              </event>
              <event>
                <sub_title>Pyrexia</sub_title>
                <counts group_id="E1" subjects_affected="31" subjects_at_risk="161"/>
                <counts group_id="E2" subjects_affected="29" subjects_at_risk="166"/>
                <counts group_id="E3" subjects_affected="24" subjects_at_risk="167"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>Urinary tract infection</sub_title>
                <counts group_id="E1" subjects_affected="13" subjects_at_risk="161"/>
                <counts group_id="E2" subjects_affected="12" subjects_at_risk="166"/>
                <counts group_id="E3" subjects_affected="8" subjects_at_risk="167"/>
              </event>
              <event>
                <sub_title>Wound infection</sub_title>
                <counts group_id="E1" subjects_affected="5" subjects_at_risk="161"/>
                <counts group_id="E2" subjects_affected="5" subjects_at_risk="166"/>
                <counts group_id="E3" subjects_affected="3" subjects_at_risk="167"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Injury, poisoning and procedural complications</title>
            <event_list>
              <event>
                <sub_title>Procedural pain</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="161"/>
                <counts group_id="E2" subjects_affected="4" subjects_at_risk="166"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="167"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Musculoskeletal and connective tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Back pain</sub_title>
                <counts group_id="E1" subjects_affected="6" subjects_at_risk="161"/>
                <counts group_id="E2" subjects_affected="4" subjects_at_risk="166"/>
                <counts group_id="E3" subjects_affected="4" subjects_at_risk="167"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>Disturbance in attention</sub_title>
                <counts group_id="E1" subjects_affected="24" subjects_at_risk="161"/>
                <counts group_id="E2" subjects_affected="30" subjects_at_risk="166"/>
                <counts group_id="E3" subjects_affected="23" subjects_at_risk="167"/>
              </event>
              <event>
                <sub_title>Dizziness</sub_title>
                <counts group_id="E1" subjects_affected="51" subjects_at_risk="161"/>
                <counts group_id="E2" subjects_affected="52" subjects_at_risk="166"/>
                <counts group_id="E3" subjects_affected="37" subjects_at_risk="167"/>
              </event>
              <event>
                <sub_title>Headache</sub_title>
                <counts group_id="E1" subjects_affected="27" subjects_at_risk="161"/>
                <counts group_id="E2" subjects_affected="23" subjects_at_risk="166"/>
                <counts group_id="E3" subjects_affected="19" subjects_at_risk="167"/>
              </event>
              <event>
                <sub_title>Hypoaesthesia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="161"/>
                <counts group_id="E2" subjects_affected="4" subjects_at_risk="166"/>
                <counts group_id="E3" subjects_affected="4" subjects_at_risk="167"/>
              </event>
              <event>
                <sub_title>Migraine</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="161"/>
                <counts group_id="E2" subjects_affected="4" subjects_at_risk="166"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="167"/>
              </event>
              <event>
                <sub_title>Paraesthesia</sub_title>
                <counts group_id="E1" subjects_affected="4" subjects_at_risk="161"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="166"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="167"/>
              </event>
              <event>
                <sub_title>Somnolence</sub_title>
                <counts group_id="E1" subjects_affected="39" subjects_at_risk="161"/>
                <counts group_id="E2" subjects_affected="39" subjects_at_risk="166"/>
                <counts group_id="E3" subjects_affected="36" subjects_at_risk="167"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Psychiatric disorders</title>
            <event_list>
              <event>
                <sub_title>Confusional state</sub_title>
                <counts group_id="E1" subjects_affected="12" subjects_at_risk="161"/>
                <counts group_id="E2" subjects_affected="12" subjects_at_risk="166"/>
                <counts group_id="E3" subjects_affected="9" subjects_at_risk="167"/>
              </event>
              <event>
                <sub_title>Insomnia</sub_title>
                <counts group_id="E1" subjects_affected="9" subjects_at_risk="161"/>
                <counts group_id="E2" subjects_affected="9" subjects_at_risk="166"/>
                <counts group_id="E3" subjects_affected="10" subjects_at_risk="167"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Renal and urinary disorders</title>
            <event_list>
              <event>
                <sub_title>Dysuria</sub_title>
                <counts group_id="E1" subjects_affected="14" subjects_at_risk="161"/>
                <counts group_id="E2" subjects_affected="22" subjects_at_risk="166"/>
                <counts group_id="E3" subjects_affected="16" subjects_at_risk="167"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Respiratory, thoracic and mediastinal disorders</title>
            <event_list>
              <event>
                <sub_title>Cough</sub_title>
                <counts group_id="E1" subjects_affected="4" subjects_at_risk="161"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="166"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="167"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Skin and subcutaneous tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Pruritus</sub_title>
                <counts group_id="E1" subjects_affected="27" subjects_at_risk="161"/>
                <counts group_id="E2" subjects_affected="22" subjects_at_risk="166"/>
                <counts group_id="E3" subjects_affected="26" subjects_at_risk="167"/>
              </event>
              <event>
                <sub_title>Rash</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="161"/>
                <counts group_id="E2" subjects_affected="4" subjects_at_risk="166"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="167"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Vascular disorders</title>
            <event_list>
              <event>
                <sub_title>Haematoma</sub_title>
                <counts group_id="E1" subjects_affected="6" subjects_at_risk="161"/>
                <counts group_id="E2" subjects_affected="6" subjects_at_risk="166"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="167"/>
              </event>
              <event>
                <sub_title>Hypertension</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="161"/>
                <counts group_id="E2" subjects_affected="4" subjects_at_risk="166"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="167"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Pfizer ClinicalTrials.gov Call Center</name_or_title>
      <organization>Pfizer, Inc.</organization>
      <phone>1-800-718-1021</phone>
      <email>ClinicalTrials.gov_Inquiries@pfizer.com</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

